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Sub-Saharan Africa is disproportionately affected by the HIV-1 pandemic and whilst 
antiretroviral therapy and social interventions are having a positive impact, a 
successful vaccine remains humanity’s best hope to combat the virus. This study 
served to develop a heterologous DNA prime-protein boost vaccine combination by 
exploiting existing genetic immunization and plant expression platforms developed by 
our research group. An antigenically promising HIV-1 envelope, with known 
sensitivity to prototype broadly neutralizing monoclonal antibodies, was selected for 
development into 3 vaccine immunogens. The first antigen, gp150, comprised of a 
truncated derivative of the full length envelope protein designed to enhance 
expression and the exposure of antibody sensitive epitopes. The remaining 2 antigens, 
gp120-HA2 and gp140-HA2tr, comprised of chimeric HIV envelope antigens fused to 
portions of the influenza haemagglutinin (HA) transmembrane subunit. 
 
DNA vaccines encoding each of the immunogens were constructed using a plasmid 
which exploits a porcine circovirus type 1 enhancer element to drive high levels of 
antigen expression. The expression and localization of each of the antigens was 
verified following transfection of HEK 293 cells. High levels of expression of all 
three immunogens were observed by both western blotting and immunostaining of 
HEK 293 cells transfected with the DNA vaccines. The parental envelope from which 
the vaccines were designed exhibited poor expression, possibly due to either the 
expression vector or intrinsic properties of the envelope gene itself.  The gp150 and 
gp140-HA2tr vaccine antigens displayed a diffuse subcellular localization pattern and 
the proteins were evident both intracellularly and at the cell periphery, similar to the 
HIV-1 Du151 envelope antigen encoded by the SAAVI-C2 DNA vaccine. 
Interestingly, the chimeric immunogen containing the influenza haemagglutinin HA2 
subunit translationally fused to HIV-1 gp120 (gp120-HA2) appeared to be localized to 





Recombinant strains of Agrobacterium tumefaciens were generated for each 
immunogen and antigen expression optimized in plants, using a systematic approach 
to evaluate multiple variables known to influence expression and recovery of 
heterologous proteins. The most successful approach involved infiltrating high 
densities of the bacterial culture into plant leaves and extracting protein directly from 
the apoplast. The co-expression of a post-transcriptional gene silencing suppressor 
also had a profound influence on expression, enabling the duration and magnitude of 
expression to be improved. The use of denaturing conditions to extract protein proved 
successful for gp140-HA2tr antigen only but this approach was deemed impractical as 
it would preclude the recovery of intact protein. Variation in antigen expression was 
seen when experiments were repeated highlighting the influence of plant development 
on recombinant protein expression. At best low level expression of the recombinant 
antigens were achieved in plants that was insufficient for further characterization or 
immunization studies.  
 
Future studies of antigen expression in plants will likely benefit from the optimization 
of the gene coding sequences of the immunogens for both codon usage and GC 
content, as well as exploring different subcellular localizations for the accumulation 
of the proteins. The promising in vivo data generated for the DNA vaccines warrants 
further evaluation and immunogenicity studies are being planned in rabbits to 
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CHAPTER 1: INTRODUCTION 
 
1.1. Origin and diversity of the Human Immunodeficiency Virus 
(HIV) 
 
HIV, a retrovirus of simian origin, is the etiological agent responsible for the global 
Acquired Immunodeficiency Syndrome (AIDS) pandemic (13, 99). The origin of the 
pandemic has been traced to multiple zoonotic transmissions of Simian 
Immunodeficiency Virus (SIV), from African primates to humans, in west and central 
Africa (371). Although the earliest documented sample of HIV dates back to 1959, it 
is suspected that the virus first entered humans in the early 20
th
 century, most likely 
from the butchering of nonhuman primates during hunting (402, 420).  
 
The virus is broadly classified into 2 lineages (HIV-1 and HIV-2) which are distinct in 
terms of both pathogenicity and geographical distribution (217). HIV-1, the more 
pathogenic of the 2 types, is globally distributed, whereas HIV-2 is largely confined 
to west Africa (213, 217, 271). The HIV-1 lineage comprises of 4 sub-lineages 
denoted as groups M, N, O and P, each of which arose through independent zoonotic 
events (Figure 1.1) (119, 162, 269, 329, 366, 367). Groups M and N are believed to 
have been derived from SIVCPZ, a simian virus endemic to chimpanzees (Pan 
troglodytes troglodytes) in Southern Cameroon (100, 162). In contrast, groups O and 
P appear more closely related to an SIV strain occurring in gorillas (Gorilla gorilla 
gorilla) that inhabit western Cameroon (119, 269).  
 
Whilst group M accounts for the majority of HIV-1 infections worldwide, the other 
HIV-1 lineages only make a minor contribution to the global pandemic. Group M is 
estimated to be responsible for approximately 33 million infections globally (135). In 
contrast group O infections are largely confined to Cameroon and account for less 
than 1 percent of the global pandemic (119, 424). Reports of group N and P infections 
have been rare and thus far only 13 group N and 2 group P infections have been 
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confirmed (269, 366, 367). Group M, the pandemic group, is further divided into 9 
subtypes (A-D, F-H, J and K) and a myriad of circulating recombinant forms arising 
from genetic recombination in co-infected individuals (314). The pandemic is highly 
dynamic and each of these subtypes and recombinants differs in terms of both 
geographical distribution and prevalence.  Notably subtype C is the predominating 
strain in Sub-Saharan Africa, including South Africa, and India and accounts for 
































Figure 1.1: Phylogenetic relationships between circulating HIV-1 and HIV-2 isolates and 




The HIV-2 lineage is believed to have originated from SIVSM,  with the Sooty 
Mangabey implicated as the reservoir host (101, 141). HIV-2 is defined by 8 groups 
(A-H) and is estimated to cause less than 1 million infections, globally (355). Only 
groups A and B appear to have spread appreciably, with the other groups confined to 
single individuals (327). It is noteworthy that in recent years HIV-2 has exhibited a 
noticeable  trend towards decreasing prevalence (185, 273, 328). 
1.2. Gravity of the HIV pandemic in the context of Sub-Saharan 
Africa 
 
The global dissemination of HIV-1 has culminated in an epidemic of unparalleled 
proportions. The virus has been implicated in over 60 million worldwide infections, of 
which 25 million have proven fatal. It is estimated that in the year 2012 alone, HIV-1 
was responsible for 1.9 million new infections in middle and low income countries 
alone, with 1.6 million AIDS related deaths (423). The epidemic also has far reaching 
social and economic implications with low to middle income countries being 
disproportionately affected in the global context (314). 
 
The severity of the epidemic and the failures of current intervention strategies to 
effectively combat the virus are particularly evident in Sub-Saharan Africa (Figure 
1.2). The region remains the most heavily effected in the context of the global 
pandemic and accounted for 68% of all infected people in 2010, despite representing 
only 12% of the global population. Sub-Saharan Africa was responsible for an 
alarming 70% of new infections in 2010 and 22.9 million of the estimated 34 million 
people living with the virus resided in this region. The same year bore witness to 1.2 
million AIDS related deaths in sub-Saharan Africa alone (363). Unsurprisingly, 
Swaziland, the country with the highest adult HIV prevalence (25.9%) and South 
Africa, the country with the highest number of people living with HIV-1 (5.6 million), 
are both located in Sub-Saharan Africa. Globally, the virus has orphaned 16.6 million 


























Figure 1.2: Estimates of the global HIV-1 prevalence (A) and incidence (B) in 2012 
highlighting the disproportionate role of Sub-Saharan Africa in the global HIV-1 
epidemic (423). 
 
The HIV epidemic also has far reaching economic ramifications and estimates suggest 
that the annual HIV related expenditure in low to middle income countries exceeded 
US$ 4.1 billion in 2008 (364). It is estimated that the annual cost of achieving 
universal access to antiretroviral therapy (ART) and care will fall within the region of 
US$22 billion (309).  However, the economic impact of HIV is not merely confined 
to HIV-associated costs but also extends to the concomitant loss of labour supply and 
reduction in productivity (77, 330).  
 
Although a marked 30% decrease in the global incidence of HIV-1 has been 
witnessed since 2001, these figures underestimate the gravity of the epidemic (Figure 
1.3) (423). In spite of the promising impact of antiretroviral therapy and the 
















are unlikely to eradicate the virus. In the light of the gravity of the global epidemic 
and the far reaching social, economic and medical ramifications it imposes, a 




Figure 1.3: Global estimates of new HIV-1 infections and AIDS related deaths from 
1990-2010 (363). 
 
1.3. Synthesis and Structure of the HIV envelope Glycoprotein Spike  
 
The surface-bound envelope glycoprotein of HIV-1 is the target of all known 
antibodies capable of mediating cross-clade neutralization of the virus and is therefore 
of considerable interest to immunogen design (178).  The structure of the glycoprotein 
will be briefly reviewed in the text to follow in order to provide background to the 
vaccine  antigens designed in this study. The HIV-1 envelope glycoprotein encodes an 
approximately 845-870 amino acid glycoprotein product that mediates entry into 
target cells (65, 408). Following translation, the gp160 precursor is subjected to N-
linked glycosylation as it passes through the endoplasmic reticulum (ER) and 
proteolytic cleavage by furin proteases in the Golgi apparatus (76, 124, 340, 391). The 
envelope protein oligomerizes as it translocates through the ER to form trimeric 
complexes, although other oligomers have also been reported (81, 391). The 
transmembrane (gp41) and surface (gp120) envelope subunits remain non-covalently 
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attached to form  heterodimers, which remain closely associated in membrane-bound 
glycoprotein complexes that populate the surface of the virion (82, 168, 391, 419). 
 
The gp41 subunit protrudes through the virion membrane to form a compact 
mushroom shaped base of the glycoprotein trimer from which the surface unit, gp120, 
extends (Figure 1.4) (393). The transmembrane subunit is divided into 3 major 
structural regions; a long cytoplasmic tail extending into the virion core, a 
transmembrane domain anchoring the transmembrane glycoprotein in the virion lipid 
bilayer and an extracellular domain which protrudes to the exterior of the virion (168, 
392). The extracellulular domain contains crucial functional elements involved in 
entry and fusion of the virus with target cells. These include the hydrophobic N-
terminal fusion peptide, two disulphide-linked alpha helical coiled coils (Heptad 
Repeats 1 and 2) and a tryptophan-rich region referred to as the membrane-proximal 
external region (MPER) (29, 48, 94, 296, 352).  
 
The surface envelope subunit is composed of 5 hypervariable regions, four of which 
form disulphide bonded loops, interspersed with 5 conserved regions (187, 338, 396).  
The core of gp120 comprises of an inner domain, an outer domain and an 
intermediate bridging sheet (146, 175). The inner domain is comparatively more 
conserved and devoid of glycans, unlike the outer domain which exhibits extensive 
variability and glycosylation (407). The first and second variable loops (V1/V2) are 
positioned at the apex of the glycoprotein trimer, in proximity to the point of contact 
between the virus and host cell (393). The third variable loop (V3) is in close 



































Figure 1.4: Structure of the HIV-1 envelope glycoprotein in its trimeric (A) and 
monomeric (B) forms (adapted from Nabel et al. (241)). The crystal structure of the 
envelope glycoprotein has been overlayed with the density plot of the glycoprotein spike as 
predicted by cryoelectron tomography. N-linked glycosylation is represented in cyan and the 
peptide backbone depicted using ribbon diagrams. The relative positions of the inner domain, 
outer domain and bridging sheet are indicated in gray, blue and red respectively. 
 
1.4. The Neutralizing antibody response during natural HIV-1 
infection  
 
HIV-1 infection is associated with a robust humoral response which fails to prevent 
the inevitable onset of AIDS defining illness (283). The earliest detectable humoral 
response following infection takes the form of antigen-antibody complexes which are 
present approximately 8 days following the detection of plasma viremia (Figure 1.5). 
After a further delay; free serum binding antibodies targeting gp41 appear, followed 
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not long after by gp120 binding antibodies (358). Most individuals develop 
neutralizing antibodies to the autologous virus within several months of infection (1, 
113, 186, 230, 280, 390). However, these antibodies are type specific and fail to 
neutralize heterologous primary viral isolates (113, 228, 230, 280). Antibodies 
targeting the V3 loop comprise a significant proportion of the early antibody response 
to gp120 and can be detected as early as 3 weeks, following the transmission event 
(69, 70, 231, 358). Yet despite developing high titers and demonstrating considerable 
cross reactivity, these antibodies do not contribute to autologous neutralization (69, 
70, 231, 358). This is presumably due to the occlusion of neutralization sensitive 
epitopes in the context of the functional glycoprotein trimer (69, 70, 169, 170). The 
autologous neutralizing antibody response largely targets the hypervariable loops of 
the virus, particularly the V1/V2 regions, with V4 and V5 appearing to play a less 
prominent role (231, 234, 288). Consistent with these findings, experimental SHIV 
infection of rhesus macaques has been shown to be associated with autologous 
antibodies targeting the V1/V2 region of the envelope protein (179). In subtype C 
infection an epitope encompassing the C3-V4 region is commonly targeted by 
autologous neutralizing antibodies, but this appears to be subtype specific and has not 
been observed in infection with other clades (231). The detection of frequent escape 
mutations in the alpha-2 helix of C3 is further evidence of the selective pressure 
imposed on this region by the antibody response of the infected host (234, 287). 
Antibodies directed at epitopes induced by CD4 binding are often elicited prior to 
autologous neutralizing antibodies, but are of negligible functional significance (113). 
MPER-specific binding antibodies are less common in natural infection during the 
first year but when elicited also make no discernible contribution to autologous 
neutralization (113). Antibodies targeting the CD4-binding site usually develop within 
the first 16 weeks of infection but are usually of weak affinity and low potency (205).  
 
Although the autologous neutralizing antibody response is usually of a high titer, it 
fails to successfully mediate clearance of the virus. Instead the antibody response 
imposes strong selective pressure on the virus and drives the evolution of the viral 
envelope (32, 234, 280). Interestingly, it has been demonstrated that the antibody 
response to HIV-1 infection, during the first year, is usually only directed at 1 or 2 
epitopes of the envelope glycoprotein (234). The virus easily escapes antibody 
































neutralize contemporaneous virus, despite neutralizing virus from earlier time points 
(32, 71, 230, 234, 288, 390). Escape from neutralizing antibodies is achieved through 
multiple mechanisms including single amino acid substitutions, insertions, deletions, 
expansion of variable loops, changes in N-linked glycosylation and conformational 
masking of vulnerable epitopes (32, 96, 176, 234, 288, 390). The development of 
antibodies with cross-neutralizing activity against heterologous primary isolates 
usually only develops later in infection (71, 228, 230). Such antibodies are typically 
evident after about 2.5 years of infection, but may be detected as early as 1 year in 











Figure 1.5: Development of the antibody response to HIV-1 after infection (358). 
 
1.5. Broadly neutralizing HIV-1 antibodies and sites of vulnerability 
on the HIV-1 envelope glycoprotein 
 
Despite the perceived paucity of antibodies capable of mediating broad neutralization 
of heterologous primary isolates, it has become apparent that a subset of HIV-1  
infected individuals develop antibodies with considerable cross-neutralizing activity 
(177). A series of studies have demonstrated that these responses occur in about 20% 
of infected individuals, but are only detectable late in infection and are of little 
clinical significance (25, 80, 193, 302, 337, 380). In the last several years a milieu of 
broadly neutralizing monoclonal antibodies have been isolated from HIV-1 infected 
individuals delineating 4 distinct sites of vulnerability present on the HIV-1 envelope 
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glycoprotein (Figure 1.6) (177). These include the CD4 binding site, the MPER of 
gp41 and glycan dependent epitopes in the V1/V2 and V3 regions of the HIV-1 
envelope (193, 194, 379, 380, 422). Passive transfer experiments with these 
antibodies have demonstrated their protective efficacy against SHIV challenge, 
supporting the notion that if similar responses could be elicited by vaccination they 
would be protective (138, 139, 318). 
 
 
Figure 1.6: Regions of vulnerability of the HIV-1 envelope targeted by broadly 
neutralizing antibodies (adapted from Kwong et al., 2013 ) (178). A model of the envelope 
glycoprotein, rendered by cryo-electron microscopy, is depicted with prototype broadly 
neutralizing antibodies that target each of the main regions of vulnerability. 
 
 
1.5.1. The CD4 binding site (CD4bs) 
 
The CD4-binding site is responsible for initiating entry into permissive target cells 
and therefore antibodies with the potential to block this interaction are likely to be 
protective (175). Several highly potent broadly neutralizing antibodies have been 
isolated that recognize the functionally conserved CD4 binding site including the likes 
of; VRC01, VRC-CH31, VRC-PG04, 3BNC117, 12A12 and PGV04 (84, 303, 404, 
405). Several other antibodies that target the CD4 binding site with considerably less 
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breadth and potency have also been identified (37, 58). It has become apparent that 
the differences in neutralization breadth and potency between these groups of 
antibodies appears to be related to their modes of recognition (51). Antibodies, such 
as VRC01, achieve neutralization by partial mimicry of the CD4 receptor interaction 
whereby they target the initial site of CD4 attachment (404, 418). Deep sequence 
analysis has revealed that this is in fact a common mode of recognition for the 
development of broadly neutralizing CD4-binding site antibodies, achieved by 
convergent evolution in unrelated donors (303, 405). 
 
Lynch and colleagues have reported that the CD4-binding site is immunogenic in 
natural infection and that 88% of seroconverters from a longitudinal study developed 
antibodies recognizing this target (205). However, broadly cross-neutralizing 
antibodies targeting the CD4-binding site are associated with unusually high levels of 
affinity maturation which poses a formidable challenge to their induction by 
vaccination (405, 418). Although at this venture it is unclear how these antibodies can 
be elicited by vaccination, it may be necessary to guide the evolution of the antibody 
response by mimicking the complex interplay between the virus and the immune 
system (197). 
 
1.5.2 The Membrane-Proximal External region of gp41 
(MPER) 
 
Amongst the earliest broadly neutralizing antibodies identified, the gp41-specific 2F5 
and 4E10 monoclonal antibodies defined a distinct region of vulnerability in the 
MPER region of the envelope glycoprotein (41, 240, 249). Other gp41-specific 
neutralizing antibodies have also been isolated but with considerably less potency and 
breadth, such as the CAP206-CH12, Z13 and m66 monoclonal antibodies (236, 421, 
422). These MPER-specific broadly neutralizing antibodies recognize a linear epitope 
in gp41 which is considered an attractive vaccine target (41, 229, 240, 249). However, 
the MPER is poorly immunogenic and MPER-specific antibodies are often 
polyreactive preventing their induction via vaccination due to immunological 
tolerance mechanisms (131, 229). More recently a novel antibody, 10E8, was isolated 
and demonstrated to have a greater neutralization breadth than other previously 
12 
 
isolated MPER-specific antibodies. Additionally, 10E8 was not found to be 
autoreactive and antibodies of a similar specificity were reported in 8% of a 72 person 
cohort of HIV-1 infected donors (147). 
 
1.5.3. V1/V2 glycans 
 
The identification of antibodies PG9 and PG16, from the activated memory B cells 
derived from a clade A donor in 2009, defined a new site of envelope vulnerability in 
the V1/V2 region (379). Subsequent studies have resulted in the isolation of similar 
antibodies, such as PGT141-145 and CH01-4 (26, 377). This class of antibodies all 
recognizes a quaternary epitope that is preferentially expressed on trimeric envelope  
and is dependant on the glycan attached to the asparagine at amino acid 160 (N160) 
(26, 220, 377). Interestingly, a similar antibody (2909) has been identified that 
recognizes an epitope involving lysine at residue 160, instead of a glycan (403). This 
antibody, although similar to PG9 and PG16, is strain specific due to the conservation 
of asparagine at residue 160 (49, 403). Similar antibody specificities have also been 
reported in rhesus macaques after experimental SHIV infection (284). Broadly 
neutralizing antibodies targeting epitopes involving the glycan at N160 are commonly 
responsible for neutralization breadth in infected individuals who display cross 
neutralizing activity (380). 
  
1.5.4. V3 glycans 
 
A second class of glycan dependent antibodies was identified by the monoclonal 
antibody 2G12 which recognizes a cluster of glycans proximal to the V3 loop (299, 
359). Although 2G12 was initially believed to  represent a unique competition group, 
a number of broadly neutralizing antibodies of overlapping specificities were recently 
identified from Protocol G donors including; PGT121-123, PGT125-128, PGT130, 
PGT131 and PGT135-138 (299, 377). The majority of these antibodies all recognized 
epitopes involving glycans at N301 or N332 (377). Delineation of the crystal 
structures of the antigen binding fragments of PGT127 and PGT128 with synthetic 
glycan ligands have revealed that their epitopes encompass 2 glycans and a β-strand 
region of the V3 loop (259). It has been demonstrated that this unique class of 
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antibodies often displays diverse modes of interaction with their epitopes, although 
the key N301 and N332 glycans remain central for recognition (253). A recent study 
by Walker and colleagues revealed that broadly neutralizing antibodies targeting the 
N332 epitope was the most common specificity in a cohort of 19 donors selected for 
their potency of cross-clade serum neutralizing activity (380). Experimental SHIV 
infection in Rhesus monkeys has also been associated with the development of cross-
clade neutralizing antibodies dependant on the N332 glycan (381).  A recent study has 
suggested that these antibody responses target escape variants and that the N332 
glycan is often not present on the transmitted founder virus, undermining the efficacy 
of these responses should they be elicited by vaccination (233). 
 
1.6. Vaccine concepts evaluated in efficacy trials 
 
Despite over three decades of scientific research since the discovery of HIV, only 4 
vaccine concepts have completed evaluation in efficacy trials (30, 93, 115, 125, 267, 
279). Whilst these trials have only demonstrated modest efficacy at best, they have 
played an important role in guiding future vaccine development and have highlighted 
the nature of immunological responses that may confer protection (132, 164, 279). 
Even efficacy trials that have failed to demonstrate any overt vaccine efficacy have 
proved enlightening in retrospect and can be viewed as a dynamic part of the vaccine 
development process (30, 93, 115, 267). Notably, these studies have highlighted 
shortcomings of nonhuman primate models and the limitations of in vitro assays to 
faithfully predict in vivo vaccine efficacy (30, 115, 388). The outcome of these studies 
has drawn attention to the potential impact of pre-existing immunity to viral vectors 
and the possibility of interference between mucosal immunity and antibody-mediated 
effector functions (30, 115, 132). Lastly, one of the largest caveats to these trials is the 
biased representation of immunogens derived from subtype B and CRF01_AE which 








1.6.1. VaxGen’s AIDSVAX Recombinant gp120 envelope 
Vaccines 
 
The majority of clinically licensed vaccines mediate their protective efficacy via the 
induction of serum or mucosal neutralizing antibodies (270). The first HIV-1 vaccine 
efficacy trials were therefore based on the premise that the induction of neutralizing 
antibodies directed at the envelope glycoprotein gp120 could confer sterilizing 
immunity (112). Preliminary studies in nonhuman primates demonstrated that 
envelope subunit vaccines could confer protection against both homologous and 
heterologous viral challenges, giving credence to the logic of this approach (21, 22, 
97, 105). These studies were followed by promising phase 1 and 2 clinical trials 
suggesting that monomeric gp120 envelope-based vaccines, derived from subtype B 
and E strains, were safe and immunogenic (17, 266, 268) .  
 
Based on these studies, two bivalent recombinant envelope vaccine regimens were 
conceived for efficacy testing. The first of these vaccines (AIDSVAX B/B) was 
evaluated in men who have sex with men (MSM) and women at high risk for 
heterosexual HIV-1 acquisition in North America and the Netherlands. The vaccine 
comprising of a bivalent formulation of the gp120 envelope subunits of the HIV-1 
subtype B MN and GNE strains, achieved a mere 6% vaccine efficacy (93). The 
second efficacy trial evaluated a similar vaccine modality in injection drug users in 
Bangkok, Thailand. This time however, the vaccine (AIDSVAX B/E) was formulated 
from the envelope subunits derived from HIV-1 MN and CRF_01AE. This trial 
demonstrated a negligible 0.1% efficacy (267). A subsequent post-hoc analysis has 
suggested that despite the lack of apparent efficacy of either vaccine; the AIDSVAX 
B/B regimen elicited a greater magnitude of antibody responses in non-white and 
female vaccinees. Furthermore peak antibody titers appear to be inversely correlated 
with the incidence of HIV-1 infection (103).  Notably, both vaccines failed to impact 
plasma viral load, maintance of peripheral CD4+ T cell count or other clinical 
outcomes following HIV-1 infection (93, 267). These failures have been attributed to 
the inability of either vaccine to generate antibodies capable of neutralizing diverse 
primary viral isolates (103). This may be partly due to the envelope immunogen not 
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accurately replicating the native structure of the envelope glycoprotein spike, which 
occurs as a trimer in the context of the HIV-1 virion (46). 
 
1.6.2. Merck Replication-Defective Adenovirus Serotype 5 
(Ad5) Vector Based Vaccine  
 
In the aftermath of the failed AIDSVAX clinical trials, HIV-1 vaccine development 
gravitated towards vector based vaccines for the induction of cellular immunity (376). 
Although sterilizing immunity remains the holy grail of HIV vaccinology, this 
idealistic notion was largely perceived as unrealistic in the light of the outcome of the 
AIDSVAX clinical trials (190). Encouraged by the importance of cellular responses in 
temporal control of acute phase viremia in both humans and nonhuman primates and 
the presence of strong cellular responses in long term non-progressors, vaccines were 
developed in the hope of ameliorating the course of infection (27, 39, 95, 167, 254, 
306). Although such a vaccine would be unable to prevent infection, a robust cellular 
response would be expected to limit acute phase viremia and lower the concomitant 
viral set point (154). Additionally, cell-mediated immune control would reduce the 
risk of HIV transmission as the viral load is directly related to the risk of transmission 
(116, 276). Therefore based on promising nonhuman primate vaccine studies 
demonstrating viremic control of chimeric SHIV 89.6P and partial control of 
SIVmac239, a prototype Ad5 vector based vaccine was developed for clinical trials 
(43, 195, 322, 398). 
 
The vaccine was developed by Merck and comprised of a trivalent, replication-
defective adenovirus serotype 5 vector expressing the gag, polymerase and nef genes 
derived from subtype B isolates (30, 115, 274). Based on promising immunogenicity 
results in early clinical trials, the vaccine was evaluated in two phase 2b proof-of-
concept trials despite the high prevalence of pre-existing Ad5 vector immunity (30, 
115, 216, 246, 274). The first, termed the STEP trial, tested the efficacy of the vaccine 
in the face of high risk heterosexual and homosexual behaviour in a predominantly 
subtype B epidemic (30). The second trial took place in South Africa (Phambili), to 
evaluate the cross reactivity of the vaccine to subtype C, the predominant viral 




However, despite the favourable immunogenicity of the vaccine in the trial 
participants, both trials were prematurely terminated after interim analysis showed 
that the STEP trial failed to meet predetermined efficacy criteria (30, 115, 218, 274). 
Not only did the MRK Ad5 vaccine fail to impact HIV-1 acquisition or viral load, but 
the vaccine appeared to enhance HIV infection in a subset of uncircumcised men and 
participants with pre-existing immunity to the Ad5 vector (30, 115). Subsequent 
attempts to identify the underlying mechanism for this phenomenon have raised a 
number of plausible hypotheses (20, 149, 247, 262). It is noteworthy that despite the 
lack of efficacy of the vaccine, an analysis of breakthrough infections has suggested 
the presence of cell-mediated selective pressure on the virus (286). In retrospect, the 
failures of the STEP and Phambili trials have highlighted the need for more 
fundamental scientific research, particularly with regard to the stringency of 
nonhuman primate challenge models and the need for more qualitative in vitro 
assessments of vaccine induced cellular responses (12, 312, 388). 
 
1.6.3. RV144 Heterologous Poxvirus Prime – Recombinant 
Glycoprotein Boost Vaccination Regimen 
 
The failure of the STEP and Phambili trials lead to the development of the 
heterologous prime-boost concept aimed at inducing both the humoral and cellular 
arms of immunity (279). A series of phase 1/2 clinical trials demonstrated the utility 
of combination vaccines, comprising of priming with poxvirus vectors followed by 
boosting with recombinant envelope proteins, at inducing both antibodies and 
cytotoxic T lymphocyte (CTL) responses (18, 55, 244, 291, 370). A candidate prime 
boost vaccine combination was advanced to phase 3 in Thailand in spite of cynicism 
and the cancellation of a similar trial in America due to a perceived lack of 
compelling evidence to justify such a study (16, 36, 221, 291). The priming vaccine 
comprised of a recombinant canarypox vector expressing HIV-1 CRF01_AE gp120 
fused to the transmembrane region of subtype B gp41 (LAI strain) containing a 
deletion in the immunodominant region. The poxvirus vector also expressed the gag 
and protease genes from the subtype B LAI strain (244). This was later followed by a 
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boost with the bivalent AIDSVAX B/E vaccine that had completed efficacy testing in 
Thailand (267).  
 
The RV144 trial was conducted in Thailand in a community based population at 
heterosexual risk of HIV-1 acquisition. The vaccine demonstrated a modest 31.2% 
efficacy at preventing HIV acquisition but had no discernable impact on either viral 
load or preservation of peripheral CD4+ T cell count in subsequently infected 
vaccinees. Despite the declining vaccine efficacy (from 59.9% after 12 months) and 
evidence suggesting that the vaccine efficacy was greater in people at low risk of 
infection, the RV144 trial was the first to demonstrate any meaningful protection from 
HIV-1 infection (279). A subsequent immune correlates analysis has revealed that 
plasma IgG binding antibodies to scaffolded variable regions 1 and 2 (V1/V2) of the 
HIV envelope protein was inversely correlated with risk of infection. In contrast, 
binding of plasma IgA to the envelope glycoprotein was correlated with infection risk. 
Secondary analysis suggested that envelope specific IgA may have negated the 
beneficial effect of other protective antibodies.  Although the latter appears to 
undermine the rationale of vaccine-elicited mucosal antibodies, no mucosal samples 
were available from the study for analysis. Secondary analysis of plasma samples also 
suggested that in the presence of low levels of envelope-specific IgA, IgG avidity, 
antibody dependent cellular cytotoxicity (ADCC), neutralizing antibodies, and CD4+ 
T cells all correlated with reduced infection risk, albeit of borderline significance 
(132).  Consistant with these observations the vaccination combination was shown to 
elicit strong ADCC activity in phase 1/2 trials (160). A sieve analysis of breakthrough 
infections has revealed the presence of selective pressure on residues 169 and 181 in 
the V1/V2 region of breakthrough viruses, suggesting that vaccine induced immunity 
to this region was responsible for the protective effect reported (285). Liao and 
colleagues went on to isolate 4 monoclonal antibodies from participants in the RV144 
trial, targetting epitopes involving the K169 residue, and demonstrated their ability to 
mediate antibody-dependant cellular cytotoxicity (196). An analogous study to the 
RV144 vaccine regimen has partly recapitulated these findings by demonstrating a 
correlation between V2 antibodies and protection from SIVMAC251 challenge (257). 
Additional studies have also suggested that the vaccine regimen may have lowered the 
seminal viral load post infection and that vaccine-induced T cells preferentially 
targeted the V2 region of the envelope glycoprotein (333, 334). In the light of these 
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promising findings, a series of follow up studies have been conceived to evaluate the 
impact of RV144-like trials in South Africa (11). 
 
1.6.4. Heterologous DNA prime-recombinant Adenovirus 
serotype 5 boost immunization regimen (HVTN 505) 
 
The most recent vaccine concept to be evaluated for efficacy is the heterologous DNA 
prime-recombinant adenovirus boost vaccine, designed by the Betty Bumpers Vaccine 
Research Centre, with the aim of inducing polyfunctional T cell and cross-reactive 
antibody responses (125). The priming immunization comprised of an equimolar 
mixture of 6 plasmids encoding Subtype B Gag, Pol and Nef Proteins and truncated 
envelope antigens from Clade A, B and C viruses (45, 111). This was followed by 
boosting immunizations with replication-defective adenovirus serotype 5 vectors 
encoding a Subtype B Gag-Pol fusion protein and matched envelope antigens from 
clades A, B and C (44). Participants received 3 genetic immunizations at weeks 0, 4 
and 8 followed by a single boosting vaccine at week 24 (125). Both vaccines were 
proven to be safe and immunogenic in early phase clinical assessments when 
administered alone or in combination (44, 54, 111, 152, 163, 258). Furthermore, the 
immunogenicity of the adenovirus vector did not appear to be negatively impacted by 
the presence of pre-existing vector immunity when this phenomenon was evaluated in 
an early phase 1 trial (152). However, the clinical trial was prematurely terminated 
due to a lack of efficacy. Additionally concerns were raised that the vaccination 
regimen may have enhanced HIV infection, although this aspersion was not 
statistically significant and was later disproved (125). Despite the lack of statistical 
evidence to confirm these concerns, this is the second adenovirus serotype 5-vectored 
vaccine which has raised concerns of increased infection risk (30, 115, 218). 
However, if the vaccination regimen did in fact enhance the risk of HIV-1 infection, 
the factors responsible were likely to be different as all participants in the HVTN 505 






1.7. Genetic immunization as an in vivo expression platform  
 
The potential to use naked DNA as a vaccine vector was first demonstrated by Tang 
and Johnston, in 1992, when they exploited a plasmid to induce immunity against 
human growth hormone in mice (353). This was followed shortly by several studies 
that reported similar results for viral antigens, giving further credence to the logic of 
genetic immunization (98, 362, 382). DNA vaccines boast the promise of an 
improved safety profile compared to conventional live and whole-killed vaccines, 
along with ease of manufacture for large scale production and the potential to induce 
both humoral and cellular immunity (173, 201). Additionally, plasmid DNA has 
intrinsic adjuvant properties due to the presence of unmethylated CpG DNA motifs 
which are recognized by toll-like receptor 9 (171).  
 
DNA vaccines are minimalistic vaccines that comprise of a bacterially-derived 
plasmid that has been engineered to express a heterologous antigen in mammalian 
cells (79, 120, 201). The basic elements that constitute a DNA vaccine include: 
promoter and polyadenylation (Poly (A)) signals to regulate expression of the 
heterologous gene, a multiple cloning site to facilitate genetic manipulation of the 
plasmid, a bacterial origin of replication to enable large scale production of the 
plasmid in bacterial cells and a selectable marker to ensure the maintance of the 
plasmid during culturing (Figure 1.7) (120, 173).  
 
The use of various transactivator and enhancer elements may also be included in the 
plasmid vector to increase the levels of antigen expression in vivo (10, 102, 151, 174). 
Our lab has developed an improved DNA vaccine vector, pTHPcapR, which employs 
a porcine circovirus enhancer element to improve the expression of heterologous 
genes. The use of this enhancer element has been demonstrated to improve the 
expression levels of an HIV-1 polyprotein antigen up to 2-fold, in transfected HEK 
293 cells, relative to the parental vector which lacks the enhancer element. Consistent 
with these findings, immunization of mice with the improved vector achieved a 3-fold 















Figure 1.7: Schematic indicating the important functional features of a typical DNA 
vaccine (modified from Kutzler and Weiner, 2008) (173).  
 
However, despite the initial promise in small animal models, candidate DNA vaccines 
were found to be poorly immunogenic in clinical trials and high plasmid dosages were 
required for sub-optimal responses (79, 150, 201, 384). Several different delivery 
systems have been explored to improve immunogenicity including various needle free 
devices such as gene gun systems, patch systems, jet injections, electroporation (150). 
Modification of the antigen coding sequence by codon optimization and the removal 
of inhibitory sequences has been reported to improve immunogenicity (223). Lastly, 
the co-administration of cytokines along with the DNA vaccine has also shown 
promise (173). 
 
To date however, the most promising approach has been the use of DNA vaccines in 
combination with either matched recombinant proteins or a viral vector encoding the 
same antigen (204, 304). This strategy, termed heterologous prime-boost, results in 
high levels of T cell memory and is often associated with a synergistic improvement 
in immune responses (401). Prime-boost vaccination strategies have been employed 
extensively against HIV as well as other pathogens including; Mycobacterium 
tuberculosis, Herpes Simplex virus-2, Plasmodium falciparum, Listeria 
monocytogenes, Leishmania infantum and Ebola virus, amongst others (87, 88, 110, 
150, 222, 225, 307, 348, 349).  
 
The DNA prime-protein boost combination is a particularly attractive approach to 
induce cross-neutralizing antibodies against the HIV-1 envelope glycoprotein (150). 
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Wang and colleagues reported the induction of antibodies capable of neutralizing JR-
FL, a hard to neutralize HIV primary isolate, by immunizing rabbits with a DNA 
vaccine encoding envelope followed by a recombinant envelope protein boost. 
Neither approach on its own induced comparable antibody responses, even after 
multiple immunizations (385). A similar study by Vain and colleagues demonstrated 
that the DNA prime-protein boost approach could induce antibodies targeting a 
conformational epitope in the HIV envelope CD4 binding site, whereas immunization 
with the individual components could not (365). There is also evidence to suggest that 
DNA priming, followed by a protein boost may enhance antibody avidity (385). 
These studies strongly support the development of prime-boost vaccination regimens 
against HIV-1, particularly for the induction of neutralizing antibodies. 
 
1.8. Plants as an expression system for heterologous proteins 
 
The concept of using plants as an expression platform for heterologous protein 
production, although over 2 decades old, is only now receiving widespread 
acceptance as a commercially viable expression system (207). The idealistic ambition 
to exploit plants to produce edible antigens has remained elusive, but instead has been 
replaced by attempts to create formulatable vaccines that are amenable to standard 
delivery methods (292). The earliest documented example of a pharmaceutically 
relevant protein, produced in plants, was reported by Barta and Colleagues in 1986 
who expressed a chimeric human growth hormone protein in transgenic tobacco (14). 
This was followed soon after by the successful expression of plant-derived mouse 
monoclonal antibodies and then the hepatitis B surface antigen which proved to be 
immunogenic in mice (140, 214, 356). Yet, in spite of the promise of this early work, 
only 3 plant produced products have achieved licensure to date (251, 275, 293). 
Although partly attributable to lack of big pharma buy-in and general public 
resistance, a major barrier is the low yields associated with many proteins expressed 
in plants which in most cases fails to reach the 1% total souble protein threshold 
considered to constitute a feasible product (207, 293). In the light of this, extensive 
effort has been devoted to understanding the variables that influence protein 
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expression in planta. These variables are discussed in the following sections with 
emphasis on how they may impact this study. 
 
1.9. Advantages of plants as a heterologous expression system for 
vaccine antigens 
 
Plants offer a number of distinct advantages over conventional expression platforms 
that make them a potentially promising source of recombinant proteins. The 
production of recombinant pharmacuticals in plants is significantly cheaper than 
conventional cell culture and bacterial fermentation technology (66, 91, 256, 346). It 
has been estimated that the production of recombinant proteins in plants could 
potentially circumvent both batch and site production expenses, representing 
approximately 31% of the overall cost. Additionally, the raw material expenses are 
approximated to be 1000-fold less than traditional cell culture based protein 
production and 100-fold less than proteins produced by bacterial fermentation (293). 
 
Another advantage of plant-based proteins is the potential to produce edible vaccines 
enabling oral administration, without the extensive purification associated with 
conventional vaccines (66, 67, 295, 346). Important proofs of concept include the use 
of transgenic tobacco containing a measles haemagglutinin antigen to boost antibodies 
induced by a matched DNA vaccine (389), the induction of mucosal neutralizing 
antibodies in mice against rotavirus VP7 by oral vaccination with transgenic potatoes 
(406) and the use of transgenic corn seed to boost lactogenic immunity in swine 
against a porcine transmissible gastroenteritis virus (180). Similar promise has been 
demonstrated in a clinical context where transgenic potato tubers, containing hepatitis 
B surface antigen, were reported to boost blood serum antibodies (357). 
 
Additionally plant-based expression platforms are potentially infinitely scalable and 
uniquely suited to the rapid response required for pandemic disease outbreaks (292). 
This has been demonstrated best by Medicago who reported the production of a 
candidate virus-like particle (VLP) vaccine against influenza H5N1 within 3 weeks 
from the release of the viral sequence. Additionally, researchers at Medicago have 
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also illustrated the scalability of their expression platform by successfully producing 
10 million doses of an H1N1 VLP vaccine in under a month (62).  
 
Plants also have the capacity to mediate proper eukaryotic post-translational 
modifications and the assembly of VLPs has been observed for several antigens, as 
described for other expression systems (207, 311). Lastly, plant-produced 
pharmaceuticals offer an improved safety profile, relative to conventional 
pharmaceutical production platforms, as they do not support the growth of human 
pathogens or endotoxins (66, 207, 346). 
 
1.10. The impact of plant-specific N-linked glycosylation 
 
Although plants are capable of reproducing many of the post translation modifications 
of mammalian expression systems, they differ with respect to the glycosylation they 
impart onto recombinant proteins (109). Whilst the first phase of glycosylation 
occurring in the Endoplamic Reticulum (ER), is conserved amongst both plants and 
animals, the subsequent modifications that occur in the Golgi apparatus differ (256). 
Plant-derived N-glycan moieties are devoid of terminal galacatose and sialic acid 
residues and contain non-mammalian β (1,2)-xylose and α (1,3)-fucose carbohydrate 
groups resulting in a glycan profile that is distinct from conventional mammalian 
expression platforms (86, 109, 207, 415). An additional complication is the variability 
of glycosylation imparted by a given host plant depending on the subcellular 
localization of a recombinant protein. Heterologous proteins expressed in the plant 
chloroplast are not glycosylated (40, 415). Conversely heterologous proteins retained 
in the ER typically exhibit only high mannose glycans whereas proteins passing 
through the Golgi into the apoplast will undergo further modification resulting in 
plant-specific glycan structures (28, 92). 
 
Concerns have been raised regarding the potential implications of the structural 
differences of plant glycans in a pharmaceutical context, particularly with regard to 
their potential immunogenicity (28). The detection of antibodies in human serum that 
recognize core xylose and α (1,3)-fucose moieties of plant glycans has raised concerns 
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that plant antigens may induce adverse reactions (9). Furthermore, a series of small 
animal studies have suggested that plant glycans may be immunogenic, although 
reports have been inconsistent between different models (9, 50, 153). However, as Ma 
and colleagues have succinctly reflected, the mere presence of antibodies recognizing 
plant carbohydrate moieties is not a sufficient indication that they are harmful, 
especially as these plant glycans are commonly encountered in our diets (207). A 
recent clinical trial of a candidate  influenza haemagglutinin vaccine, produced in 
Nicotiana benthamiana plants, did not detect any increase in plant carbohydrate-
specific antibodies following vaccination suggesting that concern is unwarranted 
(183). Furthermore, the inherent differences in plant glycosylation may even be 
beneficial in certain settings. Recombinant antibodies expressed in plants may exhibit 
enhanced effector functions due to the lack of fucose residues in the mammalian α 
(1,6)-linkage which is believed to limit these non-neutralizing activities (319). 
Additionally, the lack of terminal sialic acid residues in plant-produced antigens may 
promote increased binding to cellular receptors enhancing the immunogenicity of 
vaccines (243). 
 
Despite the potential benefits of plant derived glycans, considerable effort has been 
devoted to generate plant produced proteins with a humanized glycosylation profile, 
that is more closely comparable to conventional expression platforms. Promising 
approaches have included using genetically engineered plants expressing β 1,4-
galactosyltransferase to produce glycans with terminal β 1,4-galactose moieties (8, 
344) and the generation of knockout mutants lacking the glycosyltransferases 
responsible for the addition of plant specific carbohydrate groups (343, 345). 
 
1.11. Approaches to the expression of heterologous proteins in plants 
 
A number of different approaches have been developed to express heterologous 
proteins in plants. These approaches can be broadly divided into either stable or 
transient expression (Figure 1.8) (75). Although much of the early research into using 
plants as an expression platform relied on stable expression, this approach is limited 
by the long time scale required to generate transgenic plants (415). Despite initially 
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being used merely as a vehicle for the validation of expression constructs, the speed 
and versatility of transient expression systems has seen their widespread acceptance 
as the method of choice for heterologous protein production in plants (75, 292).  
 
Figure 1.8: Summary of possible approaches to the expression of heterologous proteins 
in plants (adapted from Scotti and Rybicki, 2013) (311). 
 
Stable expression involves the generation of nuclear transgenic or transplastomic 
plants by the stable integration of a transgene into the nuclear or plastid genome 
respectively (248). This can be achieved by transformation with either Agrobacterium 
tumefaciens or by microparticle bombardment (188, 415). Conversely, the generation 
of transplastomic plants can only be achieved by biolistics or using polyethylene 
glycol, as A. tumefaciens can only deliver DNA to the plant nucleus (40). 
 
Transient expression in plants is typically achieved using either A. tumefaciens, plant 
viral vectors or the A. tumefaciens-mediated delivery of viral replicons (166). A. 
tumefaciens-mediated transient expression is achieved by infiltrating a bacterial 
suspension into plant leaves to enable the transfer of the T-DNA region, encoding the 
gene of interest, to the plant nucleus (159, 292). This approach has been used 
routinely by our research group to express antigens from influenza, HPV and HIV 
amongst others (209, 227, 238, 264). Medicago have championed the use of a similar 
transient A. tumefaciens-mediated expression system for the production of influenza 




The use of plant viral vectors is another promising tool for transient protein 
expression in plants, enabling rapid onset of transgene expression and systemic spread 
of the virus (75). This approach exploits a modified plant virus to deliver a transgene 
to the host plant nucleus for expression, without stable integration (272). Alternately, 
plant viruses can be used for the display of heterologous epitopes on the surface of 
chimeric particles (416). A range of plant viruses have been exploited as vectors 
including Tobomaviruses, Potexviruses, Potyviruses, Bromoviruses, Comoviruses and 
Geminiviruses (166).  
 
A third approach to transient expression in plants employs A. tumefaciens as a vector 
to deliver viral replicons. The feasibility of this approach was first demonstrated by 
Icon Genetics (http://icongenetics.com/) who exploited agroinfiltration for the 
delivery of a “deconstructed” tobacco mosaic viral vector (TMV) (211, 212). This 
approach enables amplification of the viral replicons leading to expression leves of up 
to 80% of the total soluble protein (TSP) (106). The technology has subsequently 
been exploited for the expression of antigens from hepatitis B and Yersinia pestis 
(148, 301). A similar TMV replicon system delivered by agroinfiltration, termed the 
“launch vector”, has also shown promise for the expression of antigens from Bacillus 
anthracis, HPV, Y. pestis and influenza (53, 215, 226, 239, 324). Our research group 
has pioneered the development of a novel bean yellow dwarf virus replicon system, 
pRIC, delivered by A. tumefaciens (278).  
 
1.12. Factors influencing the expression of heterologous antigens in 
planta 
 
The expression of heterologous proteins in plants is a complex process which is 
influenced by many factors. Although the optimization of expression for any given 
protein can only be determined impirically, several variables have been identified 
which can profoundly influence heterologous protein expression in planta (292). 





1.12.1. Host species 
 
The choice of expression host is an important consideration that influences the yield 
of the final recombinant protein product. A variety of different plant species have 
been explored as potential hosts for the expression of pharmaceutical proteins 
including leafy crops, cereals and legumes, fruit and vegetables; as well as plant cell 
culture systems (91, 207). However, in spite of the extensive range of plant species 
that have been exploited for the experimental production of recombinant proteins, it is 
acknowledged that a limited number of proven systems exist that are capable of 
industrial scale protein production (292).  
 
Tobacco species remain the workhorse of recombinant  plant-derived pharmaceuticals 
and have been adapted as the expression host of choice by several established 
biotechnology companies including the likes of Medicago 
(http://www.medicago.com/), Planet Biotechnology (http://planetbiotechnology.com/) 
and Meristem Therapeutics (http://www.meristem-therapeutics.com/). Tobacco-based 
expression systems offer the advantages of high biomass yields, rapid scalability  and 
existing infrastructure for large scale processing, with minimal concerns for 
contamination of food supplies (342). However, tobacco plants also contain high 
levels of nicotine and other undesirable alkaloids which complicate down-stream 
purification (91, 248). Menassa and colleagues have managed to partly circumvent 
this limitation of tobacco as a production platform by developing a hybrid tobacco 
platform with lower levels of toxic alkaloids (224). Other promising leafy crops 
include lettuce, alfalfa and clover although they all share the limitation of intrinsic 
protein instability (91, 315). Medicago’s early stage research has demonstrated the 
feasibility of alfalfa as an expression host by exploiting  novel promoters to achieve 
high level protein expression in leaf tissue (89). Alfalfa is a particularly attractive 
expression system for glycoproteins as recombinant proteins have homogenous 
glycan structures, ensuring batch-to-batch consistency (91). 
 
The use of cereals crops as expression hosts offers the advantage of improved protein 
stability compared to leafy crops, which require freezing or immediate processing 
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after harvesting (207). The endosperm tissue of seeds enables high levels of protein 
accumulation in specialized protein bodies and storage organelles. Additionally, the 
dessicated environment of seeds ensures that recombinant proteins are protected from 
proteolytic degradation and enzymatic hydrolysis enabling prolonged storage (277). 
Recombinant proteins accumulating in seeds are associated with unusual stability and 
both enzymes and antibodies have been reported to retain full biological activity after 
refrigeration for more than 3 years (184). Maize appears to have been accepted as the 
commercial crop of choice for farming; most likely a reflection of its scalability, ease 
of genetic manipulation and high biomass yields (207). The now defunct, ProdiGene 
Corp championed maize as an expression host successfully producing proteins, such 
as avidin and β-glucuronidase, as well as exploring the feasibility of the system for 
antibodies, enzymes and vaccine antigens (6, 143, 144, 181, 400). Ventria biosciences 
(http://www.ventria.com/) have also adopted cereal crops as their platform of choice 
with promising rice and barley-based expression platforms (315). However, the 
inherent caveat of using food crops as expression hosts is the public concern of 
inadvertent contamination of the food supply chain (207). The highly publicized 2002 
incident, whereby Prodigene Corp was fined for contaminating soybean and maize 
harvests in 2 states in America, did nothing to appease these concerns (293). 
 
Fruit and vegetables are another popular expression host and boast the appeal of 
potentially serving as edible vaccines, with minimal processing (207). Potatoes have 
received a considerable amount of attention and have been evaluated for the 
expression of vaccine antigens such as the rotavirus VP6, Norwalk virus capsid, 
Escherichia coli heat labile enterotoxin (LT-B), human papillomavirus (HPV) L1 and 
hepatitis B surface antigen (24, 127, 357, 414, 417). Potatoes have also been exploited 
for the production of recombinant antibodies and proteins of potential therapeutic 
value including tumour necrosis factor-α and human serum albumin, amongst others 
(85, 250, 308, 395). Prototype potato-derived vaccine antigens for hepatitis B and E. 
coli LT-B have even been evaluated in early stage clinical studies, although licensure 
has not been acheived (350, 357). Tomatoes are also a promising host for edible 
antigens as they are more palatable than raw potatoes and offer a higher biomass yield 
(207). Numerous vaccine relevant antigens have been expressed in tomatoes including 
bacterial antigens from the likes of Yersinia pestis, Corynebacterium diphteriae, 
Bordetella pertussis and Clostridium tetani (4, 331) as well as viral antigens from 
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hepatits B, hepatitis E, Norwalk virus, respitatory syncytial virus and rabies (202, 208, 
219, 300, 417).  Other production hosts have also been investigated including 
bananas, carrots, and lettuce with varying degrees of success (91). Obstacles 
hindering plant-derived oral vaccines include the inability to ensure dose consistency 
without processing, concerns of antigenic tolerance and poor immunogenicity (293). 
This unfortunate limitation is best demonstrated by the clinical evaluation of 
transgenic potatoes containing hepatitis B surface antigen which demonstrated that 25 
times the routinely administered parental dose was required to achieve similar 
immune responses by oral immunization (357). 
 
Plant cell cultures have also been used to produce recombinant proteins, but have 
comprised only a small part of the overall biopharming effort (292). Although plant 
cell cultured-based expression offers the potential for ease of biological containment 
and production under Good Manufacturing Practise conditions, there is little 
advantage over conventional cell culture platforms (293). In spite of this, the most 
recently licenced plant-derived product is a recombinant glucocerebrosidase protein 
produced in plant cells for the treatment of Gauchers disease (313). 
 
Clearly choosing the optimal plant host must take into account a number of variables 
and the best approach is often determined empirically. Studies conducted in our lab 
have reinforced the necessity for an empirical approach by demonstrating the 
differences in recombinant HPV 11 L1 protein yields between different plant host 
species. It has been the experience of our research group that Arabidopsis thaliana 
yields greater amounts of recombinant L1 than tobacco plants. Furthermore, we have 
also found that significant variations exist in the expression levels of closely related 
Nicotiana tabacum varieities (294).  
 
1.12.2. Optimization of the gene coding sequence  
 
Optimization of the gene coding sequence is another crucial consideration for the 
expression of foreign proteins in plants. The observation that tRNA abundance 
correlates with preferred codon usage and the belief that rare codons may be a rate 
limiting step in translation has lead researchers to explore different codon biases for 
30 
 
the expression of proteins in heterologous systems (31, 121). Perlak and colleagues 
demonstrated that optimizing the Bacillus thuringiensis insect control cryIA (b) 
coding sequence, for preferred plant codon usage, culminated in 100-fold increase in 
expression in transgenic tomato and tobacco plants (261). Similar findings were also 
reported for the expression of a plant codon optimized variant of the gene encoding 
the Green Fluorescent Protein in Nicotiana tabacum cv. SR1 (290). 
 
However, the ideal codon usage for a given gene in plants is unpredictable and is best 
determined empirically (292, 294). This point is best illustrated by Biemelt and 
colleagues who described the successful expression of a humanized variant of the 
HPV-16 L1 protein in tobacco plants, but could not detect expression of either the 
wildtype or plantized variants (24). Our group has reiterated these findings by 
demonstrating higher levels of expression of the HPV-16 L1 protein optimized for the 
preferred human codon usage versus both native and plant codon usage. Interestingly, 
in this study the native gene sequence was observed to express at higher levels than 
the corresponding plant codon optimized version (209). Conversely, attempts to 
express variants of HIV gag demonstrated higher levels of expression of the plantized 
gene than the wildtype sequence (294). 
 
These findings clearly highlight the profound, yet unpredictable, influence that codon 
usage can have on the expression of heterologous proteins in plants. Interestingly 
codon optimization of the terminal 40 amino acids of a gene alone, without alteration 
of the remainder of the sequence, may be sufficient to significantly increase gene 
expression (15). A further complication in optimizing the codon usage of a given gene 
is the observation that the preferred codon usage differs between monocotyledonous 
and dicotyledonous plants (15). In addition to the codon usage, other elements in the 
coding sequence also require optimization. These include the removal of message 
destabilizing sequences from the construct as well as modification of the region 
containing the translational start site to suit the expression host (346). Other important 
considerations during optimization of the gene coding sequence include avoiding 
extensive nucleotide runs or repeating codons to avoid the cognate tRNA becoming a 
rate limiting variable in protein expression. Lastly, the impact of codon optimization 
on secondary RNA structure should also be considered to avoid the formation of 




1.12.3. Regulatory elements 
 
The expression of recombinant proteins in a heterologous expression platform is 
largely governed by cis acting elements in the gene sequence. Therefore significant 
effort has been invested in improving the transcription and stability of foreign genes 
in planta. Heterologous promoters are often exploited in planta to increase 
transcription and manipulate the timing or site of recombinant protein expression. 
These promoters are typically divided into 3 main categories, namely: constitutive, 
inducible and tissue specific (75). Strong, constitutive promoters are most commonly 
used to drive transcription of a desired gene, with the cauliflower mosaic virus 35S 
RNA promoter (CaMV 35S) and the maize ubiquitin-1 promoter often being the 
preferred choice for dicotyledonous and monocotyledonous  plant hosts respectively 
(248). However, whilst constitutive promoters are generally associated with the 
highest levels of protein expression, accumulation of excessive levels of the 
recombinant protein often has a deleterious affect on host metabolism. Alternatively, 
organ and tissue specific promoters, as well as inducible promoters may be employed 
to circumvent these negative effects on plant growth and development (75, 315).  
 
In addition to the CaMV 35S promoter, other plant viral promoters have also shown 
promise including;  the promotor of milk vetch dwarf virus component 8 (321), a 
cassava vein mosaic virus promoter (369) and the C1 gene promoter of cotton leaf 
curl multan virus (409) amongst others. Promoters derived from A. tumefaciens, such 
as the nopaline synthetase and mannopine synthetase promoters, as well as various 
plant promoters have also been investigated (5, 75, 129). In some cases, researchers 
have even engineered hybrid promoters comprising of chimeric elements derived 
from different regulator sequences such as in the case of the synthetic Mac promoter 
(56, 242). Inducible promoters have also been used to regulate the expression of 
foreign genes in planta and offer the potential to minimize the toxicity associated with 
overexpression of heterologous proteins (315). The sucrose starvation inducible 
promoter of the rice alpha amylase gene has been exploited to produce a number of 
recombinant proteins with human therapeutic potential including; human growth 
hormone, human granulocyte macrophage-colony stimulating factor and human 
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interferon gamma (52, 165, 320). Another promising inducible promoter system is the 
stress responsive hydroxyl-3-methylglutaryl CoA reductase 2 promoter, used by 
CropTech Corp, to rapidly induce recombinant protein expression during the 
harvesting of plant leaves (207). Other inducible promoter systems have also been 
described that are regulated by chemicals such as ethanol, copper, ecdysone, 
oestrogen, tetracycline and glucocorticoids (252). It has also been reported that 
promoter activity can be further improved by stacking transcriptional activators in the 
promoter region (118). 
 
In addition to the promoter, a number of other cis elements also influence 
recombinant gene expression in plants. Studies have shown that flanking the gene of 
interest with heterologous scaffold or matrix attachment regions can significantly 
improve protein expression in plants (2, 3, 411). Although their exact mechanism of 
action is undefined they are believed to function by interacting with plant nuclear 
scaffolds to promote the recruitment of transcription factors to drive gene expression 
(335). The use of heterologous polyadenylation sites has also been exploited to 
improve mRNA stability and ultimately levels of the recombinant protein (281). 
Similarly, the inclusion of 5’ untranslated regions in the coding sequence, such as 
those from alfalfa mosaic virus mRNA 4 or the rice polyubiquitin gene, have also 
been shown to improve the translational efficiency of heterologous genes (68, 203). 
 
1.12.4. Subcellular localization 
 
The subcellular localization of a heterologous protein impacts both the stability and 
yield (90). Therefore the choice of localization is an important variable, especially 
considering that stability is cited as the single greatest factor limiting the yield of 
plant-produced recombinant proteins (305).  The use of heterologous signal peptides 
can be exploited to target a recombinant protein to the specific subcellular localization 
that is best suited to its accumulation (346).  Conversely, in the absence of any 
heterologous signal peptide mediating translocation through the cell secretory system 
or retention in a particular organelle, recombinant proteins will accumulate in the 
cytosol (207, 346). A number of different localization strategies have been explored 
involving targeting of recombinant proteins to the cytosol, ER, chloroplast, storage 
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vacuoles and oil bodies (315). The ER offers a protease free environment containing 
molecular chaperones to assist with protein folding and enzymes that mediate 
glycosylation (207, 245). Additionally the ER can tolerate high levels of heterologous 
protein accumulation without any adverse effect on the development of the plant host 
(394).  Retention of recombinant proteins in the ER is typically achieved by fusing the 
carboxy terminal HDEL or KDEL sequence to the protein of interest (108, 260). 
Another ER retention signal derived from γ-zein, a maize prolamin,  has also shown 
promise to increase recombinant protein yields. This particular signal also promotes 
the formation of ER-associated protein bodies, aiding downstream processing and 
recovery of the protein (210).  A comparative study comparing the protein yields of 
recombinant Phaseolin, when using the KDEL and γ-zein ER retention signals, 
demonstrated the latter to be superior. The γ-zein tagged protein accumulated at 
approximately 3.5% of the TSP compared to the 0.5% achieved by the KDEL tagged 
protein (372).  
 
Recombinant proteins can also  be targeted to the apoplast by the use of a signal 
peptide that directs the recombinant proteins through the secretory pathway into the 
extracellular spaces between leaf cells (90). Antibodies generally exhibit lower 
stability in the apoplastic spaces than when retained in the ER, presumably a 
reflection of the higher levels of protease activity in the plant apoplast (57, 75). In 
spite of this, apoplastic localization appears to be amenable to high levels of influenza 
haemagglutinin production as demonstrated by our group and Medicago, who have 
advanced their candidate vaccine into clinical trials (63, 183, 238).   
 
Unsurprisingly, considering their ancient prokaryotic origin, the chloroplast is well 
suited to the expression of bacterial antigens (292, 415). The expression of genes in 
the plant chloroplast can be achieved by biolistic transformation or by treatment with 
polyethylene glycol (40). This approach boasts the advantage of high transgene copy 
number, resulting from homologous recombination between the gene of interest and 
the plastid genome, and has been reported to result in high recombinant protein yields 
in excess of 45% of the TSP in the case of the Bacillus thuringiensis CRY2Aa2 
protein (59). Chloroplasts have also been exploited to express heterologous proteins 
of viral, protozoan and human origin (40). Staub and colleagues reported the 
expression of human somatotropin in tobacco chloroplasts with the recombinant 
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protein accumulating to levels in excess of 7% of the TSP (339). Notably, expression 
of HIV-1 pr55
gag 
VLPs have been reported in transformed tobacco chloroplasts at 
levels of between 7-8% TSP (310). Recombinant products expressed in the cytoplasm 
can be targeted to accumulate in the chloroplast by exploiting a chloroplast-transit 
sequence, such as the transit peptide derived from the potato rbcs1 gene (209). Our 
research group has also reported high transient expression levels of both HPV-16 L1 
and truncated HIV Gag proteins in tobacco chloroplasts using this approach (209, 
294). Although transformed chloroplasts also enable biological containment of 
transgenes in the absence of post transcriptional gene silencing (PTGS), their inability 
to mediate N-glycosylation is a major limitation (67, 415). In spite of this, a 
chloroplast-based expression platform has been adopted by Chlorogen Inc. for the 
development of therapeutic proteins and vaccines (315). 
 
Recombinant proteins can also be targeted to oil bodies in seeds by constructing 
translational fusions with oleosin enabling ease of downstream centrifugation by 
floatation centrifugation (315). This approach has been exploited for the production of 
the anticoagulant, hirudin (255). SemBioSys Genetics Inc. 
(http://www.sembiosis.com/) has developed an oleosin fusion protein for the 
expression of heterologous proteins in safflower or oilseed rape (91). 
 
The optimal subcellular localization for any given protein is governed by a number of 
variables including the origin of the protein, its inherent stability and the complexity 
of post translational modifications and glycosylation required. It is our experience that 
the ideal subcellular compartment is best determined empirically for each protein, due 
to the huge discrepancies in expression levels that exist between different 
compartments (292, 294). This phenomenon is best illustrated by a comparative 
expression study of the E. coli heat labile toxin which differed in expression of up to 4 
orders of magnitude across 6 cellular compartments (347). It has been suggested that 
these differences are largely a reflection of differences in biochemical environment 
and space constraints inherent in different plant cellular compartments (346). 
Consistant with these findings, Wirth and colleagues expressed Human epidermal 
growth factor in the cytoplasm and apoplast by both nuclear transformation and a 
viral vector. In both cases, the recombinant protein was barely discernable in the plant 
cytoplasm but detectable levels were observed in the plant apoplast (399). Our group 
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has reported similar findings for a number of different antigens. A comparative 
expression study examining the influence of subcellular localization on the expression 
of the HPV-16 L1 capsid protein revealed higher levels of protein accumulation in the 
chloroplast of N. benthamiana plants, than in the ER or cytoplasm. Curiously, the 
poorest expression levels of the antigens were observed in the ER (209). A similar 
study revealed higher expression levels of the HIV Gag antigen in the chloroplast than 
in either the cytoplasm or ER (292). Similar variations were observed by our research 
group for influenza haemagglutinin antigens, this time however the apoplast was 
found to be optimal (238). 
 
1.12.5. Post Transcriptional Gene Silencing (PTGS) 
 
Transgene silencing is a major obstacle for the economic exploitation of plants as an 
expression platform for recombinant proteins (394). PTGS, the phenomenon whereby 
homologous double stranded RNA molecules mediate the destruction of specific 
mRNA transcripts, has been demonstrated to be responsible for the cessation of 
recombinant protein expression in planta after several days (42, 373, 387). The effects 
of PTGS appears most pronounced for genes present in multiple copies or under the 
influence of strong constitutive promoters suggesting that this silencing mechanism is 
directly correlated with gene expression levels (75). 
 
Several strategies have been implemented to mitigate the effects of PTGS and 
increase the yield of recombinant proteins produced in plants. The most commonly 
used method involves the co-expression of a viral PTGS suppressor protein such as 
the HC-Pro suppressor from Tobacco potyvirus, the p19 supressor from Tomato 
bushy stunt virus and the NSs suppressor from tomato spotted wilt virus (155, 351, 
373). Voinnet and colleagues have reported an excess of 50-fold increase in 
expression of a range of proteins in N. benthamiana plants when co-expressing the 
p19 silencing suppressor (373). This suppressor has also been adopted by Medicago 
as part of their expression platform and has enabled the production of a number of 
chimeric VLPs for Rabies, HIV and varicella zoster amongst others (61). Similarly, 
Rosenberg and colleagues exploited the p19 supressor to express high levels of 
broadly neutralizing anti-HIV monoclonal antibodies in plants (289). Our research 
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group routinely uses the NSs silencing suppressor protein to optimize transgene 
expression in planta and has successfully reported the expression of antigens from the 
human papillomavirus, influenza virus and HIV using this approach (209, 227, 238, 
264). More recently, the 126K protein from Pepper mild mottle virus was 
demonstrated to be a superior suppressor of PTGS when compared to P19, HC-Pro 
and Begomovirus AC2 supressor proteins using a green fluorescent protein reporter 
gene in N. benthamiana (332). 
 
A number of other strategies have also been explored to circumvent the influence of 
PTGS. It has been suggested that Agrobacterium–mediated transformation is likely to 
lead to lower levels of PTGS than biolistic transformation due to the lower transgene 
copy number (64). Lastly, the use of matrix attachment regions flanking the coding 
sequence of the gene of interest has also been reported to lower the levels of PTGS 
induced upon expression of the protein, presumably by interfering with the formation 
of antisense RNA (361). 
 
1.13. Project rationale 
 
Despite the promise of strategic intervention strategies and biomedical advances in 
HIV prevention,  a prophylactic vaccine remains humanity’s best hope to curb the 
relentless spread of the HIV-1 pandemic (265). The collective body of research 
suggests that a successful prophylactic vaccine will likely comprise of multiple 
components to induce the breadth of immunity required to prevent HIV-1 infection 
(178, 341, 378). The incumbent costs of such an immunization regimen may prove to 
be prohibitive; particularly in developing countries where the pandemic is 
disproportionately severe (314). This is particularly evident in the case of HPV 
vaccines which, despite irrefutable efficacy, are too expensive to be implemented in 
the extended immunization schemes of developing countries (104, 311). Similarly, in 
the case of the Hepatitis B Virus vaccine, 15 years elapsed after the development of a 
successful vaccine before the vaccine cost became affordable for its implementation 




In this study the feasibility of developing a DNA prime-recombinant plant-derived 
protein vaccine combination will be evaluated. The priming DNA vaccines will be 
constructed from the pTHPcapR DNA vaccine vector which enables dose sparing by 
exploiting a porcine circovirus type 1 enhancer element, to drive high levels of 
antigen expression (354). The recombinant protein boost will be produced using a 
transient A. tumefaciens mediated plant-based expression platform to reduce 
production costs associated with heterologous expression systems (293). Additionally, 
this approach may result in an improved immunogen with the capacity to induce 
neutralizing antibodies with a greater breadth than associated with currently used 
vaccine antigens. The expression of these immunogens in plants may result in VLPs 
with an improved glycoprotein density or improve the accessibility of important 
antibody epitopes resulting from plant-specific glycosylation patterns. The DNA 
prime-recombinant protein boost vaccination is well established for the induction of 
neutralizing antibodies against the HIV-1 envelope glycoprotein. Several studies have 
demonstrated that the DNA prime-recombinant envelope protein boost combination is 
capable of inducing neutralizing antibodies of improved titer and longevity than either 
approach alone (378). 
 
Plants are uniquely suited to the production of cheap recombinant proteins as plant 
expression platforms are estimated to reduce generic production costs by at least 31% 
(293). Additionally, plant-based expression platforms are infinitely scalable and 
would be able to accommodate production levels suitable to the implementation of a 
vaccine on a global scale, such as is necessitated by the HIV-1 pandemic (293, 410). 
Recent advances in plant biotechnology have demonstrated the viability of plant-
based expression platforms for influenza haemagglutinin-based subunit vaccines, with 
high yields of recombinant proteins that are immunogenic in both pre-clinical and 
clinical contexts (157, 158, 183, 226, 323–326, 336). These studies, stemming largely 
from the inability of conventional influenza vaccine production platforms to respond 
to pandemic outbreaks, have demonstrated that plant-derived antigens are capable of 
competing with existing production platforms. Notably, Medicago, a clinical-stage 
biopharmaceutical company, reported the successful production of fully formulated 
haemagglutinin VLP vaccines within as little as 3 weeks (62). The research team 
responsible for these findings reported that, when targeted to the apoplast of plant 
leaves, the full length haemagglutinin protein had the capacity to form highly 
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immunogenic particulate structures.  Although the mechanism of this assembly 
remains uncertain, it has been suggested that these proteins bud from the plasma 
membrane into the apoplastic spaces of the plant leaf, along with host derived lipids 
(63) (Figure 1.9). Further research by Medicago has demonstrated that this approach 
can be exploited to generate chimeric particles for the HIV-1 envelope glycoprotein, 
Rabies glycoprotein G and Varicella Zoster Virus glycoprotein, when the antigen of 














Figure 1.9: Positive staining transmission electron microscopy demonstrating H5 VLP 
accumulation in the apoplast of agroinfiltrated plant leaves (62). The apoplastic space 
containing the VLPs is enlarged (bottom left) and position of the cell wall (CW), plasma 
membrane (pm) and VLPs indicated. 
 
Our lab has developed a similar A. tumefaciens-mediated transient expression 
platform for recombinant haemagglutinin proteins which could potentially be adapted 
to the production of HIV-1 envelope subunit vaccines (238). Similar to Medicago’s 
reports, we have also achieved the formation of haemagglutinin VLPs in the absence 
of other structural proteins, when the recombinant proteins are targeted to the 
apoplastic spaces of plant leaves (Ed Rybicki; personal correspondence) (63). To date 
this phenomenon has only been demonstrated for the full length haemagglutinin 
protein of influenza, or for antigens fused to the influenza H5 or H3 transmembrane 
and cytoplasmic domains (61, 63). However it is plausible that other structurally 
homologous glycoproteins, such as the HIV-1 envelope glycoprotein, may also 
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possess the ability to form similar enveloped particles.  The HIV-1 envelope 
glycoprotein is structurally similar to influenza haemagglutinin, both of which form 
trimeric glycoprotein complexes, in the context of the native virion (134) (Figure 
1.10). Therefor the construction of chimeric immunogens that retain the important 
structural features of these type 1 transmembrane glycoproteins may enable the 
formation of higher order oligomers, possibly even trimers. Ye at al. have reported 
the formation of trimeric oligomers when expressing a fusion protein comprising of 
gp41 and the HA1 portion of the influenza HA protein (412). Similarly, the fusion of 
the transmembrane region from the Epstein-Barr Virus major envelope glycoprotein 
gp220/350 to the gp120 portion of HIV-1 envelope has been associated with the 
formation of oligomeric species, although the study in question did not determine 
whether these were in fact trimeric (72). 
 
VLPs are a particularly promising approach for the induction of robust immune 
responses by vaccination. They are highly immunogenic due to their large size and 
dense repetitive arrays of protein which promote cross-linking of B cells (7, 47, 117). 
They also activate both MHC class I and MHC class II immune pathways culminating 
in the induction of both humoral and cellular immunity (47, 117, 172, 199). VLPs are 
efficiently taken up by professional antigen presenting cells, particularly dendritic 
cells (33, 47, 117, 172). The use of VLP-based vaccines is also considerably safer 
than other vaccine approaches, yet considerably more immunogenic than conventional 
subunit vaccines (33, 78, 199). Additionally, the formation of high density envelope 
particles would be a promising step towards developing a prophylactic HIV-1 VLP 
vaccine by circumventing the low envelope densities associated with conventional 
approaches (263). 
 
The construction of chimeric HIV-1 envelope particles with heterologous domains 
from other viral proteins is not unprecedented. Deml and colleagues managed to 
successfully increase the surface density and stability of HIV-1 envelope 
glycoproteins on Pr55
gag
 particles by fusing the exterior glycoprotein (gp120) to the 
Epstein-Barr virus major envelope glycoprotein gp220/350 transmembrane domain. 
The authors also confirmed the formation of higher order oligomeric species for the 
chimeric envelope proteins, consistent with the oligomeric structure of the native 
HIV-1 envelope glycoprotein (72). Preclinical evaluation of these vaccines confirmed 
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their immunogenicity in both murine and nonhuman primate models, with the 
induction of both humoral and cellular immunity (73, 375). Ye et al., constructed a 
chimeric HIV-1 envelope antigen by fusing the gp41 subunit of the HIV-1 to the HA1 
subunit of influenza haemagglutinin. The resulting protein retained its ability to form 
trimers, demonstrated increased reactivity with selected monoclonal antibodies and 
induced neutralizing antibodies in immunized mice (412). The increased epitope 
exposure, arising from the altered conformation of the chimeric antigens, also 
culminated in the induction of MPER-specific neutralizing activity in guinea pigs 
(413). Lastly, Wang et al., demonstrated that by substituting the native HIV-1 
envelope transmembrane and cytoplasmic domains, with the analogous regions from 
influenza haemagglutinin, the envelope glycoprotein density on the surface of Pr55
gag
 


















Figure 1.10: Schematic diagram of the virion bound glycoproteins of A) HIV-1 and B) 
influenza infecting their respective cells (modified from Hedestam et al.(134)). In both 
figure A and B surface rendered cryo-electron tomographic images are provided on the left. 
To the right of each figure the trimeric glycoprotein complex is depicted, as a structure based 
model, interacting with a host receptor to mediate cellular entry. The virion surface is 






Despite the extensive research into HIV-1 vaccine development, only 2 studies have 
reported the successful expression of an envelope candidate in plants which retains 
the neutralizing epitopes of the functional glycoprotein (61, 289). Despite successfully 
generating chimeric HIV-1 envelope-based particles Medicago are not pursuing these 
candidate vaccines further (61). More recently, Rosenberg and colleagues have 
reported the production of different glycoforms of an extensively engineered gp140 
protein via both transient and transgenic expression. The recombinant antigen was 
antigenically representative of the native glycoprotein and demonstrated reactivity 
with selected prototype monoclonal antibodies (289). Immunogenicity studies for 
these vaccine candidates are ongoing and the scientific community eagerly awaits 
their outcome. Lastly, the analogous SIV protein, gp130, has been expressed in 
transgenic corn, although the immunogenicity of the vaccine has not been reported 
(145).  
 
This project will explore the viability of 3 novel HIV-1 subtype C immunogens using 
genetic immunization and plant expression platforms. The DNA vaccines constructed 
in this study will be evaluated in vivo to evaluate expression levels and subcellular 
localization of the immunogen. We will also explore the feasibility of adapting our A. 
tumefaciens-transient expression platform, used for influenza haemagglutinin subunit 
vaccines, for the production of recombinant HIV-1 envelope proteins (238). In this 
study we will apply a systematic approach to investigate various parameters known to 
influence the expression of recombinant antigens in plants. We will also explore 
various purification strategies to recover our protein from contaminating plant 
proteins.We will specifically focus on the production of variants of an HIV-1 subtype 
C envelope protein, with the hope of generating HIV-1 envelope particles. To account 
for the possibility that the formation of glycoprotein particles in planta is an intrinsic 
property of the influenza transmembrane and cytoplasmic regions, we will also 
construct chimeric proteins containing these elements. It is noteworthy that Medicago 
were unable to detect expression of their HIV-1 envelope protein when expressed 
without being fused to the cytoplasmic and transmembrane regions of the influenza 
glycoprotein, suggesting that these elements may somehow aid with protein 




1.14. Aims and Objectives 
  
The ultimate aim of this project is to develop a heterologous DNA prime-recombinant 
protein boost vaccination scheme, that is both affordable and relevant to the HIV 
strains predominating in Sub-Saharan Africa. The secondary aim of this study will be 
to explore the feasibility of a plant-based expression platform for the production of 
recombinant HIV-1 envelope subunit vaccines, with the capacity to induce 
neutralizing antibodies. The study comprises a pilot project to investigate whether 
plants have the capacity to express the HIV-1 envelope glycoprotein and to 
investigate the various parameters that influence the expression of these 
immunogens in planta. Matched DNA vaccines will be constructed and characterized 
for each recombinant protein, enabling their potential use in a prime-boost 
immunization regimen at a later stage. The vaccines will be constructed from a 
subtype C HIV-1 isolate that conforms to a stringent series of criteria that are likely to 
favour the induction of cross-neutralizing antibodies. The study will also address the 
influence of substituting analogous regions of the influenza H5 transmembrane 
subunit with gp41 on recombinant protein expression. This approach will also be 
investigated in order to potentially improve the immunogenicity of the antigens by 
altering the exposure of antibody sensitive epitopes. Additionally, these influenza H5 
elements may faciliate the formation of particulate structures in planta, containing 
high densities of the surface-bound antigens, which are expected to be highly 
immunogenic. 
 
The recombinant proteins will be transiently expressed in the leaves of tobacco plants 
and targeted to the apoplastic spaces between leaf cells. Recombinant A. tumefaciens 
strains will be infiltrated into N. benthamiana plants and the influence of various 
parameters, on the expression of the recombinant antigens, will be systematically 
investigated: 
  
 The timing and duration of protein expression in leaf tissue following infiltration 
of tobacco plants with recombinant A. tumefaciens strains. 




 The use of a detergent to extract crude leaf protein under stringent denaturing 
conditions  
 The influence of the density of the bacterial suspension infiltrated into tobacco 
leaves on recombinant antigen expression 
 The feasibility of recovering recombinant protein directly from the apoplastic 
spaces of agroinfiltrated plant leaves.  
 
DNA vaccines will be constructed for each immunogen using the pTHPcapR DNA 
vaccine vector and evaluated in vivo (354). As a preliminary indication of their 
feasibility, expression of the antigens from the pTHPcapR DNA vaccines will be 
verified by immunostaining and western blotting of transfected cells. 
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CHAPTER 2:                         
MATERIALS AND METHODS 
 
2.1. Bacterial strains and culturing conditions 
 
2.1.1. Escherichia coli DH5α 
 
E. coli DH5α cells were used as a surrogate cloning host for the construction of the 
recombinant pTRA-A plant expression vectors and pTHPcapR vectored DNA 
vaccines used in this study. Liquid cultures were cultivated in Luria Bertani (LB) 
broth and incubated overnight at 37⁰C, with gentle agitation. E. coli DH5α cells 
grown on solid media were inoculated onto Luria Agar (LA) and incubated overnight 
at 37⁰C. Both liquid and solid media were supplemented with antibiotics, when 
appropriate, to impose selective pressure on the bacteria to ensure the maintenance of 
episomal plasmid vectors. 
 
2.1.2. Agrobacterium tumefaciens GV3101::pMP90RK 
 
A. tumefaciens GV3101::pMP90RK cells were obtained from Dr. Rainer Fischer 
(Fraunhofer Institute for Molecular Biology and Applied Ecology, IME, Germany). 
The Agrobacterium strain contains the pMP90RK helper plasmid which encodes the 
vir genes, enabling the transfer of foreign DNA from a disarmed Ti plasmid to the 
nucleus of the plant host. Collectively A. tumefaciens GV3101::pMP90RK and a 
disarmed Ti plasmid form a functional binary vector system capable of mediating 
expression of a foreign gene in planta. 
 
Liquid cultures were propagated in LB media, supplemented with 50 µg/ml 
rifampicin (Sigma-Aldrich, South Africa) and 30 µg/ml Kanamycin (Sigma-Aldrich, 
South Africa), and shaken overnight at 27⁰C. In contrast, bacteria grown on solid 
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media were inoculated onto LA plates and incubated at 27⁰C for 2-3 days. Both solid 
and liquid media were further supplemented with antibiotics, when appropriate, to 
impose selective pressure on the recombinant bacteria. 
 
2.1.3. A. tumefaciens LBA4404 (pBIN-NSs) 
 
The A. tumefaciens LBA4404 (pBIN-NSs) strain was supplied by Dr Marcel Prins 
(Laboratory of virology, Wageningen University, Binnenhaven, Netherlands). This 
strain of A. tumefaciens has been transformed with an episomal plasmid vector that 
expresses NSs, an RNA silencing suppressor derived from Tomato spotted wilt virus 
(351). A. tumefaciens LBA4404 (pBIN-NSs) has been used extensively within our 
group to prolong the duration of protein expression and to improve the yield of 
recombinant proteins in plants, by mitigating the effect of PTGS (209, 238, 264).  
 
Liquid cultures of A. tumefaciens LBA4404 (pBIN-NSs) were propagated in LB broth 
supplemented with 2mM MgSO4, 50 µg/ml rifampicin (Sigma-Aldrich, South Africa) 
and 30 µg/ml kanamycin (Sigma-Aldrich, South Africa). The growing cultures were 
incubated overnight at 27°C, with agitation at 200 rpm. The propagation of  A. 
tumefaciens LBA4404 (pBIN-NSs) on solid media was achieved by the transfer of a 
bacterial inoculum onto Luria agar plates, supplemented as for broth cultures, and 
their subsequent incubation at 27°C for 2-3 days. 
 
 
Table 2.1: Summary table of selectable markers for A. tumefaciens and E. coli host 
strains used in this study. 
 
Bacterial Strain Resistance gene Concentration 
(µg/ml) 
E. coli DH5α None NA 
A. tumefaciens GV3101::pMP90RK Rifampicin 30 
Kanamycin 50 






2.2. Preparation of competent bacterial cells for genetic manipulation  
 
2.2.1. Preparation of competent Escherichia coli DH5α cells  
 
Competent DH5α cells were prepared using an amended version of the DMSO 
method described by Chung and Miller (38). A single colony of DH5α cells was 
propagated overnight in 5 ml of LB media as described in Section 2.1.1. The 
following morning a 250 µl inoculum of the growing culture was transferred to 50 ml 
of fresh LB broth and the cells cultivated, as before, until early logarithmic phase 
growth (OD600 0.2-0.4). The entire culture volume was transferred to a pre-chilled 50 
ml falcon tube and the cells harvested by centrifugation at 4000 rpm, for 5 minutes.  
The supernatant was discarded and the bacterial pellet was gently resuspended in 5 ml 
of ice cold transfer and storage buffer (TSB) (Appendix B) by aspiration with a 
Gilson pipette. The bacterial suspension was incubated on ice for 10 minutes and then 
stored at -70°C in 100 µl aliquots. The competency of the cells was assessed by 
transformation with 0.1 ng and 1 ng aliquots of pSK plasmid DNA and determined as 
the number of colony forming units yielded per microgram of DNA transformed. 
 
2.2.2. Preparation of electrocompetent Agrobacterium 
tumefaciens GV3101::pMP90RK cells 
 
Electrocompetent Agrobacterium tumefaciens GV3101::pMP90RK were prepared as 
described by Shen and Forde, 1989 (316). A glycerol stock of Agrobacterium 
tumefaciens GV3101::pMP90RK cells was propagated in 100 ml LB media and the 
culture cultivated until logarithmic phase growth (OD600 0.5-1.0), as outlined in 
Section 2.1.2. The following morning, the entire culture volume was equally 
distributed between 2 sterile falcon tubes and the bacterial cells harvested by 
centrifugation at 4000 rpm, for 10 minutes. The supernatant was discarded and the 
cells resuspended in 50 ml sterile water.  The cells were pelleted by centrifugation, as 
before, and the rinse step repeated. The bacterial suspension was then subjected to 
centrifugation at 4000 rpm for 10 minutes, the supernatant discarded and the cell 
pellet resuspended in 10 ml 10% glycerol. The glycerol wash was repeated and the 
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pellet resuspended in a final volume of 5 ml sterile 10% glycerol. The bacterial 
suspension was then divided into 500 µl aliquots and frozen at -70 ⁰C until required. 
 
2.3. Transformation of bacterial cells 
 
2.3.1. Transformation of competent E. coli DH5α cells by heat 
shock 
 
The transformation of competent E. coli DH5α cells was achieved using the protocol 
outlined by Chung and Miller (38). Aliquots of 100 µl of competent E. coli cells were 
thawed on ice prior to the transformation procedure. An aliquot of 0.1-10 ng of 
plasmid DNA was added to the competent cells and the contents gently mixed by 
aspiration with a Gilson pipette. The bacterial suspension was incubated on ice for 20-
30 minutes and then heat shocked at 42°C for 30 seconds. The samples were then 
incubated on ice for a further 2 minutes prior to the addition of 900 µl of TSGB media 
(Appendix B). The cells were incubated at 37°C, with shaking, for 1 hour to enable 
induction of the antibiotic resistance gene encoded by the plasmid. Aliquots of 100 µl 
and 200 µl of each transformation sample were plated on LA media, supplemented 
with the appropriate antibiotics. The remaining sample volume was subjected to 
centrifugation at 5000 rpm, for 5 minutes, the cell pellets resuspended in 200 µl of 
fresh LB broth and plated as before. All experimental transformations were performed 
in parallel with a positive control transformation comprising of 0.1 ng of pSK plasmid 
DNA and a negative control transformation whereby plasmid DNA was omitted.  
 
2.3.2. Transformation of A. tumefaciens GV3101::pMP90RK 
by electroporation 
 
Recombinant A. tumefaciens GV3101::pMP90RK strains were generated by 
electroporation using the method described by Shen and Forde, 1989 (316).   
Electrocompetent A. tumefaciens GV3101::pMP90RK cells, prepared as indicated in 
Section 2.2.2, were thawed on ice prior to the transformation procedure. An aliquot of 
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100 µl of competent cells was transfered to a sterile eppendorf tube containing 400 ng 
of plasmid DNA. The contents of the eppendorf were gently mixed and the sample 
incubated on ice for 5 minutes.  The sample was then transferred to a chilled 1 mm 
gap electroporation curvette and electroporated at 1.8 kV, 25 µF and 200 Ω using the 
GenePulser (BioRad), before being returned to ice. The samples were then transferred 
to sterile eppendorf tubes and supplemented with 900 µl of LB media. The cells were 
incubated at 27⁰ C, for 2 hours with gentle agitation prior to plating. Aliquots of 100 
µl and 200 µl of the transformation reaction were plated on LA media, containing the 
appropriate antibiotics, as indicated in Section 2.1.2. The remaining cells were 
harvested by centrifugation at 5000 rpm, for 5 minutes, resuspended in 200 µl of fresh 
LB media and plated as before. All transformations were performed in parallel with a 
positive control of pTRA-A: H5 plasmid DNA and a negative control whereby 
plasmid DNA was omitted. 
 
2.4. Recovery of HEK 293 cells from liquid nitrogen 
 
A cryovial of HEK 293 cells, stored in liquid nitrogen, was obtained from the 
ATCC® (CRL-1573™). The cells were rapidly thawed by gentle agitation in a 37⁰C 
water bath. The outside of the cryovial was decontaminated by swabbing with 70% 
ethanol and the contents transferred to a sterile tube containing 9 ml complete Growth 
Media (GM) (Appendix B). The cells were harvested by centrifugation at 125 ×g for 
5 minutes and the supernatant discarded. The cell pellet was resuspended in 5 ml 
complete GM and the cell suspension dispensed into a 25 cm
2
 culture flask.  
 
2.5. Growth and maintenance of HEK 293 cells  
 
HEK 293 cells were cultivated at 37⁰C, in an incubator with 5% atmospheric CO2 and 
95% humidity. The growth medium was replaced every 2-3 days, with fresh GM, 
until the cell monolayers were confluent. Confluent monolayers were passaged 
approximately every 3 days with a subculture ratio of 1:6. The culture medium was 
discarded and residual serum removed by rinsing the monolayers with 5 ml sterile 
Gibco® Dulbecco’s Phosphate Buffered Saline (dPBS) (without magnesium or 
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calcium) (Gibco®, South Africa). A 2 ml aliquot of 1× Trypsin-EDTA solution  
(Gibco®, South Africa)  was gently dispensed over the cell monolayer and the flask 
incubated at 37⁰C for 2 minutes to facilitate detachment of the cells. The reaction was 
terminated by the addition of 8 ml of complete GM and the cells gently resuspended 
in the medium. An aliquot of 20 µl of the cell suspension was diluted 2-fold in 0.4% 
Trypan Blue (Gibco®, South Africa) and 10 µl transferred to a haemocytometer. The 
number of viable cells in the 4 major quadrants were determined and multiplied by 
5000 to obtain an estimate of the number of cells per ml and an appropriate volume 
used for sub-culturing. 
 
2.6. Growth of N. benthamiana biomass 
 
N. benthamiana seeds were propagated in flat trays filled with soil. The plants were 
incubated at 22⁰C, under a 16 h light/8 h dark photocycle. Individual seedlings were 
transplanted to pots after 3 weeks, containing a 2:1 ratio of peat to vermiculite, and 
left to grow under the same environmental conditions. Plants were infiltrated with 
recombinant A. tumefaciens 6-8 weeks after germination and returned to the 
greenhouse until the optimal time for protein extraction. 
 
2.7. Isolation of recombinant plasmid DNA 
 
2.7.1. Small scale isolation of plasmid DNA from recombinant 
E. coli cells 
 
Small scale plasmid DNA isolations were performed using the method described by 
Sambrook and Russel (297). A single recombinant E. coli colony was inoculated into 
800 µl of LB media and cultured overnight as outlined in Section 2.1.1. The 
following morning the cells were harvested by centrifugation at 5000 rpm for 3 
minutes, the supernatant discarded and the bacterial pellet resuspended in 200 µl of 
solution I (Appendix B). A 400 µl aliquot of freshly prepared solution II (Appendix 
B) was added to the bacterial suspension and the samples incubated on ice for 5 
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minutes to lyse the cells. The lysis reaction was terminated by the addition of 300 µl 
of solution III (Appendix B). The samples was inverted several times to mix the 
contents and the contaminating protein and residual bacterial contaminants pelleted by 
centrifugation at 14000 rpm, for 5 minutes. The supernatant was retained and 
transferred to a sterile eppindorf tube containing 600 µl of isopropanol. The tube was 
inverted several times and the DNA was precipitated by subjecting the sample to 10 
minutes of centrifugation at 14000 rpm. The supernatant was discarded and 200 µl of 
70% ethanol was added to the DNA pellet. The pellet was rinsed to remove any 
residual salts by centrifugation at 14000 rpm for 5 minutes. The ethanol was carefully 
removed with a Gilson pipette and the pellet resuspended in 50 µl sterile water. The 
DNA was stored at -20⁰ C until needed. 
 
2.7.2. Medium scale isolation of plasmid DNA from 
recombinant E. coli cells 
 
Medium scale plasmid DNA isolations were performed using the Genopure Plasmid 
Midi Kit (Roche, South Africa), in accordance with the protocol described for low 
copy number plasmid DNA. A single recombinant E. coli colony was inoculated into 
50 ml of LB media and cultured as described in Section 2.1.1. The bacterial cells 
were harvested by centrifugation at 4000 rpm, for 10 minutes, and the spent media 
discarded. The resulting cell pellet was gently resuspended in 8 ml of chilled 
Resuspension buffer, supplemented with RNAse A.  An aliquot of 8 ml of Lysis 
buffer was added to the bacterial suspension and the tubes inverted gently. The 
sample was incubated at room temperature for 2 minutes, prior to termination of the 
lysis reaction by the addition of 8 ml chilled Neutralization buffer. The cell lysate was 
inverted gently several times and incubated on ice for 5 minutes. The sample was then 
applied to an equilibrated piece of folded filter paper, placed in the mouth of a sterile 
50 ml falcon tube, and allowed to drain through under the influence of gravity. A 
NucleoBond AX 100 Column was mounted in the mouth of a sterile 50 ml falcon tube 
and equilibrated with 2.5 ml of Equilibration Buffer. The flow through was discarded 
and the bacterial lysate applied to the column. The flow through was retained and 
reapplied to the column for a second time followed by 3 sequential wash steps of the 
membrane, to which the DNA had bound, with 4 ml Wash Buffer. The column was 
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transferred to another sterile 50 ml conical tube and the DNA eluted in 5 ml of 
prewarmed Elution buffer. Aliquots of 1 ml of the eluate were transferred to sterile 
eppendorfs containing 700 µl isopropanol. The DNA was precipitated by 
centrifugation for 10 minutes and the pellet rinsed by the addition of 200 µl 70% 
ethanol. The sample was centrifuged at 14000 rpm for 5 minutes and the residual 
ethanol drawn off with a Gilson pipette. Lastly, a 20 µl aliquot of sterile water was 
added to each sample and the samples left at 4⁰C for an hour to resuspend. The 
samples were pooled together and then stored at -20⁰C until needed. 
 
2.7.3. Small scale isolation of crude plasmid DNA from 
recombinant A. tumefaciens 
 
Crude plasmid DNA isolations from recombinant A. tumefaciens were achieved using 
the Biospin Plasmid DNA Extraction Kit (Bioflux, China). A single recombinant 
colony or glycerol stock was propagated in 8-10 ml of liquid both, in accordance with 
Section 2.1.2. The bacterial cells were harvested by centrifugation, for 30 seconds at 
10 000 rpm, the supernatant discarded and the cells gently resuspended in 250 µl 
chilled Resuspension Buffer. A 250 µl aliquot of Lysis Buffer was added to the 
sample and the cells incubated for 5 minutes, before the reaction was terminated by 
the addition of 350 µl of Neutralization Buffer. The sample was gently inverted 
several times and the contaminating cell debris pelleted by centrifugation at 13 000 
rpm for 10 minutes. The supernatant was retained and applied to a spin column. The 
sample was subjected to 1 minute of centrifugation at 5 000 rpm and the flow through 
discarded. An aliquot of 650 µl Wash Buffer was applied to the column and the 
membrane bound DNA washed by centrifugation at 12 000 rpm, for 1 minute. The 
flow through was discarded and the wash step repeated again. The spin column was 
centrifuged for an additional minute, as before, to remove any residual reagents 
trapped in the column. The column was transferred to a sterile 1.5 ml eppindorf tube 
and 50 µl of Elution Buffer added directly to the membrane of the spin column. The 
sample was incubated for 1 minute at room temperature prior to the elution of the 
DNA from the membrane; by subjecting the column to 1 minute of centrifugation at 





2.8. Enzymatic manipulation of DNA 
 
2.8.1. Enzymatic cleavage of plasmid DNA with restriction 
endonucleases 
 
Plasmid DNA was enzymatically cleaved for the purposes of cloning and screening of 
recombinant DNA using Fermentas Fastdigest® enzymes (Fermentas, South Africa), 
in accordance with the manufacturer’s instructions. Briefly, all reactions were 
conducted in a volume of 20 µl comprising of 250 ng - 1 µg of plasmid DNA, 2 µl of 
10× FastDigest® Green Buffer, 1 µl FastDigest® enzyme and an appropriate volume 
of sterile water to make up the reaction volume. The samples were incubated in a 
37⁰C water bath for 30 minutes to allow the reaction to occur to completion. The 
reaction was either terminated by heat inactivation, as indicated by the manufacturer, 
or the resulting DNA fragments purified from contaminating restriction enzymes by 
means of the Wizard® SV Gel and PCR Clean-up System (Promega, South Africa); 
as per the protocol outlined for PCR products (to follow in Section 2.11) 
 
2.8.2. Covalent linkage of DNA fragments by ligation   
 
DNA fragments were ligated into plasmid vector backbones using either the Clonejet 
PCR Cloning Kit (Thermo Scientific, South Africa) for PCR products or Fermentas 
T4 DNA ligase (Thermo Scientific, South Africa) for DNA fragments derived from 
other sources. DNA fragments amplified by PCR were subjected to a blunt end 
ligation into the pJET1.2/blunt plasmid provided with the CloneJET™ PCR Cloning 
Kit. The enzymatic reactions were carried out in a 20 µl reaction volume containing 2 
µl purified PCR product, 10 µl 2× Reaction buffer, 50 ng pJET1.2/blunt plasmid 
DNA, 1 µl T4 DNA ligase and an aliquot of sterile water to make up the reaction 
volume. The samples were incubated at room temperature for 30 minutes prior to heat 




Sticky end cloning of DNA was mediated by T4 DNA ligase in a 20 µl volume; using 
a 3:1 molar ratio of insert DNA to plasmid backbone. In addition to 1 µl of T4 DNA 
ligase and appropriate volumes of the 2 DNA species, the reaction also comprised of 
2 µl 10× DNA ligase reaction buffer and an aliquot of sterile water to make up the 
reaction volume. The reaction was allowed to proceed overnight, at room temperature, 
prior to heat inactivation of the enzyme at 70⁰C for 5 minutes. In the case of both 
blunt and sticky end ligations; the reactions were conducted in parallel with controls 
whereby a) insert DNA was omitted or b) both insert DNA and DNA ligase were 
omitted. 
 
2.9. Separation of DNA fragments by agarose gel electrophoresis 
 
DNA samples were resolved on the basis of their molecular weight by agarose gel 
electrophoresis in 1× TBE running buffer. Aliquots of 20-50 µl of DNA were 
supplemented with 1×Fast Digest Green Buffer and loaded into each well of an 
agarose gel. Unless otherwise indicated; The samples were electrophoresed at 100V, 
for 2 and half hours alongside 10 µl Fermentas O’GeneRuler™ 1kb DNA ladder 
(Thermo Scientific, South Africa). The TBE running buffer was further supplemented 
with 6 µl of Ethidium Bromide (Sigma-Aldrich, South Africa) to enhance 
visualization of the DNA. Agarose gels were visualized using the UviPro Silver Gel 
Documentation System and the resulting images captured with UviPro software. 
 
2.10. Excision and purification of DNA fragments from agarose gels  
 
The desired DNA fragment was excised from the agarose gel using a scalpel, over a 
UV light box, and purified from contaminating agarose using the Wizard® SV Gel 
and PCR Clean-up System (Promega, South Africa). The agarose slice was weighed 
and a volume of Membrane Binding Solution added to the agarose at a ratio of 10 µl 
Membrane Binding Solution to 10 mg agarose. The sample was vortexed and 
incubated at 55⁰C for 10 minutes to allow the agarose to dissolve completely. The 
sample was then applied to a SV Minicolumn assembly and incubated at room 
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temperature for 1 minute enabling the DNA to bind to the column. The SV 
Minicolumn assembly was centrifuged at 14 000 rpm for 1 minute and the flow 
through discarded from the collection tube. An aliquot of 700 µl of Membrane Wash 
Solution was applied to the membrane and the column centrifuged at 14 000 rpm, for 
1 minute. The supernatant was discarded and the wash step repeated, but for 5 
minutes this time, with 500 µl of Membrane Wash Solution. The supernatant was 
discarded and the column centrifuged as before, for an addition minute, to ensure the 
removal of any residual ethanol. Lastly, the column was transferred to a sterile 1.5 ml 
eppendorf tube and a 20-30 µl aliquot of nuclease-free water added directly to the 
membrane to which the DNA was adsorbed. The sample was incubated at room 
temperature for 5 minutes and the DNA eluted by centrifuging the sample for 1 
minute at 14 000 rpm. The plasmid DNA was either used directly or stored at -20⁰C 
for further use. 
 
2.11. Purification of PCR products after amplification  
 
Following the amplification of DNA by PCR, the products of the reaction were 
purified from contaminating reagents using the Wizard® SV Gel and PCR Clean-up 
System (Promega, South Africa). An equal volume of Membrane Binding Solution 
was added to the PCR reaction and the PCR products purified as outlined for DNA 
fragments excised from agarose gels (Section 2.10). 
 
2.12. Plasmid Vectors used for the construction of recombinant plant 
expression vectors and DNA vaccines 
 
2.12.1. pJET1.2/blunt cloning vector 
 
The commercially available cloning vector pJET1.2/blunt (Thermo Scientific, South 
Africa) was used in this study, as a cloning intermediate, for the construction of both 
the recombinant pTRA-A expression vectors and pTHPcapR DNA vaccines. The 
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plasmid is amenable to highly efficient cloning of PCR fragments by exploiting a 
lethal selection system to select for recombinant clones. 
 
2.12.2. pBluescript SK (pSK) cloning vector 
 
The commercially available cloning vector pSK (Agilent Technologies, South Africa) 
was used in this study as a positive control during transformations and to assess the 
competency of E. coli DH5α cells.  
 
2.12.3. pTRA-A plant expression vector  
 
The pTRA-A plasmid comprises of a disarmed Ti plasmid that targets the expression 
of heterologous proteins to the apoplastic spaces of plant leaves (238). The Ti plasmid 
backbone has been augmented with a number of additional features to enhance the 
expression of heterologous genes (Figure 2.1) (209). Collectively A. tumefaciens 
GV3101::pMP90RK and the disarmed Ti plasmid form a functional binary vector 
system enabling the expression of heterologous genes in planta.  
 
The expression of the foreign gene is regulated by the Cauliflower mosaic virus 
(CaMV) 35S promoter (p35SS), with a duplicated transcriptional enhancer and the 
CaMV 35S polyadenylation signal (pA35S). Upstream of the gene of interest; the 
vector encodes a plant codon optimized signal peptide sequence (LPH), derived from 
murine mAb24 heavy chain, to ensure the translocation of the recombinant protein 
through the ER of the plant cell. Additionally, the insert is flanked by tobacco rb7 
derived scaffold attachment regions (SAR) to enhance transgene expression and 
stability. The left  border (LB) and right border (RB) elements are located on either 
end of the scaffold attachment regions; defining the termini of the DNA region that 
will be transferred from A. tumefaciens to the plant nucleus. The plasmid contains 
origins of replication for both E. coli (ColE1 ori) and A. tumefaciens (Rk2 ori) as well 
as ampicillin/carbenicillin (bla) and kanamycin (nptII) resistance genes which serve 
as selectable markers. The expression of the nptII gene is regulated by the nopaline 
synthase promoter (Pnos) and polyadenylation signal (pAnos). Lastly the plasmid also 
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contains the Chalcone synthase 5’ untranslated region (CHS) to enhance mRNA 













Figure 2.1: Annotated plasmid map of the pTRA-A binary plant expression vector. The 
disarmed Ti plasmid backbone has been augmented with numerous additional features to 
enhance the expression and stability of a foreign gene and to direct its translocation to the 
apoplast of plant leaves (209, 238). (RK2 ori = A. tumefaciens origin of replication, ColE1 = 
E. coli origin of replication, bla = ampicillin/carbenicillin resistance gene, SAR = Scaffold 
attachment region, LB = left border, RB = Right border, p35SS = CaMV duplicated 
transcriptional enhancer, pA35S = CaMV polyadenylation signal, LPH = signal peptide, CHS 
= chalcone synthase 5’ untranslated region, Pnos = nopaline synthase promoter,  pAnos = 
nopaline synthase polyadenylation signal, nptII = kanamycin resistance gene).  
 
2.12.4. pTHPcapR DNA vaccine vector  
 
The pTHPcapR DNA vaccine vector was obtained from Tsungai Jongwe (PhD 
candidate, Department of Medical Virology, University of Cape Town) as pTJDNA4, 
a recombinant construct used in an independent study. The recombinant plasmid 
encodes a full length HIV-1 subtype C gag mosaic immunogen flanked by HindIII 
and XbaI restriction enzyme recognition sequences. The pTHPcapR DNA vaccine has 
ultimately been derived from the pRc/CMV commercial expression vector 
(Invitrogen, South Africa). In an unrelated study Thomas Hanke and colleagues 
developed a minimalistic pTH DNA vaccine vector from the pRc/CMV expression 
vector. The resulting plasmid retained the ColE1 origin of replication and the β-
lactamase genes from pRc/CMV facilitating cloning in E. coli cells. The expression of 
the foreign gene is regulated by the Human CMV enhancer/promoter/intron region 
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(pCMV) and bovine growth hormone polyadenylation signal (BGH PolyA) (126). 
Fiona Tanzer et al., reported further modifying the pTH vector backbone by 
incorporating a porcine circovirus type 1 enhancer element (PcapR) upstream of the 
multiple cloning site culminating in the formation of the pTHPcapR vaccine vector 












Figure 2.2: Annotated plasmid map of the pTHPcapR DNA vaccine vector. The DNA 
vaccine vector has been designed to maximize antigen expression by employing the Human 
CMV enhancer/promoter/intron region (Pcmv) and a porcine circovirus type 1 enhancer 
element (PcapR) to drive expression of a heterologous gene (126, 354). Additional elements 
include an E. coli origin of replication (ColE1), the polyadenylation signal from bovine 
growth hormone (BGH PolyA) and a β-lactamase gene for use as a selectable marker (bla). 
 
Table 2.2: Summary table of selectable markers on the plasmid vectors used in this 
study. 
 
Plasmid Resistance gene Concentration (µg/ml) 
pSK Ampicillin 100 µg/ml 
pJET1.2/blunt Ampicillin 100 µg/ml 
pTHPcapR Ampicillin 100 µg/ml 
pTRA-A Ampicillin/carbenicillin 50 µg/ml 
 
2.13. Amplification of HIV-1 envelope antigen coding sequences 
 
The gene coding sequences designed in this study were constructed by PCR using 
plasmid DNA templates encoding the HIV-1 envelope from the CAP256 
superinfecting virus (pLM1) and the full length influenza H5 haemagglutinin gene of 
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H5N1 (pTRA-A:H5). The pLM1 plasmid comprised of the pcDNA3.1D/V5-His-
Topo® plasmid vector (Invitrogen, South Africa) encoding the CAP256 
superinfecting virus envelope (clone 256.3mo.9C) as part of an HIV-1 expression 
cassette. In addition to the envelope gene sequence, the plasmid also encoded the 3' 
end of rev exon 1, the vpu gene and the 5' end of the nef coding sequence. All PCR 
reactions were conducted in a 50 µl reaction volume using Fermentas Pfu DNA 
Polymerase (Thermo Scientific, South Africa) in accordance with the manufacturer’s 
instructions. Unless indicated otherwise; 0.5 µM of both the forward and reverse 
primer were used to initiate amplification from a 10 ng template of plasmid DNA in 
the presence of 0.2 mM dNTPs. The PCR reactions were buffered by 1 × Pfu Buffer 
and the reaction volume adjusted to 50 µl with sterile dH2O. The Mg
2+
 ion 
concentration was titrated and the annealing temperatures optimized for each reaction; 
prior to the amplification of the products used for cloning. Pfu DNA Polymerase was 
only added once the sample temperature had reached 95⁰C. The reaction was then 
allowed to proceed for 25 cycles. Control samples lacking the forward primer, reverse 
primer or template DNA were subjected to the same experimental conditions 
alongside the experimental samples. The primers used for the amplification of the 
envelope antigens, used in the construction of the recombinant pTRA-A plasmid 
vectors, are indicated below in Table 2.3. 
 
Table 2.3: Summary table of the primers used for the amplification and assembly of the 
plant antigen coding sequences designed in this study. The NcoI (red) and SpeI (blue) 
restriction enzyme sites that were engineered into the primers are underlined. 
 
Primer Orientation Sequence (5’-3’) Use 
FWDCAP2561 Forward CGCGCCATGGTCAAT 
GGCTTGTGGGTTACA 
PCR amplification of 
gp150, gp140 and gp120 
coding sequences as well 
as the assembly of the 
chimeric gp120-HA2 and 
gp140-HA2tr genes.  
RVSCAP2561 Reverse ATGGCGCCGAACAGGCCT
CTTTTCTCTTTCTGCAC 
PCR amplification of the 
gp120 coding sequence. 
RVSCAP2562 Reverse CGCACTAGTAGTCTCTGTC
TTGCTCTCCACCTTCTTC 
PCR amplification of the 




PCR amplification of the 
gp140 coding sequence. 
FWDH51 Forward GTGCAGAAAGAGAAAAGA
GGCCTGTTCGGCGCCATC 
PCR amplification of the 






PCR amplification of the 
HA2tr coding sequence. 
RVSH51 Reverse CCGCACTAGTTTATGCGGC
CGCTCTACACTGC 
PCR amplification of the 
HA2 and HA2tr coding 
sequences as well as the 





2.13.1. PCR amplification of the gp150 coding sequence 
 
The gp150 coding sequence was amplified directly from 1 ng of pLM1 template DNA 
using the FWDCAP2561 and RVSCAP2562 primers (Table 2.3). The reaction was 
conducted at 3.0 mM MgSO4 using the cycling parameters outlined in Table 2.4 
below. A 20 µl aliquot of the resulting PCR products were resolved on a 0.8% agarose 
gel to verify the successful amplification of the desired DNA fragment. 
 
Table 2.4: PCR cycling parameters used for the amplification of the HIV-1 gp150 coding 
sequence. 
 
Reaction stage Temperature (⁰C) Duration Number of cycles 
Initial Denaturing 95 3 minutes 1 
Denaturing 95 30 seconds 25 
Annealing  65.5 30 seconds 25 
Extension 72 4.5 minutes 25 
Final Extension 72 7 minutes 1 
 
2.13.2. Assembly of the chimeric gp120-HA2 coding sequence 
by overlap extension PCR 
 
The gp120 DNA fragment was amplified from 10 ng of pLM1 template DNA using 
the FWDCAP2561 and RVSCAP2561 primers (Table 2.3). The reaction was conducted at 
2.5 mM MgSO4 in accordance with the cycling conditions outlined in Table 2.5. The 
successful amplification of the desired DNA fragment was verified by resolving a 
20µl aliquot of the PCR products on a 0.8% agarose gel (Section 2.9) alongside a 10 
µl aliquot of Fermentas O’GeneRuler™ 100 bp Plus DNA ladder. 
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Table 2.5: PCR cycling parameters used for the amplification of the HIV-1 gp120 coding 
sequence. 
 
Reaction stage Temperature (⁰C) Duration Number of cycles 
Initial Denaturing 95 3 minutes 1 
Denaturing 95 30 seconds 25 
Annealing  70 30 seconds 25 
Extension 72 3 minutes, 5 
seconds 
25 
Final Extension 72 7 minutes 1 
 
The full length HA2 coding sequence was amplified from 10 ng of pTRA-A: H5 
template DNA using the FWDH51 and RVSH51 primers (Table 2.3). The DNA 
fragment was amplified at 2.5 Mm MgSO4, using the PCR parameters described in 
Table 2.6, and the amplification of the desired product confirmed by 1.5% agarose 
gel electrophoresis (Section 2.9).  
 
Table 2.6: PCR cycling parameters used for the amplification of the full length HA2 
coding sequence. 
 
Reaction stage Temperature (⁰C) Duration Number of cycles 
Initial Denaturing 95 3 minutes 1 
Denaturing 95 30 seconds 25 
Annealing  63 30 seconds 25 
Extension 72 1 minute, 30 
seconds 
25 
Final Extension 72 7 minutes 1 
 
The HIV-1 gp120 and influenza HA2 DNA fragments were excised from their 
respective agarose gels and recovered using the Wizard® SV Gel and PCR Clean-up 
System in accordance with Section 2.10.  The chimeric gp120-HA2 gene was 
assembled from an equimolar ratio of the purified gp120 and HA2 PCR products 
using the FWDCAP2561 and RVSH51 primers (Table 2.3). The reaction was conducted 
at 1.75 mM MgSO4 using the cycling parameters outlined in Table 2.7. The PCR 
products were subjected to 0.8% agarose gel electrophoresis to verify the successful 





Table 2.7: PCR cycling parameters used for the amplification of the chimeric gp120-
HA2 coding sequence. 
 
Reaction stage Temperature (⁰C) Duration Number of cycles 
Initial Denaturing 95 3 minutes 1 
Denaturing 95 30 seconds 25 
Annealing  63 30 seconds 25 
Extension 72 1 minute, 30 
seconds 
25 
Final Extension 72 7 minutes 1 
 
2.13.3. Assembly of the chimeric gp140-HA2tr coding sequence 
by overlap extension PCR 
 
The gp140 coding sequence was amplified from 2 ng pLM1 using the FWDCAP2561 
and RVSCAP2563 primers (Table 2.3). The reaction was conducted at 3.0 mM MgSO4 
using the cycling parameters delineated in Table 2.8. The resulting PCR products 
were resolved on a 0.8% agarose gel as outlined in Section 2.9. 
 
Table 2.8: PCR cycling parameters used for the amplification of the gp140 coding 
sequence. 
 
Reaction stage Temperature (⁰C) Duration Number of cycles 
Initial Denaturing 95 3 minutes 1 
Denaturing 95 30 seconds 25 
Annealing  62.4 30 seconds 25 
Extension 72 4 minute, 35 
seconds 
25 
Final Extension 72 7 minutes 1 
 
The HA2tr coding sequence was amplified from 1 ng pTRA-A: H5 plasmid DNA 
template using the FWDH52 and RVSH51 primers (Table 2.3). The PCR reaction was 
performed at 3.0 mM MgSO4 in accordance with the cycling parameters described in 
Table 2.9. A 10 µl aliquot of the PCR product was resolved on a 1.5% agarose gel 







Table 2.9: PCR cycling parameters used for the amplification of the HA2tr coding 
sequence. 
 
Reaction stage Temperature (⁰C) Duration Number of cycles 
Initial Denaturing 95 3 minutes 1 
Denaturing 95 30 seconds 25 
Annealing  62.6 30 seconds 25 
Extension 72 22 seconds 25 
Final Extension 72 7 minutes 1 
 
The HIV-1 gp140 coding sequence and the influenza HA2tr DNA fragments were 
separately amplified by PCR and resolved by agarose gel electrophoresis, as described 
in Section 2.9. The desired fragments were recovered from the agarose gels using the 
Wizard® SV Gel and PCR Clean-up System (Section 2.10) and an equimolar amount 
of the purified PCR products used as template to assemble the gp140-HA2tr chimera; 
as indicated in Table 2.10. The reaction was conducted at 3.0 mM MgSO4 and 
allowed to proceed for 5 cycles prior to the addition of the FWDCAP2561 and RVSH51 
primers (Table 2.3).  
 
Table 2.10: PCR cycling parameters used for the assembly of the gp140-HA2tr chimera 
coding sequence. 
 
Reaction stage Temperature (⁰C) Duration Number of cycles 
Initial Denaturing 95 3 minutes 1 
Denaturing 95 30 seconds 25 
Annealing  72 30 seconds 25 
Extension 72 4 minutes 
(+5 seconds)* 
25 
Final Extension 72 7 minutes 1 
*An additional 5 seconds were added to the extension time after each successive cycle 
  
2.14. Construction of recombinant pTRA-A:gp150, pTRA-A:gp120-
HA2 and pTRA-A:gp140-HA2tr plant expression vectors. 
 
The gp150 coding sequence was amplified as described in Section 2.13.1 and the 2 
chimeric genes assembled as delineated in Section 2.13.2 and Section 2.13.3. The 
resulting PCR products were purified using the Wizard® SV Gel and PCR Clean-up 
System in accordance with Section 2.11. The purified PCR products were then ligated 
into the pJET1.2/blunt cloning vector as outlined in Section 2.8.2. Following heat 
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inactivation of the residual DNA Ligase; half the reaction volume was transformed 
into competent E. coli DH5α cells (Section 2.3.1) that were prepared using the 
DMSO method reported by Chung and Miller (38) (Section 2.2.1). Ten recombinant 
colonies for each construct were propagated in 800 µl of LB media (Section 2.1.1) 
and the bacterial cultures subjected to a small scale DNA extraction using the 
alkaline-lysis method described by Sambrook and Russel (297) (Section 2.7.1). An 
aliquot of 10 µl of each DNA sample was screened by XhoI- XbaI restriction analysis, 
and the resulting restriction fragments resolved on a 0.8% agarose gel (Section 2.8.1 
and Section 2.9 respectively). A single recombinant colony, containing the desired 
recombinant pTRA-A plasmid, was cultivated in 100 ml of liquid broth (Section 
2.1.1). A medium scale DNA isolation was performed on the bacterial culture 
(Section 2.7.2) and the antigen coding sequence excised from a 1 µg aliquot of the 
pJET1.2/blunt vector backbone by dual NcoI- SpeI enzymatic digestion (Section 
2.8.1). The products of the restriction digest reaction were separated on a 0.8% 
agarose gel and the band corresponding to the antigen coding sequence excised and 
purified (Section 2.9 and Section 2.10 respectively).  
 
The pTRA-A plasmid vector backbone was recovered from the recombinant pTRA-
A:H5 plasmid construct by digesting 1 µg of plasmid DNA with NcoI and XbaI 
(Section 2.8.1). The products of the reaction were separated on a 0.8% agarose gel in 
accordance with Section 2.9. In order to ensure optimal separation of the pTRA-A 
backbone and H5 insert the samples were electrophoresed at 80 V for 20 minutes, 
followed by 15 V overnight. The DNA fragments corresponding to the pTRA-A 
backbone were excised from the agarose slab and purified as outlined in Section 2.10. 
The purified PCR product was then ligated into the pTRA-A plasmid backbone 
(Section 2.8.2) and half the ligation reaction transformed into E. coli DH5α cells 
(Section 2.3.1). Ten putative recombinant colonies were cultivated in 800 µl of LB 
media (Section 2.1.1) and DNA isolated using the small scale extraction protocol 
described in Section 2.7.1. A 10 µl aliquot of each sample was subjected to restriction 
analysis to identify samples containing the final recombinant plasmid (Section 2.8.1) 
and the resulting DNA fragments resolved by 0.8% agarose gel electrophoresis 
(Section 2.9). Putative pTRA-A: gp150 samples were screened by separate NcoI and 
PstI restriction enzyme digests. In contrast putative pTRA-A: gp120-HA2 and pTRA-




A single recombinant colony, containing the recombinant plasmid, was cultivated in 
100 ml of LB (Section 2.1.1) and subjected to a medium scale DNA isolation 
procedure using the Genopure Plasmid Midi Kit (Section 2.7.2). Aliquots of 250 ng 
of the plasmid DNA were analysed by restriction analysis (Section 2.8.1) and the 
resulting DNA fragments resolved on a 0.8% agarose gel (Section 2.9) to verify that 
the reaction yielded fragments of the desired size. The genetic integrity of the final 
constructs was independently verified by sequencing using the complete gp160 primer 
set along with the pTRA-kc F and pTRA-kc R primers (indicated below in Table 
2.11). The sequence data was generated by Stellenbosch sequencing unit and aligned 
to a hypothetical reference sequence, generated in silico, using CLC Main Workbench 
(Version 6).  
 
Table 2.11: Summary table of the primers used for sequencing of the recombinant 
plasmid vectors constructed in this study. 
 
Primer Orientation Sequence (5’-3’) Use 
pTRA-kc F Forward CATTTCATTTGGAGAG
GACACG 
Sequencing of recombinant 
pTRA-A plasmid DNA. 
pTRA-kc R Reverse GAACTACTCACACATT
ATTCTGG 
Sequencing of recombinant 
pTRA-A plasmid DNA. 
FOR14 Forward TATGGGACCAAAGCCT
AAAGCCATGTG 
Sequencing of recombinant 
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Sequencing of recombinant 
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Sequencing of recombinant 
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Sequencing of recombinant 
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Sequencing of recombinant 




Sequencing of recombinant 
pTRA-A and pTHPcapR 
plasmid DNA. 
 
2.15. Construction of matched pTHPcapR-vectored DNA vaccines 
 
The coding sequences of the 3 antigens were amplified, from the recombinant pTRA-
A expression vectors constructed in Section 2.14. Unless indicated otherwise; all PCR 
reactions were conducted using Pfu DNA Polymerase; in accordance with Section 
2.13. The gp150 coding sequence was amplified from 1ng of pTRA-A: gp150 plasmid 
DNA template using the FWDDNA1 and RVSDNA1 primers (Table 2.12). The reaction 
was conducted at 1.75 mM MgSO4 as outlined in Table 2.13. The amplification of the 
desired DNA fragment was confirmed by subjecting a 25 µl aliquot of the PCR 
product to agarose gel electrophoresis on a 0.8% agarose gel (Section 2.9). 
 
Table 2.12: Summary table of the primers used for the construction of the pTHPcapR 
DNA vaccines designed in this study. The HindIII (red) and XbaI (blue) restriction enzyme 
sites that were engineered into the primers are underlined.  
 
Primer Orientation Sequence (5’-3’) Use 
FWDDNA1 Forward GCAAAGCTTATGGAG
TGGAGCTGGATC 
PCR amplification of gp150, 




PCR amplification of the 
gp150 coding sequence 
RVSDNA2 Reverse AACTCTAGATTATGC
GGCCGCTCTACACTG 
PCR amplification of the 









Table 2.13: PCR cycling parameters used for the amplification of the gp150 DNA 
vaccine antigen coding sequence.  
 
Reaction stage Temperature (⁰C) Duration Number of cycles 
Initial Denaturing 95 3 minutes 1 
Denaturing 95 30 seconds 25 
Annealing  65 30 seconds 25 
Extension 72 4 minutes, 12 
seconds 
25 
Final Extension 72 7 minutes 1 
 
 
Similarly, the gp120-HA2 coding sequence was amplified from 1ng pTRA-A: gp120-
HA2 plasmid DNA template using the FWDDNA1 and RVSDNA2 primers (Table 2.12). 
The reaction was carried out at 1.75 mM using the cycling parameters elucidated in 
Table 2.14. The entire reaction volume was resolved on a 0.8% agarose gel to verify 
that the desired DNA fragment had been successfully amplified (Section 2.9). 
 
 
Table 2.14: PCR cycling parameters used for the amplification of the gp120-HA2 DNA 
vaccine coding sequence.  
 
Reaction stage Temperature (⁰C) Duration Number of cycles 
Initial Denaturing 95 3 minutes 1 
Denaturing 95 30 seconds 25 
Annealing  71 30 seconds 25 
Extension 72 4 minutes, 20 
seconds 
25 
Final Extension 72 7 minutes 1 
 
Lastly, the gp140-HA2tr PCR product was amplified from 1 ng of pTRA-A: gp140 
plasmid DNA template using the FWDDNA1 and RVSDNA2 primers (Table 2.12). The 
reaction was conducted at 3.0 mM MgSO4 in accordance with Table 2.15. The entire 
reaction volume was subjected to 0.8% agarose gel electrophoresis to confirm that the 








Table 2.15: PCR cycling parameters used for the amplification of the gp140-HA2tr DNA 
vaccine coding sequence.  
 
Reaction stage Temperature (⁰C) Duration Number of cycles 
Initial Denaturing 95 3 minutes 1 
Denaturing 95 30 seconds 25 
Annealing  66 30 seconds 25 
Extension 72 4 minutes, 16 
seconds 
25 
Final Extension 72 7 minutes 1 
 
The gp150, gp120-HA2 and gp140-HA2tr antigen coding sequences were amplified by 
PCR and the gene products purified using the Wizard® SV Gel and PCR Clean-up 
System (Promega, South Africa) (Section 2.11). Each PCR product was ligated into 
the pJET1.2/blunt cloning vector and the reaction allowed to occur overnight, at room 
temperature (Section 2.8.2). A 10 µl aliquot from each ligation reaction was then 
transformed into competent E. coli DH5α cells (Section 2.3.1); prepared in 
accordance with Section 2.2.1. Five to ten putative recombinant colonies were 
cultivated overnight in 800 µl of LB broth (Section 2.1.1) and subjected to a small 
scale DNA isolation (Section 2.7.1). A 10 µl aliquot of plasmid DNA from each 
sample was screened by HindIII-XbaI dual restriction enzyme digestion (Section 
2.8.1) to identify recombinant pJET1.2/blunt samples containing the desired insert. 
The resulting restriction fragments were resolved on a 0.8% agrose gel (Section 2.9) 
alongside a 10 µl aliquot of undigested plasmid DNA, prepared in accordance with 
Section 2.7.1. A single colony containing the desired insert for each plasmid construct 
was propagated overnight in 50 ml LB broth (Section 2.1.1) and subjected to a 
medium scale DNA isolation using the Genopure Plasmid Midi Kit (Roche, South 
Africa) (Section 2.7.2). A 1 µg aliquot of each recombinant pJET1.2/blunt plasmid 
construct was subjected to a HindIII-XbaI dual restriction enzyme digest to liberate 
the PCR products from the cloning vector backbone (Section 2.8.1). The resulting 
restriction fragments were resolved on a 0.8% agarose gel (Section 2.9) and the 
desired DNA fragments were excised and purified from contaminating agarose 
(Section 2.10).  
 
A 1 µg aliquot of pTJDNA4 was simultaneously digested with HindIII-XbaI (Section 
2.8.1) and the resulting DNA fragments resolved on a 0.8% agarose gel (Section 2.9). 
The DNA fragments corresponding to the pTHPcapR vaccine vector backbone were 
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recovered from the agarose gel and purified (Section 2.10). The purified DNA 
fragments corresponding to the antigen coding sequences were then ligated into the 
pTHPcapR backbone (Section 2.8.2) and half the ligation reaction transformed into 
competent E. coli DH5α cells (Section 2.3.1). Ten putative recombinant colonies for 
each construct were propagated overnight in 800 µl of LB broth (Section 2.1.1), and 
subjected to a small scale DNA isolation procedure as described in Section 2.7.1. A 
10 µl aliquot of the resulting plasmid DNA was screened by HindIII-XbaI restriction 
digestion (Section 2.8.1) and the restriction fragments separated on a 0.8% agarose 
gel to identify samples containing the desired ligation products (Section 2.9). A single 
recombinant colony for each construct was cultivated overnight in 100 ml of liquid 
broth (Section 2.1.1) and the culture subjected to a medium scale DNA isolation 
procedure (Section 2.7.2). The structural integrity of the 3 recombinant DNA 
vaccines was then verified by restriction analysis and sequencing as described for the 
recombinant pTRA-A plasmid vectors in Section 2.15.  
 
2.16. Medium scale transfection of HEK 293 cells with recombinant 
pTHPcapR DNA vaccines 
 
Medium scale transfections of HEK 293 cells were performed, in triplicate, in 6 well 
culture plates (Nest Biotech Co., Ltd). Each well was seeded with 0.4 ×10
6
 cells in a 
volume of 2 ml complete GM (Appendix B). The cells were incubated for 24 hours at 
37⁰C, prior to the transfection, to allow the cells to reach 70-90% confluence. 
Aliquots of 2 µg of recombinant plasmid DNA were gently mixed with 50 ng 
pGL4.13 (luc2/SV40) reporter plasmid in a sterile 1.5 ml eppendorf tube (Sigma-
Aldrich, South Africa) containing 100 µl unsupplemented Gibco ®DMEM (Life 
Technologies, South Africa).  
 
A 3 µl aliquot of X-tremeGENE HP DNA Transfection Reagent (Roche, South 
Africa) was added to the DNA suspension and the sample incubated at room 
temperature for 30 minutes to facilitate the formation of complexes between the 
transfection reagent and the recombinant plasmid DNA. The transfection complex 
was then added directly to the cells in a drop wise manner and the 6 well plates briefly 
agitated to evenly distribute the complexes across the surface of the wells. The cells 
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were incubated at 37⁰C for 48 hours to enable protein expression. All transfections 
were performed in parallel with controls comprising cells alone, cells with 
transfection reagent and cells transfected with the SAAVI C2 DNA vaccine (positive 
control). 
 
2.17. Harvesting of transfected HEK293 cell lysate for Western 
blotting 
 
The spent media was discarded and the transfected cells gently washed with 1 ml 
sterile Gibco® dPBS (without magnesium or calcium) (Life Technologies, South 
Africa). An aliquot of 200 µl 1× Glo Lysis Buffer (Promega, South Africa), 
supplemented with 1× Complete EDTA-free Protease Inhibitor (Roche, South Africa), 
was dispensed over the cell monolayer and the cells incubated at room temperature 
for 5 minutes. The cell lysate, from triplicate samples, was gently mixed by pipette 
aspiration and pooled in a single 1.5 ml eppendorf tube. The cell debris was collected 
by centrifugation for 10 minutes at 13000 rpm and the supernatant retained at -20⁰C, 
as 50 µl aliquots. The cell lysate was quantified (Appendix A.1) and subjected to a 
luciferase assay (Appendix A.2) to measure the transfection efficiency of the 
pGL4.13 (luc2/SV40) reporter plasmid. 
  
2.18. Western blotting to detect recombinant HIV-1 envelope in 
transfected cell lysate 
 
The transfected cell lysate samples were analysed for the presence of the recombinant 
antigens by Western blotting; under denaturing conditions. Aliquots of 10 µl of XT 
Sample Buffer (Bio-Rad, South Africa) and 2 µl of XT Reducing Agent (Bio-Rad, 
South Africa) were added to 28 µl of unquantified cell lysate; in a sterile 1.5 ml 
eppendorf tube. A positive control sample, comprising of 100 ng of recombinant 
CN54 gp120 was also prepared in this way. The CN54 envelope was obtained from 
the AIDS reagent programme as a recombinant HIV-1 Subtype C protein expressed in 
insect cells via recombinant baculovirus (#7749). The protein was produced as a 
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translational fusion with maltose binding protein and a C terminal histidine tag 
culminating in an approximate molecular weight of 130 kDa (386). The samples were 
boiled at 95 ⁰C for 5 minutes and the entire volume loaded onto a precast 7% 
Criterion Tris-Acetate Gel, suspended in 1 × XT Tricine Running buffer (Bio-Rad, 
South AfricaO. The samples were electrophoresed at 150V for 1 hour, alongside a 10 
µl aliquot of either Thermo Scientific PageRuler Prestained Protein Ladder 
(Fermentas, South Africa) or Precision Plus Protein™ Kaleidoscope™ Standards 
(Bio-Rad, South Africa). 
 
A pre-cut sheet of Immun-Blot™ PVDF membrane (Bio-Rad, South Africa) was 
soaked in methanol for 2 minutes and then equilibrated in 20 ml Transfer buffer for 
20 minutes. Similarly, following electrophoresis the Criterion Tris-Acetate Gel and 2 
pre-cut pieces of Extra Thick Blot Paper (Bio-Rad, South Africa) were also 
equilibrated in 20-30 ml Transfer buffer for 20 minutes. A piece of the saturated Extra 
Thick Blot Paper (Bio-Rad) was placed on top of a Semi-dry Blot apparatus (Bio-Rad, 
South Africa), followed by the equilibrated PVDF membrane and then the Criterion 
Tris-Acetate Gel. A second piece of saturated Extra Thick Blot Paper was placed on 
top of the gel essentially sandwiching the gel between the membrane and 2 pieces of 
saturated blotting paper. The proteins were electrophoretically transferred from the 
gel to the membrane at 15V for 1 hour. The successful electrophoretic transfer of 
protein, from the gel to the PVDF membrane, was verified by staining the membrane 
with Ponceau S solution for 2 minutes.  
 
Following Ponceau S staining, the membrane was rinsed in RO water and incubated 
with 30 ml Block/Wash buffer for 4 hours, with gentle shaking. The Block/Wash 
buffer was discarded and the membrane incubated overnight at 4⁰ C with a 1: 1000 
dilution of either the Serotech Polyclonal anti-gp120 primary antibody or the MRC 
ADP 408/5104 polyclonal anti-gp160 primary antibody. The antibody suspension was 
then discarded and the membrane rinsed for 4×15 minute intervals with Block/Wash 
buffer (Appendix B). The membrane was then incubated with a 1:10 000 dilution of 
GT34 anti-Sheep/Goat secondary antibody conjugated to alkaline phosphatase 
(Sigma-Aldrich). The wash was repeated 4 times, as before, and the HIV-1 envelope 
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detected by incubating the membrane with 5 ml of NBT/BCIP (Roche) solution for 5 
minutes. 
 
2.19. Small-scale transfection of HEK293 cells  
 
Small scale transfections of HEK293 cells were performed, in duplicate, in 8 well 
Permanox® Chamber slides (Lab-tek®). Each well was seeded with 80 000 cells, in a 
volume of 200 µl complete GM, and incubated at 37⁰C overnight. An aliquot of 400 
ng of plasmid DNA was suspended in 100 µl of DMEM and X-tremeGENE HP DNA 
Transfection Reagent added at a 1:1 ratio to plasmid DNA. The DNA suspension was 
gently agitated and incubated at room temperature for 20-30 minutes. The transfection 
complex was then added, dropwise, to each well and the microchamber plate gently 
agitated to distribute the transfection reaction in the wells. A further 200 µl of 
complete GM was added to each well and the microchamber plate incubated at 37⁰C 
for 48 hours before detection of recombinant protein. All transfections were 
performed in duplicate alongside controls comprising cells alone, cells with 
transfection reagent and cells transfected with a positive control plasmid; the SAAVI  
C2 DNA vaccine. The SAAVI DNA-C2 vaccine comprises of a bivalent mixture of 2 
plasmids. The first plasmid encodes a truncated HIV-1 envelope protein (gp150), 
whereas the second encodes a heavily engineered fusion protein (Grttn) comprising of 
Gag, Reverse Transcriptase, Tat and Nef (397).  
 
2.20. Immunodetection of recombinant HIV-1 envelope protein in 
transfected HEK293 cells 
 
The excess medium was removed from each well and the cells fixed in 500 µl 
acetone; for 10 minutes at 4⁰ C. The acetone was removed and the cells left to air dry 
at room temperature. Each well was briefly rinsed with PBS and then blocked with 
500 µl 2% Bovine Serum Albumin (BSA); for 20 minutes at room temperature. The 
residual blocking solution was removed and the cells subjected to 2 ten minute 
washes with PBS.  This was followed by the addition of 500 µl of MRC ADP 
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408/5104 polyclonal anti-gp160 primary antibody (1:200), suspended in 1.5% BSA 
solution. The cells were incubated with the primary antibody for 1 hour at 37⁰C. The 
antibody dilution was then removed and the cells washed twice with PBS, as before, 
to remove any unbound antibody. An aliquot of 500 µl of Donkey anti-goat CΥ3 
secondary antibody (1:500), suspended in 1.5% BSA solution, was added to each 
well. The cells were incubated at 37⁰ C for 1 hour. The residual antibody was 
removed and the cells washed twice with PBS, as before. An aliquot of 500 µl of 
Hoechst nuclear stain (diluted 1:10 000 in PBS) was dispensed into each well and the 
microchamber plate incubated for 10 minutes, at room temperature. The Hoechst stain 
was removed and the cells washed twice with PBS. The wells were then removed 
from the microchamber slide and the cells gently rinsed with sterile dH2O. The cells 
were allowed to air dry and then mounted with a coverslip using Mobial. The slides 
were viewed for fluorescence, at the blue and red light emission spectra, using the 
Zeiss Axiovert 200M LSM 510 Meta Confocal microscope. 
 
2.21. Generation of recombinant A. tumefaciens GV3101::pMP90RK 
strains 
 
Electrocompetent A. tumefaciens GV3101::pMP90RK cells were transformed with 
each of the recombinant pTRA-A plasmid vectors (constructed in Section 2.14), in 
accordance with Section 2.3.2. Putative recombinants were screened by back-
transformation of crude DNA extract into E. coli cells to assess the integrity of the 
recombinant plasmid DNA. A single colony of each putative A. tumefaciens 
recombinant was inoculated into 10 ml of LB media and cultured as outlined in 
Section 2.1.2. A 1 ml aliquot of the bacterial culture was retained and stored as a 25% 
glycerol stock, and the remaining culture volume was subjected to a small scale DNA 
isolation procedure using the Biospin Plasmid DNA Extraction kit (Bioflux) (Section 
2.7.3). An aliquot of 5 µl of the crude plasmid DNA sample was transformed into 
competent E. coli DH5α cells and plated onto LA media supplemented with 50 µg/ml 
carbenicillin; as outlined in Section 2.3.1. Five putative recombinant colonies, derived 
from each A. tumefaciens clone, were cultured overnight in 800 µl of LB media and 
subjected to a small scale DNA isolation procedure as outlined in Section 2.1.1 and 
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Section 2.7.1 respectively.  Aliquots of 10 µl of each sample were screened by 
restriction enzyme digestion to verify the genetic integrity of the plasmid samples 
after growth in vitro. Recombinant pTRA-A: gp150 plasmid DNA was screened by 
NcoI-SphI dual enzyme digestion. The pTRA-A:gp120-HA2 and pTRA-A:gp140-
HA2tr plasmid samples were screened by NcoI- NotI enzyme digestion. 
 
The resulting restriction fragments were resolved by electrophoresis on a 0.8% 
agarose gel (Section 2.9). Once the success of the transformation had been verified 
and the genetic integrity of the plasmid DNA confirmed; the original A. tumefaciens 
glycerol stocks were cultivated in 10 ml of selective media, in accordance with 
Section 2.1.2, and stored as 25% glycerol stocks. 
 
2.22. Syringe infiltration of N. benthamiana leaves with recombinant 
A. tumefaciens strains 
 
Transient protein expression time trials were conducted by syringe infiltration of N. 
benthamiana plant leaves using the method described by Maclean et al., 2007 (209). 
All recombinant strains were infiltrated alone or co-infiltrated with the LBA4404 
(pBIN-NSs) Agrobacterium strain. A 1 ml glycerol stock of recombinant A. 
tumefaciens GV3101::pMP90RK or LBA4404 (pBIN-NSs) was propagated in 10 ml 
LB media; as described in Section 2.1.2 or Section 2.1.3 respectively. After 
overnight incubation a 1 ml inoculum of the growing culture was transferred to a 10 
ml aliquot of Induction medium (Appendix B), augmented with antibiotics as before. 
The growing LBA4404 (pBIN-NSs) culture was further supplemented with 2mM 
MgSO4 to prevent the bacterial cells from aggregating together. The cells were 
cultivated overnight, harvested by centrifugation at 4000 rpm, for 10 minutes and 
resuspended in 500 µl freshly prepared Infiltration medium (Appendix B). The 
bacterial suspension was adjusted to an OD600 of 0.5-1.5 with infiltration medium and 
incubated at room temperature for 2-3 hours. In the case of recombinant strains that 
were co-infiltrated with LBA4404 (pBIN-NSs); the OD600 was individually adjusted 




Aliquots of 1-2 ml of the bacterial suspension were infiltrated into the abaxial 
airspaces on the ventral side of the leaves of 6-8 week old tobacco plants. The plants 
were returned to the greenhouse and incubated under the same environmental 
conditions, as delineated in Section 2.6, for the duration of the experiment. Five 
leaves were infiltrated for each construct and separate plants were used for different 
recombinant strains of A. tumefaciens. Additionally, a negative control infiltration 
was performed alongside the experimental infiltrations whereby N. benthamiana 
leaves were infiltrated with infiltration media only. 
 
2.23. Harvesting of crude protein extract from agroinfiltrated leaves 
 
Six leaf discs were harvested from agroinfiltrated plant leaves, using the cap of an 
eppendorf tube, and finely ground in liquid nitrogen.  The leaf matter was 
resuspended in 300 µl PBS containing Complete EDTA-free Protease Inhibitor 
(Roche). The residual plant matter was collected by centrifugation at 13000 rpm, for 5 
minutes and the supernatant stored at -20°C. The pellet comprising of residual plant 
matter was also retained and stored at -20°C for later use. 
 
2.24. Protein extraction from agroinfiltrated plant tissue under 
denaturing conditions 
 
The agroinfiltrated leaf matter, retained from Section 2.23, was resuspended in 300 µl 
PBS containing 8M Urea and Complete EDTA-free Protease Inhibitor (Roche, South 
Africa). The plant matter was vigorously vortexed to ensure the complete 
resuspension of agroinfiltrated leaf tissue and the samples incubated at 4ºC for 1 hour; 
with gentle shaking. The samples were clarified by 10 minutes of centrifugation, at 





2.25. Direct protein extraction from the apoplastic spaces of 
agroinfiltrated plant leaves  
 
Agroinfiltrated leaves were syringe infiltrated with 1 ml of sterile PBS supplemented 
with 1× Complete EDTA-free Protease Inhibitor (Roche, South Africa); as indicated 
in Section 2.22. The leaves were sliced vertically, with a scalpel, on either side of the 
leaf midrib. The leaf slices were carefully rolled and placed inside the mouth of a spin 
column from which the silica membrane had been removed (QIAprep Spin Miniprep 
Kit) (QIAGEN, South Africa). The spin column, containing the agroinfiltrated leaf 
tissue was transferred to a sterile 2 ml eppindorf tube. The samples were centrifuged 
at 5000 rpm for 5 minutes; to draw protein from the apoplastic spaces of plant leaves. 
Residual plant debris remaining in the flow through was collected by centrifugation, 
at 14 000 rpm for 15 minutes and the supernatant retained at -20⁰C. 
 
2.26. Western blotting to detect recombinant HIV-1 envelope in 
extract from agroinfiltrated plant leaves 
 
The crude leaf extract samples were analysed for the presence of the recombinant 
antigens by western blotting as indicated in Section 2.18 or using the Mini-
PROTEAN® Tetra SDS-PAGE System (Bio-Rad, South Africa). In the case of the 
latter approach, an 8 µl aliquot of 5× Loading dye (Appendix B) was added to 32 µl 
of leaf extract and the samples resolved on a 7% Acrylamide suspended in 10× 
Electrophoresis running buffer (Appendix B). The protein samples were 
electrophoresed for 2 hours, at 130 V. The remainder of the western blotting protocol 
was conducted in accordance with Section 2.18. Aliquots of 8 µl of crude E. coli 
inclusion body-derived H5, was used as a positive control during western blotting of 
the recombinant H5 and H5-ELP antigens (infiltration controls).  
 
Recombinant envelope antigens were detected using a 1:1000 dilution of either 
Polyclonal anti-gp120 primary antibody (Serotec) or MRC ADP 408/5104 polyclonal 
anti-gp160 primary antibody. In turn the primary antibody was detected with 1:10 000 
dilution of GT34 anti-Sheep/Goat antibody conjugated to alkaline phosphatase 
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(Sigma-Aldrich). The protocol was later refined by increasing the primary antibody 
concentration to 1:500, decreasing the secondary antibody concentration to 1:20 000 
and increasing the incubation time of the PVDF membrane with the substrate to 1 
hour. Additionally, the amount of the recombinant CN54 envelope positive control 
was decreased to 20 ng.  
 
In contrast recombinant H5-ELP and full length H5 proteins were detected with 
1:2000 dilution of anti-his mouse monoclonal primary antibody (AD1.1.10) (Serotec) 
and 1:5000 dilution of mouse monoclonal H5N1 primary antibody [8D2] (Abcam) 
respectively. Both primary antibodies were detected with a 1:10 000 dilution of poly-
clonal anti-mouse IgG conjugated to alkaline phosphatase (Sigma). 
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CHAPTER 3: RESULTS 
 
3.1. Selection of an antigenically promising HIV-1 envelope protein 
for vaccine development 
 
The first stage of this study comprised a highly rational selection process to identify a 
suitable HIV-1 envelope protein for the development of candidate HIV-1 subunit 
vaccines. Several candidate viruses were identified from the CAPRISA Acute 
Infection cohort from participants who developed broadly neutralizing antibodies. All 
of these viruses were of subtype C origin and had been isolated within the first year 
post infection, ensuring that the vaccine immunogen was representative of transmitted 
viruses that are likely to be encountered by sexual exposure (114). An HIV-1 Subtype 
C viral isolate was specifically chosen for the design of the vaccine immunogens as 
this clade represents the predominant strain in South Africa  and accounts for the 
majority of infections worldwide (128, 136, 137).  
 
A viral isolate from participant CAP256 was selected for the development of the 
candidate vaccine immunogens described in this study. The virus of interest was 
responsible for a secondary HIV-1 infection, approximately 13-15 weeks after 
primary infection, ultimately leading to the development of broadly cross-neutralizing 
antibodies that overlapped the PG9/16 antibody epitope (232, 235). It was further 
demonstrated, by Penny Moore and colleagues, that the viral envelope was highly 
sensitive to prototype broadly cross-neutralizing monoclonal antibodies comprising 
all known regions of vulnerability of the envelope glycoprotein (summarized below in 
Table 3.1) (235). The use of this envelope therefore ensured the structural integrity 
and exposure of important antibody epitopes and allowed us to partly account for any 
virological variables that may have been responsible for the induction of such a 





Table 3.1: Neutralization sensitivity of the CAP256 superinfecting envelope glycoprotein 
to prototype broadly neutralizing monoclonal antibodies (modified from (235).  
 
Specificity CD4bs MPER N332 Anti-V2, N160 
Prototype mAb VRC01 4E10 PGT128 PG9 PG16 PGT145 
Sensitivity (µg/ml) 0.6811 3.59 0.0447 0.0453 0.0055 1.25 
 
3.2. Overview of immunogen design  
 
Three novel HIV-1 envelope antigens were designed for use in a heterologous DNA 
prime-protein boost immunization regimen. The coding sequences of all 3 
recombinant proteins were derived from the native viral sequence of the 
superinfecting CAP256 envelope glycoprotein (gp160) (114, 232, 235). The envelope 
clone (clone 256.3mo.9C) was provided by Dr Penny Moore (Senior Medical 
Scientist, Centre for HIV and STIs, National Institute for Communicable Diseases, 
Johannesburg) in the form of an expression cassette cloned into the pcDNA3.1D/V5-
His-TOPO® plasmid vector (pLM1). In addition to the CAP256 envelope coding 
sequence, the plasmid also encoded the 3' end of rev exon 1, the vpu coding sequence 
in its entirety and the 5' end of the nef gene. 
 
In the case of all 3 antigens, the native HIV-1 envelope signal peptide was substituted 
with a heterologous signal peptide (LPH) derived from the heavy chain of murine 
mAb24. The rationale underlying this decision was largely due to the retarded 
maturation of the HIV-1 envelope glycoprotein during its biosynthesis which has been 
attributed to the inefficient cleavage of the signal peptide (60, 82, 192). This 
ultimately results in prolonged retention of the glycoprotein in the ER and hinders its 
efficient production (182, 191). Additionally, several studies have shown that the 
expression of the glycoprotein could be dramatically improved in heterologous 
systems by the use of foreign signal peptides in place of the native HIV-1 envelope 
signal sequence (23, 107, 189). Furthermore the LPH signal peptide ensures the 
translocation of the recombinant protein through the ER and into the apoplastic spaces 




The first antigen comprised of a truncated derivative of the full length HIV-1 
envelope glycoprotein, gp160. The coding sequence was prematurely terminated by 
means of a truncation in the C terminal cytoplasmic tail (Cyt) to generate gp150, as 
described  for the SAAVI DNA and MVA vaccines currently being evaluated in 
clinical trials (34, 35, 317). The rationale underlying this approach was based on 
reports that truncation of the HIV-1 envelope cytoplasmic tail results in a partially 
triggered conformation that favours the exposure of conserved neutralization sensitive 
epitopes (83). Additionally, Vzorov et al. have reported that truncation of the SIV 
envelope cytoplasmic tail culminated in enhanced expression by DNA vaccines in 
vitro which correlated with improved immunogenicity in vivo (374). The gp150 
immunogen retained the exterior subunit region of the HIV envelope glycoprotein 
(gp120) along with the native ectodomain (Ecto), transmembrane domain (TM) and a 
portion of the cytoplasmic tail of the gp41 transmembrane subunit. The putative 
structure of the monomeric form of the gp150 glycoprotein is shown in the schematic 
in Figure 3.1. It should be noted, however that the gp150 glycoprotein normally 
exists as a trimer. 
 
The other 2 immunogens comprised of chimeric fusion proteins encompassing 
elements of the HIV-1 envelope glycoprotein (gp160) and the transmembrane subunit 
(HA2) of H5N1 influenza haemagglutinin glycoprotein. The first chimera, gp120-
HA2, retained the full length exterior subunit of the HIV-1 envelope glycoprotein 
(gp120) translationally fused to the full length transmembrane subunit of influenza H5 
(HA2). The transmembrane subunit, HA2, comprised the cytoplasmic tail, 
transmembrane and ectodomain portions of the influenza haemagglutinin; essentially 
replacing the analogous regions of the HIV-1 gp41 subunit (Figure 3.2). 
 
The second chimera, gp140-HA2tr, comprised of the exterior subunit (gp120) and 
ectodomain of HIV-1 gp160 translationally fused to a truncated derivative of the HA2 
subunit of haemagglutinin. The HA2 subunit was truncated at the N terminus to 
remove the ectodomain of the protein which protrudes beyond the exterior of the 
virion. The chimeric glycoprotein retained both the transmembrane region and 
cytoplasmic tail of haemagglutinin with the ectodomain of HIV-1 envelope replacing 































Figure 3.1: Annotated schematic of A) the coding sequence and B) the putative structure 
of the recombinant gp150 glycoprotein in its monomeric form. The gp150 immunogen 
was derived from the native coding sequence of the CAP256 superinfecting virus which has 
been truncated in the cytoplasmic tail region and the native signal sequence substituted for the 
LPH signal peptide. The ectodomain (Ecto), transmembrane domain (TM) and cytoplasmic 














































Figure 3.2: Annotated schematic of A) the coding sequence and B) the putative structure 
of the chimeric gp120-HA2 and gp140-HA2tr antigens in their monomeric form. The 
chimeric antigens comprised of translation fusions between elements of the HIV-1 CAP256 
superinfecting virus envelope glycoprotein and the influenza transmembrane subunit (HA2) of 
influenza H5 glycoprotein. The ectodomain (Ecto), transmembrane domain (TM) and 
cytoplasmic tail (Cyt) of the antigens are indicated in the figure above.















3.3. Cloning strategy used for the construction of recombinant 
pTRA-A expression vectors encoding novel HIV-1 envelope antigens  
 
The coding sequences of the antigens were constructed by PCR using plasmid DNA 
templates encoding the HIV-1 CAP256 superinfecting virus envelope and the full 
length influenza H5 haemagglutinin gene of H5N1. As alluded to earlier, the 
superinfecting envelope clone was received as a rev-vpu-env-nef expression cassette 
encoded by the pcDNA3.1D/V5-His-TOPO® plasmid vector (pLM1). In the case of 
the influenza H5 haemagglutinin template; the A. tumefaciens GV3101::pMP90RK 
(pTRA-H5) clone, generated in an independent study, was obtained from Sandiswa 
Mbewana (PhD candidate, Department of Molecular and Cell Biology, University of 
Cape Town) (238). This recombinant strain of A. tumefaciens had been transformed 
with recombinant pTRA-A encoding a humananized version of the influenza H5 
haemagglutinin gene (A/Viet Nam/1194/2004).  
 
The gp150 PCR product was amplified directly from the CAP256 envelope coding 
sequence in a single PCR reaction. In contrast, the 2 chimeric glycoproteins were 
constructed by overlap-extension PCR (Figure 3.3). This technique allowed the in 
frame fusion of 2 DNA fragments from unrelated sources, without the introduction of 
synthetic restriction enzyme recognition sequences which would alter the amino acid 
sequence of the protein (133). The overlap-extension PCR involved 3 sequential PCR 
reactions to generate a translational fusion between 2 DNA fragments. The 2 
fragments were first amplified in separate reactions using primers that generated a 
complementary overlap at the 3’ end of the HIV-1 envelope PCR product and the 5’ 
end of the influenza HA2 PCR product. The 2 DNA fragments were then used as 
templates in a third reaction where the templates were denatured and annealed to each 
other by their complementary overlap to prime the final reaction (360). The coding 
sequences of each of the antigens were then cloned into the pJET1.2/blunt vector. The 
PCR fragment was excised from the plasmid backbone by means of a NcoI-SpeI dual 
restriction enzyme digest and cloned into the pTRA-A plasmid vector, in place of the 
H5 insert which had been liberated from the plasmid using NcoI and XbaI restriction 




























Figure 3.3: Construction of; A) the gp120-HA2  and B) gp140-HA2tr chimeric 
glycoprotein gene sequences by overlap extension PCR.  
 
In order to maintain the reading frame a single nucleotide was incorporated into the 
coding sequence of each of the recombinant proteins resulting in the addition of a 
valine residue at the N terminus of the protein, immediately after the LPH signal 
peptide. Synthetic NcoI and SpeI restriction enzyme recognition sites were 
incorporated into the primers that annealed to the terminal ends of the coding 
sequences in order to facilitate the cloning of all 3 PCR products into the pTRA-A 






























Figure 3.4: Overview of the cloning strategy used for the construction of the 
recombinant pTRA-A: gp150 plant expression vector. (RK2 ori = A. tumefaciens origin of 
replication, ColE1 = E. coli origin of replication, bla = ampicillin/carbenicillin resistance 
gene, SAR = Scaffold attachment region, LB = left border, RB = Right border, p35SS = 
CaMV duplicated transcriptional enhancer, pA35S = CaMV polyadenylation signal, LPH = 
signal peptide, CHS = chalcone synthase 5’ untranslated region, Pnos = nopaline synthase 
promoter,  pAnos = nopaline synthase polyadenylation signal, nptII = kanamycin resistance 
gene, Eco471R = lethal selection gene, PlacUV5 = modified Plac promoter, rep(pMB1) = 





























Figure 3.5: Overview of the cloning strategy used for the construction of the 
recombinant pTRA-A: gp120-HA2 plant expression vector. (RK2 ori = A. tumefaciens 
origin of replication, ColE1 = E. coli origin of replication, bla = ampicillin/carbenicillin 
resistance gene, SAR = Scaffold attachment region, LB = left border, RB = Right border, 
p35SS = CaMV duplicated transcriptional enhancer, pA35S = CaMV polyadenylation signal, 
LPH = signal peptide, CHS = chalcone synthase 5’ untranslated region, Pnos = nopaline 
synthase promoter,  pAnos = nopaline synthase polyadenylation signal, nptII = kanamycin 
resistance gene, Eco471R = lethal selection gene, PlacUV5 = modified Plac promoter, 































Figure 3.6: Overview of the cloning strategy used for the construction of the 
recombinant pTRA-A: gp140-HA2tr plant expression vector. (RK2 ori = A. tumefaciens 
origin of replication, ColE1 = E. coli origin of replication, bla = ampicillin/carbenicillin 
resistance gene, SAR = Scaffold attachment region, LB = left border, RB = Right border, 
p35SS = CaMV duplicated transcriptional enhancer, pA35S = CaMV polyadenylation signal, 
LPH = signal peptide, CHS = chalcone synthase 5’ untranslated region, Pnos = nopaline 
synthase promoter,  pAnos = nopaline synthase polyadenylation signal, nptII = kanamycin 
resistance gene, Eco471R = lethal selection gene, PlacUV5 = modified Plac promoter, 
rep(pMB1) = E.coli origin of replication, MCS = multiple cloning site ). 
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3.4. PCR amplification of the gp150 coding sequence and assembly of 
the chimeric gp120-HA2 and gp140-HA2tr genes 
 
A 2137 bp DNA fragment, comprising of the gp150 coding sequence, was amplified 

















Figure 3.7: Agarose gel electrophoresis of the gp150 PCR product along with controls 
whereby template DNA (No DNA), Forward primer (No F) and reverse primer (No R) 
were omitted. The PCR products were resolved on a 0.8% agarose gel alongside a 10 µl 
aliquot of Fermentas O’GeneRuler™ 1kb DNA ladder. 
 
The gp120-HA2 and gp140-HA2tr coding sequences were both assembled by overlap 
extension PCR using sequential PCR reactions. In the case of the chimeric gp120-
HA2 antigen; the gp120 and HA2 fragments were first amplified in separate PCR 
reactions giving rise to DNA fragments of 1445 bp and 697 bp respectively (Figure 
3.8 A and Figure 3.8 B). The 2 PCR products were then denatured and annealed to 
each other in a third reaction to prime the amplification of the chimeric gp120-HA2 
gene. The final reaction yielded a 2107 bp DNA fragment corresponding to the 
chimeric gene (Figure 3.8 C). 
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Figure 3.8: PCR amplification of A) the gp120 coding sequence, B) the HA2 coding 
sequence and C) the chimeric gp120-HA2 antigen. Each PCR reaction was performed in 
parallel with controls whereby template DNA (No DNA), forward primer (No F) and reverse 
primer (No R) were omitted. The PCR products were resolved on a 0.8% agarose gel 
alongside either 10 µl of Fermentas O’GeneRuler™ 1kb DNA ladder for the gp120 and 
gp120-HA2 PCR products or Fermentas O’GeneRuler™ 100 bp Plus DNA ladder for the HA2 
PCR products. 
 
Similarly, the gp140-HA2tr gene sequence was also assembled by overlap extension 
PCR. The gp140 and HA2tr coding sequences were first individually amplified giving 
rise to PCR products of 1971 bp and 145 bp respectively (Figure 3.9 A and Figure 
3.9 B). The 2 products were then used as templates to assemble the 2168 bp chimeric 





















Figure 3.9: PCR amplification of A) the gp140 coding sequence, B) the HA2tr coding 
sequence and C) the coding sequence of gp140-HA2tr chimeric antigen. Each PCR 
reaction was performed in parallel with controls whereby template DNA (No DNA), Forward 
primer (No f) and reverse primer (No R) were omitted. The PCR products were resolved on a 
0.8% agarose gel alongside a 10 µl aliquot of Fermentas O’GeneRuler™ 1kb DNA. 
 
3.5. Construction of recombinant pTRA-A vectors encoding the 
gp150, gp120-HA2 and gp140-HA2tr antigens 
 
The antigen coding sequence for each immunogen was amplified by PCR and the 
resulting PCR products purified and ligated into the pJET1.2/blunt cloning vector. 
The ligation products were transformed into E. coli DH5α cells and putative 
recombinants screened by restriction analysis. The PCR product was then excised 
from the pJET1.2/blunt vector backbone and ligated into the pTRA-A: H5 plasmid 
vector, in place of the H5 insert. Products of the ligation reaction were transformed 
into E. coli DH5α cells and putative recombinants screened by restriction enzyme 
digestion. A single recombinant colony was propagated and subjected to a medium 
scale DNA isolation to obtain sufficient DNA for expression studies in planta.  
 
The genetic integrity of each of the recombinant pTRA-A expression vectors was 
verified by restriction analysis using the restriction enzymes outlined in Table 3.2 
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(Figure 3.10 A-C) and independently confirmed by sequencing using the primers 
outlined in Section 2.14; Table 2.11. 
 
Table 3.2: Summary of the enzymes used to verify the genetic integrity of the 
recombinant pTRA-A expression vectors designed in this study.  
 
Plasmid Enzyme (s) Expected products (bp) 
pTRA-A:gp150 EcoRV 1405, 1652, 6669 
 KpnI 9726 
  EcoRI- SphI 3142, 6584 
 NcoI 9726 
 PstI 9726 
pTRA-A:gp120-HA2 EcoRI 9695 
 EcoRV 1405, 1652, 6638 
 KpnI- NotI 2041, 7654 
 NcoI 9695 
pTRA-A:gp140-HA2tr EcoRV 1405, 1652, 6599 
 PstI 2045, 7611 
 NcoI- NotI 2043, 7613 
 SphI- KpnI 3292, 6364 
 EcoRI 9656 




















Figure 3.10: Restriction analysis to verify the genetic integrity of A) pTRA-A: gp150, B) pTRA-A: gp120-HA2 and C) pTRA-A: gp140-HA2tr. The 
samples were electrophoresed on a 0.8% agarose gel alongside a 250 ng aliquot of undigested plasmid DNA and a 10 µl aliquot of Fermentas O’GeneRuler™ 
1kb DNA (MW). The restriction enzymes used are indicated above each lane on the agarose gel. 
A B C 
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3.6. Cloning strategy used for the construction of matched 
pTHPcapR-vectored DNA vaccines 
 
Three matched DNA vaccines were constructed, using the pTHPcapR DNA vaccine 
vector system, enabling their potential use in a heterologous prime-boost vaccination 
regimen with the recombinant plant-produced antigens. The antigen coding sequence 
of each of the 3 vaccines was amplified directly by PCR, in a single reaction, from the 
recombinant pTRA-A vectors assembled in Section 3.5. Each of the immunogens 
retained the LPH signal peptide, which was substituted for the native HIV-1 envelope 
signal sequence for expression in planta, as well as the same transcriptional initiation 
and termination signals. The immunogens were amplified with primers containing 
synthetic 5’ HindIII and 3’ XbaI restriction enzyme recognition sequences enabling 
the antigens to be cloned into the pTHPcapR DNA vaccine backbone.  
 
The pTJDNA4 plasmid, developed in an independent study, was obtained from 
Tsungai Jongwe (PhD candidate, Department of Medical Virology, University of 
Cape Town). The plasmid vector, comprising of the pTHcapR DNA vaccine vector 
with porcine circovirus-derived enhancer element, encodes a full length HIV-1 
subtype C gag mosaic immunogen flanked by HindIII and XbaI restriction enzyme 
recognition sequences. The coding sequences of each of the three antigens were 
amplified by PCR and cloned into the pJET1.2/blunt cloning vector. The gene 
sequences were then excised from the pJET1.2/blunt plasmid backbone by means of a 
HindIII-XbaI dual restriction enzyme digest and cloned into the pTHPcapR plasmid 
vector, in place of the HIV-1 mosaic insert which had been liberated from the plasmid 
































Figure 3.11: Overview of the cloning strategy used for the construction of the 
pTHPcapR: gp150 DNA vaccine. (ColE1 = E. coli origin of replication, bla = 
ampicillin/carbenicillin resistance gene, Eco471R = lethal selection gene, PlacUV5 = 
modified Plac promoter, rep(pMB1) = E. coli origin of replication, MCS = multiple cloning 
site, PcapR = porcine circovirus type 1 enhancer element, Pcmv = human CMV 






























Figure 3.12: Overview of the cloning strategy used for the construction of the 
pTHPcapR: gp120-HA2 DNA vaccine. (ColE1 = E. coli origin of replication, bla = 
ampicillin/carbenicillin resistance gene, Eco471R = lethal selection gene, PlacUV5 = 
modified Plac promoter, rep(pMB1) = E. coli origin of replication, MCS = multiple cloning 
site, PcapR = porcine circovirus type 1 enhancer element, Pcmv = human CMV 




































Figure 3.13: Overview of the cloning strategy used for the construction of the 
pTHPcapR: gp140-HA2tr DNA vaccine. (ColE1 = E. coli origin of replication, bla = 
ampicillin/carbenicillin resistance gene, Eco471R = lethal selection gene, PlacUV5 = 
modified Plac promoter, rep(pMB1) = E. coli origin of replication, MCS = multiple cloning 
site, PcapR = porcine circovirus type 1 enhancer, Pcmv = human CMV 




3.7. PCR amplification of the gp150, gp120-HA2 and gp140-HA2tr 
antigen coding sequences for the construction of pTHPcapR-vectored 
DNA vaccines 
 
The coding sequence of each of the vaccine antigens was amplified by PCR from the 
recombinant pTRA-A vectors in order to add synthetic restriction sites to the terminal 
ends of the genes for cloning. A 2199 bp fragment, comprising the gp150 coding 
sequence, was amplified directly from the pTRA-A: gp150 plasmid DNA template 
(Figure 3.14 A). Similarly the 2 chimeric antigens were amplified directly from their 
corresponding pTRA-A expression vectors in a single step PCR reaction giving rise to 
PRC products of 2166 bp and 2127 bp for the gp120-HA2 and gp140-HA2tr products 















Figure 3.14: PCR amplification of A) the gp150 coding sequence, B) the gp120-HA2 
coding sequence and C) the gp140-HA2tr coding sequence. Each PCR reaction was 
performed in parallel with controls whereby template DNA (No DNA), Forward primer (No 
F) and reverse primer (No R) were omitted. The PCR products were resolved on a 0.8% 
agarose gel alongside a 10 µl aliquot of Fermentas O’GeneRuler™ 1kb DNA. 
 
A B C 
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3.8. Construction of recombinant pTHPcapR DNA vaccines encoding 
the gp150, gp120-HA2 and gp140-HA2tr antigens 
 
The pTHPcapR-vectored DNA vaccines were constructed using the same approach 
described for the construction of the recombinant pTRA-A expression vectors 
(Section 3.3). Briefly, the antigen coding sequences were PCR amplified and cloned 
into the pJET1.2/blunt plasmid backbone. The PCR product was then excised from 
the plasmid backbone and cloned into the pTHPcapR backbone in place of the HIV 
subtype C mosaic gag gene. The genetic integrity of the DNA vaccines were verified 
by restriction analysis using the enzymes outlined in Table 3.3 (Figure 3.15). 
 
Table 3.3: Restriction enzymes used to verify the genetic integrity of the recombinant 
pTHPcapR DNA vaccines.  
 
Plasmid Enzyme (s) Expected products (bp) 
pTHPcapR:gp150 HindIII-XbaI 97, 1152, 2126, 3814 
 BglII 338, 3258, 3593 
  NcoI 97, 1152, 5940 
 SphI 3238, 3951 
 HpaI 7189 
pTHPcapR:gp120-HA2 HindIII-XbaI 5002, 2154 
 BglII 338, 3258, 3260 
 NcoI 97, 1152, 5907 
 ApaI 29, 3296, 3831 
pTHPcapR:gp140-HA2tr HindIII-XbaI 5002, 2115 
 BglII 338, 3521, 3258 
 NcoI 97, 1152, 5868 
 HpaI 7117 




















Figure 3.15: Restriction analysis to verify the structural integrity of; A) pTHPcapR: gp150, B) pTHPcapR: gp120-HA2 and C) pTHPcapR: gp140-
HA2tr plasmid DNA. The samples were electrophoresed on a 0.8% agarose gel alongside a 250 ng aliquot of undigested plasmid DNA (uncut) and a 10 µl 
aliquot of Fermentas O’GeneRuler™ 1kb DNA (MW). The restriction enzymes used are indicated above each lane on the agarose gel.
A B C 
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In the case of all 3 plasmids, the products yielded by the enzymatic reactions were of 
the expected sizes (Figure 3.15 A-C). The integrity of the 3 DNA vaccines was 
independently verified by sequencing using the primers outlined in Section 2.15; 
Table 2.11.  
3.9. Characterization of pTHPcapR DNA vaccines in vitro 
 
3.9.1. Western blotting of transfected HEK293 cell lysate 
Western blotting was used to confirm expression of the immunogens in transfected 
HEK 293 cells. Both the the MRC ADP 408/5104 polyclonal anti-gp160 primary 
antibody (Figure 3.16 A) and the Serotec polyclonal anti-gp120 primary antibody 
(Figure 3.16 B) reacted with the CAP256 derived antigens present in transfected 
HEK 293 cell lysate samples. In both western blots high levels of all 3 immunogens 
were detected with negligible non-specific reactivity. Both antibodies also yielded 
distinct bands for the recombinant CN54 positive control and the SAAVI-C2 DNA 
vaccine at the expected sizes of 130 kDa and 150 kDa respectively. However, neither 
antibody detected any discernible expression of the parental CAP256 envelope 
glycoprotein in HEK 293 cells transfected with pLM1, from which the vaccine 











Figure 3.16: Western blotting of transfected HEK293 cell lysate using; A) MRC ADP 
408/5104 polyclonal anti-gp160 primary antibody and B) Serotec polyclonal anti-gp120 
primary antibody. The cell lysate was harvested 48 hours after transfection and loaded onto 
a 7% Criterion Tris-Acetate Gel. The samples were electrophoresed in parallel with 100 ng of 
recombinant CN54 envelope (+’ve) and a 10 µl aliquot of Thermo Scientific PageRuler 




The experiment was repeated to account for any biological variation but the CAP256 
envelope could still not be detected by western blotting, despite verifying that the 
transfection was successful. A standard curve was generated for luciferase standards 
and the transfection efficiency of the pLM1 (encoding the CAP256 superinfecting 
envelope) and SAAVI DNA C2 plasmids extrapolated based on the level of luciferase 
expression of the co-transfected pGL4.13 (luc2/SV40) reporter plasmid. The lysate 
was determined to contain 258.8 pg/ml and 39.0 pg/ml of luciferase for the pLM1 and 
SAAVI DNA C2 samples respectively, confirming that the transfection was 












Figure 3.17: Standard curve of relative luminescence units generated by luciferase 
enzyme standards. The transfection efficiency was extrapolated from the standard curve and 
determined to fall within the linear range of the standard curve. 
 
3.9.2. Immunostaining of transfected HEK293 cells 
 
After successfully demonstrating expression of each of the recombinant antigens by 
western blotting, immunofluorescence assays were conducted on fixed HEK293 cells 
following transfection with the DNA vaccines. These experiments were conducted not 
only to confirm expression but also to determine the subcellular localization of 
antigens and to determine if expression of the full length CAP256 envelope 
glycoprotein could be demonstrated. The 3 DNA vaccines were transfected into 
HEK293 cells alongside the SAAVI DNA-C2 vaccine which was used as a positive 
control (SAAVI), the pLM1 expression plasmid encoding the parental envelope from 
which the vaccines were designed (CAP256) and a negative control whereby plasmid 
DNA was omitted from the transfection reaction (Negative). The cells were fixed 48 
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hours after transfection and the cell nuclei were stained blue using Hoechst nuclear 
stain. The recombinant HIV-1 antigens were stained red using MRC ADP 408/5104 
polyclonal anti-gp160 primary antibody and Donkey anti-Goat CY3 secondary 
antibody.  
 
The SAAVI DNA-C2 vaccine yielded high levels of HIV-1 envelope expression 
demonstrated by the strong red fluorescence signal of transfected cells (Figure 3.18 
B). The “cells only” control and the experimental controls whereby primary antibody 
was omitted didn’t yield any fluorescence, confirming the specificity of the antibodies 
(Figure 3.18 A,  Figure 3.18 D-F and J-L). Faint fluorescence was determined from 
cells transfected with the pLM1 plasmid suggesting very poor expression of the full 
length CAP 256 envelope glycoprotein (Figure 3.18 C). This is consistent with the 
results from the western blotting experiment, described in Section 3.9.1 (Figure 
3.16), and implies that the level of CAP256 envelope expression is below the 
threshold detectable by western blotting. High levels of expression were witnessed for 
each of the recombinant HIV-1 envelope antigens (Figure 3.18 G-I).  
 
Although the fluorescent signals were not quantified, the gp120-HA2 protein appeared 
to yield the highest apparent levels of protein expression. However it is noteworthy 
that this could be a reflection on variation in the transfection efficiency between 
experimental samples or the localization of the signal. The transfection efficiency 
could not be determined for the immunofluorescence assay as the cells were fixed and 
the assay requires lysis of transfected cells. The fluorescent signal for the gp120-HA2 
antigen appeared to be localized to the cell periphery suggesting that the protein may 
be membrane-associated (Figure 3.18 H). In contrast the other 2 antigens (gp150 and 
gp140-HA2tr) (Figure 3.18 G and Figure 3.18 H) appeared more diffuse in 
subcellular localization; reminiscent of the expression witnessed for the SAAVI 
DNA-C2 vaccine (Figure 3.18 B). The recombinant gp150 and gp140-HA2tr proteins 
appeared to be distributed within the cell, as well as at the cell periphery (Figure 3.18 
G and Figure 3.18 I). These observations suggest that the presence of the influenza 
transmembrane glycoprotein subunit (HA2) may have improved the surface density of 
the recombinant antigen. The lack of a similar observation for the gp140-HA2tr 
antigen, whereby the influenza HA2 subunit was truncated, suggests that the influenza 

































Figure 3.18: Immunostaining to detect recombinant antigen expression following 
transfection of HEK 293 cells with recombinant pTHPcapR-vectored DNA vaccines. In 
the figure above, for each experimental sample (A-C & G-I), the corresponding control 
whereby the primary antibody was omitted is included below (D-F & J-L). Control 
transfections were performed alongside the experimental samples comprising of the SAAVI 
DNA-C2 vaccine (SAAVI) (B & E), a negative transfection control (cells only) (A & D) and 
transfection with a plasmid encoding the CAP256 envelope expression cassette (pLM1) from 
which the vaccines were derived (CAP 256) (C & F). The white arrow indicates faint 






























3.10. Generation of stable recombinant A. tumefaciens 
GV3101::pMP90RK stocks for agroinfiltration of tobacco plants 
 
Recombinant A. tumefaciens strains were generated by electroporating competent 
GV3101::pMP90RK cells with the pTRA-A plant expression vectors designed in this 
study. The genetic integrity of the recombinant plasmids were verified following 
electroporation, by back-transformation of plasmid DNA isolated from recombinant 
A. tumefaciens, into E. coli DH5α cells. The DNA derived from the E. coli colonies 
was then transformed into E. coli DH5α cells and the DNA derived from the 
recombinant colonies screened by restriction analysis in accordance with Table 3.4. 
 
Table 3.4: Summary of the enzymes used for screening the stability of A. tumefaciens-
derived plasmid DNA after in vitro culturing. 
 
Plasmid Restriction enzyme (s) Expected products (bp) 
pTRA-A:gp150 NcoI- SphI 3251, 6475 
pTRA-A:gp120-HA2 NcoI- NotI 2082, 7613 
pTRA-A:gp140-HA2tr  NcoI- NotI 7613, 2043 
 
Restriction analysis revealed bands of the expected sizes for all of the putative 
recombinant clones that were screened verifying that the transformation had been 



















Figure 3.19: Screening of recombinant; A) pTRA-A: gp150, B) pTRA-A: gp120-HA2 and C) pTRA-A: gp140-HA2tr plasmid DNA derived from 
putative recombinant A. tumefaciens clones. DNA derived from 5 E. coli colonies was screened by restriction analysis and the resulting restriction 
fragments resolved on a 0.8% agarose gel (1-5). The samples were electrophoresed alongside 10 µl of undigested pTRA-A: gp150 plasmid DNA (uncut) and 
a 10 µl aliquot of Fermentas O’GeneRuler™ 1kb DNA ladder (MW). pTRA:  gp150 plasmid DNA was screened with NcoI and SphI restriction enzymes, 
whereas pTRA-A: gp120-HA2 and pTRA-A: gp140-HA2tr samples were screened with NcoI- NotI restriction enzymes. 
A B C 
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3.11. Pilot experiment to assess the transient expression of 
recombinant HIV-1 envelope antigens in planta 
 
As a proof-of-concept experiment to verify that plants had the capacity to express the 
newly designed HIV-1 envelope proteins, 6-8 week old tobacco plants were subjected 
to a 9 day protein expression time trial. Tobacco plants were infiltrated with 
recombinant A. tumefaciens strains expressing the desired HIV-1 antigen and the 
dynamics of protein expression followed over a 9 day period. A crude extract of leaf 
protein was harvested on days 3, 5, 7 and 9 post agroinfiltration and subjected to 
western blotting, to establish both the duration of protein expression and to determine 
when protein expression peaked.  
 
The western blots failed to reveal any discernible expression of any of the 3 antigens, 
at any of the time points sampled, over the 9 day period following agroinfiltration 
(Figure 3.20 A-C). In each case the positive control (recombinant CN54 envelope 
protein) was detected, verifying the reactivity of the antibodies used and that the 
















Figure 3.20: Western blotting to detect recombinant A) gp150, B) gp120-HA2 and C) gp140-HA2tr protein expression in crude leaf extract for a 9 day 
period following agroinfiltration of tobacco plants. At each time point; a negative control sample comprising of leaf tissue infiltrated with infiltration 
media (-) was loaded onto a 7% Criterion Tris Acetate Gel alongside the experimental sample (+). The samples were resolved in parallel with 100 ng of 
recombinant CN54 envelope (+’ve control) and a 10 µl aliquot of Thermo Scientific PageRuler Prestained Protein Ladder.
A B C 
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3.12. Influence of a PTGS suppressor on the yield and duration of 
antigen expression 
 
The lack of discernible protein expression following western blotting of the leaf lysate 
from agroinfiltrated tobacco plants could potentially be attributed to a number of 
variables that are known to influence the expression of heterologous antigens in 
planta. However, one of the factors most likely to be responsible for the lack of 
expression is post transcriptional gene silencing (PTGS), a phenomenon that is 
associated with the antiviral plant immune response (368). In order to determine the 
influence of PTGS on the expression of the recombinant proteins, the transient 
expression time trial was repeated with the co-infiltration of the LBA4404 (PBIN-
NSs), which contains the p19 supressor from Tomato spotted wilt virus, along with 
each recombinant A. tumefaciens strain generated in this study.  Additionally, a 
positive control comprising of A. tumefaciens (pTRA-A: H5-ELP) was infiltrated 
alongside the experimental expression, in both the presence and absence of the 
LBA4404 (pBINSs) strain. The recombinant strain encodes a 66 kDa protein product 
comprising of the full length H5 protein fused in frame to a histidine tag and a 51 bp 
ELP fragment. This was included in the experimental procedure to corroborate that 
the infiltration was successful. This particular construct has been extensively 
characterized and has been demonstrated to achieve high levels of H5-ELP antigen 
expression. 
 
The co-infiltration of LBA4404 (pBIN-NSs) along with the recombinant A. 
tumefaciens strains generated in this study failed to have any impact on the expression 
of the recombinant antigens. No expression of the antigen was detected at any of the 
time points sampled, in either the presence or absence of the NSs silencing suppressor 
(Figure 3.21 B, Figure 3.21 C and Figure 3.21 D). In contrast, expression of the 
recombinant H5-ELP protein was discernible at 3 days post infiltration in both the 
presence and absence of the NSs suppressor. On day 5 the magnitude of expression in 
the presence of the NSs suppressor was noticeably greater than when the A. 
tumefaciens (H5-ELP) construct was infiltrated alone. Additionally, on days 7 and 9 
expression of the recombinant antigen was only detectable when the LBA4404 
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(pBINSs) strain had been co-infiltrated (Figure 3.21 A). These results highlight the 
profound influence of mitigating PTGS in order to enhance the duration and 
magnitude of foreign antigens in planta. Furthermore, the successful expression of the 
H5-ELP protein confirmed the validity of the transient expression system used in this 
study. 
 
The lack of detectable antigen expression prompted rescreening recombinant A. 
tumefaciens stocks that were used to inoculate cultures to infiltrate plants. The 
plasmid DNA was screened by back-transformation, as outlined in Section 3.10, 
and demonstrated to be stable (data not shown). This confirmed that the lack of 
envelope expression was not merely a reflection of PTGS and was subject to other 





































Figure 3.21: Western blotting to detect; A) H5-ELP, B) gp150, C) gp120-HA2 and D) 
gp140-HA2tr protein expression in crude leaf extract for a 9 day period following 
agroinfiltration of tobacco plants. At each time point; In addition to the experimental 
sample (+NSs) negative control samples were included whereby leaves were infiltrated with 
infiltration media only (-‘ve) or the LBA4404 (pBINSs) strain was not coinfiltratrated with 
the recombinant A.tumefaciens strain encoding the antigen (-NSs).  
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3.13. Impact of solubilizing plant cell membranes during protein 
extraction on the yield of recombinant antigens 
 
Another possible explanation for the lack of detectable expression by western blotting 
is that the antigens may have been sequestered in the plant cell membranes due to the 
presence of a transmembrane domain in the protein structure. This may have 
prevented antigens from being liberated from leaf tissue during the crude purification 
procedure resulting in the immunogens being retained in the insoluble protein 
fraction. The gp150 protein retained the native HIV-1 envelope transmembrane region 
whereas the gp120-HA2 and gp140-HA2tr antigens retained the analogous 
transmembrane domain from the H5 glycoprotein (Section 3.2; Figure 3.1 and 
Figure 3.2). The leaf pellet retained from the protein extraction time trials (Section 
3.12) was solubilized in extraction buffer containing 8M urea, to disrupt the cell 
membranes of the plant leaf cells. The resulting supernatant was probed for 
expression of the HIV-1 envelope antigens by western blotting.  
 
The altered extraction protocol failed to make any apparent difference for the gp150 
and gp120-HA2 antigens with neither antigen detected by western blotting at any of 
the time points sampled (Figure 3.22 A and Figure 3.22 B).  Expression of the 
gp140-HA2tr antigen could be detected in urea-solubilized leaf extract 24 hours post 
infiltration, with optimal expression occurring after 3 days. Faint expression of the 
antigen was also evident on days 5-9. Notably, expression of the antigen was only 
evident when LBA4404 (pBIN-NSs) was co-infiltrated with A. tumefaciens (pTRA-A: 
gp140-HA2tr). The band corresponding to the recombinant antigen appeared 



































Figure 3.22: Western blotting to detect; A) gp150 and B) gp120-HA2 and C) gp140-
HA2tr protein expression in urea-solubilized crude leaf extract for a 9 day period 
following agroinfiltration of tobacco plants. At each time point, in addition to the 
experimental sample (+NSs); negative control samples were included whereby leaves were 
infiltrated with infiltration media only (-‘ve) or the LBA4404 (pBINSs) strain was not 
coinfiltrated with the recombinant A. tumefaciens strain encoding the antigen (-NSs). The 
samples were resolved on a 7% Criterion Tris Acetate Gel alongside 100 ng of recombinant 







3.14. Impact of varying culture densities used for infiltration on 
recombinant protein expression levels 
 
Despite the promising results yielded by the inclusion of urea in the extraction buffer, 
this approach is not suitable for the extraction of proteins where the protein 
conformation is important for biological activity. The inherent caveat with using urea, 
or other detergents, during the protein extraction process is their propensity to 
denature higher order protein conformations. This is particularly unhelpful in the case 
of the HIV-1 envelope glycoprotein which is functional only as a trimeric oligomer 
(200). Additionally, certain neutralization sensitive antibody epitopes, such as the 
PG9/16 epitopes, are preferentially recognized in the context of the trimeric envelope 
(379). We therefore continued to explore other methods to optimize expression of the 
recombinant plant-produced HIV-1 subunit vaccines. 
 
Another variable that has been shown to influence the levels of expression of 
heterologous antigens, using the transient expression system exploited in this study, is 
the density of the bacterial culture at the time of infiltration. The expression time trials 
were repeated for each recombinant strain of A. tumefaciens designed in this study, at 
3 different culture densities (OD600 of 0.5, 1 and 1.5). In each case, LBA4404 (pBIN-
NSs) was co-infiltrated with the recombinant A. tumefaciens strain of interest based 
on the profound improvement in heterologous antigen expression levels demonstrated 
for the recombinant  H5-ELP antigen demonstrated in Section 3.12, Figure 3.21 A. 
Additionally, A. tumefaciens (pTRA: H5-ELP) and LBA4404 (pBIN-NSs) were co-
infiltrated into tobacco plants, at an OD600 of 0.5, to verify that the infiltration was 
successful.  
 
In the case of all 3 antigens, faint expression was evident 1 day post infiltration at all 
3 culture densities, even at OD600 of 0.5 which had not yielded any apparent protein 
expression previously (Figure 3.23 and Figure 3.24). It is noteworthy that for the 
gp150 and gp120-HA2 antigens, the levels of expression at OD600 0.5 were barely 
discernible after detection of the western blot and may not be apparent in this 
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manuscript due to the loss of detail incumbent with capturing the image (Figure 
3.23).  
 
Expression of all 3 antigens was also detected on day 3 and the apparent band 
intensity appeared greater at higher culture densities. Expression of recombinant 
gp150 in the crude plant extract was only evident at OD600 of 1 and 1.5 on day 3. In 
the case of gp120-HA2 expression was only detectable at the highest culture density 
(OD600 1.5). In constrast gp140-HA2tr expression occured at all 3 culture densities on 
day 3. Furthermore, expression of the gp140-HA2tr antigen was also detected 5 days 
postinfiltration at the lowest culture density (OD600 0.5) but not at any of the other 
time points sampled (Figure 3.24). Lastly high levels of recombinant H5-ELP 
expression was detected at both time points sampled indicating that the infiltration 
















Figure 3.23: Western blotting to detect; A) gp150 and B) gp120-HA2 protein expression 
in crude leaf extract following agroinfiltration of tobacco plants at different culture 
densities. At each time point, recombinant A. tumefaciens was co-infiltrated into tobacco 
leaves along with LBA4404 (pBINSs) at culture densities (OD600) of 0.5, 1 and 1.5. The 
experiment was performed in parallel with a negative control comprising of leaf tissue 














Figure 3.24: Western blotting to detect recombinant gp140-HA2tr protein expression in 
crude leaf extract following agroinfiltration of tobacco plants at different culture 
densities. At each time point, recombinant A. tumefaciens was co-infiltrated into tobacco 
leaves along with LBA4404 (pBINSs) at culture densities (OD600) of 0.5, 1 and 1.5. The 
experiment was performed in parallel with a negative control comprising of leaf tissue 










Figure 3.25: Western blotting to detect recombinant H5-ELP protein expression in 
crude leaf extract following agroinfiltration of tobacco plants. A. tumefaciens (H5-ELP) 
was infiltrated into tobacco plants at an OD600 of 0.5 as a positive infiltration control. At each 
time point, in addition to the experimental sample (+NSs) a negative control sample was 
included whereby leaves were infiltrated with infiltration media only (-‘ve).  
 
In order to account for the possibility that the bands observed in Figure 3.23 and 
Figure 3.24 were due to non-specific reactivity of the antibody, the western blot was 
repeated using a different negative control. The negative control used in Figure 3.23 
and Figure 3.24 comprised of leaf tissue infiltrated with infiltration media and 
therefore may not reflect whether the antibody was reacting non-specifically with 
some A. tumefaciens protein produced early after infiltration.  The western blot was 
repeated using a negative control comprising of leaf lysate derived from tobacco 
plants agroinfiltrated with A. tumefaciens GV3101::pMP90RK (pRIC: N) at an OD600 
of 1. This recombinant strain of A. tumefaciens encodes a full length, human codon 
optimized, Crimean-Congo Hemorrhagic Fever N protein from the pRIC plasmid 
vector. The agroinfiltrated leaf lysate was obtained from Richard Atkinson (M.Sc. 
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student, Biopharming Research Unit, Department of Molecular and Cell Biology, 
University of Cape Town). It is noted that the use of material from a separate 
experiment is not an ideal control due to the potential influence of other variables that 
may not have been accounted for. 
 
The day 3 lysate samples for each antigen at OD600 of 1.5 (+NSs) were subjected to 
western blotting alongside the negative lysate sample. The western blot procedure was 
also refined to allow the incubation time between the membrane bound proteins and 
the substrate to be prolonged to 1 hour without non-specific reactivity of the 
antibodies. The primary antibody concentration was increased to 1:500, the secondary 
antibody concentration decreased to 1:20 000 and the concentration of recombinant 
CN54 positive control was decreased to 20 ng. Consistent with Figure 3.23 and 
Figure 3.24 all 3 lysate samples yielded a band slightly larger than 170 kDa that was 
not present in the negative control (Figure 3.26). This confirmed low expression 

















Figure 3.26: Western blotting to detect recombinant HIV-1 antigen expression in day 3 
crude leaf extract following agroinfiltration of tobacco plants at an OD600 of 1.5.                 
Agroinfiltrated leaf lysate samples from Day 3 (OD600 of 1.5) were resolved on a 7% 
Criterion Tris Acetate Gel alongside leaf lysate derived from tobacco plants infiltrated with A. 
tumefaciens (pRIC: N) (-‘ve). The samples were elecrophoresed in parallel with a 20 ng µl 
aliquot of recombinant CN54 envelope glycoprotein and a 10 µl aliquot of Thermo Scientific 
PageRuler Prestained Protein Ladder (MW). 
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3.15. Direct extraction of recombinant antigens from the apoplastic 
spaces of plant leaves 
 
The successful expression of the recombinant envelope subunit vaccines, 
demonstrated  in Section 3.14, confirmed that plants have the capacity to express the 
novel HIV-1 proteins designed in this study. However, the yields observed by western 
blotting were not suitable for further characterization or immunization studies. Having 
evaluated several different strategies to maximize expression of the antigens, our 
focus shifted to improving the recovery of the proteins from the plant leaves. Based 
on promising reports by Medicago and our lab at purifying recombinant proteins 
directly for the apoplastic spaces in plant leaves, we sought to apply this approach to 
our HIV-1 subunit vaccines (63, 238). The experimental infiltrations described in 
Section 3.14 were repeated at OD600 of 1.5 for the experimental strains and 0.25 for 
the A. tumefaciens (pTRA-A: H5) strain. A negative control infiltration of LBA4404 
(pBIN-NSs) was conducted in parallel with the experimental samples.  
 
Once again protein samples were harvested at day 3 for the HIV-1 antigens and day 7 
for the H5 protein. PBS was infiltrated into the abaxial airspaces on the ventral side of 
agroinfiltrated leaves and protein from the apoplastic spaces purified by low speed 
centrifugation. Protein was also purified for each of the recombinant strains using the 
crude homogenization method employed in Section 3.14. The purified apoplastic 
protein samples were subjected to western blotting alongside their corresponding 
samples purified by homogenization, to determine whether the apoplastic extraction 
method improved protein recovery. 
 
In the case of all 3 antigens, purification of protein directly from the apoplast yielded 
a band of greater intensity than the corresponding sample purified by homogenization 
(Figure 3.27). The gp150 and gp120-HA2 proteins were barely detectable when 
purified by homogenizing leaf tissue and may not be apparent in this manuscript due 
to the loss of detail associated with capturing the image (Figure 3.27). Interestingly 
the bands corresponding to the antigens of interest are located higher up on the gel 
than expected. The apparent size anomaly of the recombinant antigens may be due to 
their aggregation with inclusion bodies during their egress through the ER into the 
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apoplastic space (Figure 3.27). It is unlikely that these bands are artifacts of non-
specific antibody binding as they are not present in the NSs control and are darker 
when the samples were enriched for apoplastic proteins. These findings suggest that 
extracting protein directly from the leaf apoplast significantly improves the apparent 
yield of the recombinant antigens. 
 
Consistent with these findings, purification of recombinant H5 in this manner yielded 
a sharply defined band of the expected size (Figure 3.28 A). The corresponding 
western blot for H5 purified by homogenizing agroinfiltrated leaves is included 
alongside in Figure 3.28 B for comparison. Although the lysate samples were 
unquantified the images strongly suggest that the apoplastic method employed here 















Figure 3.27 Western blotting to detect recombinant HIV-1 antigen expression in 
apoplastic protein lysate. Apoplastic protein was harvested 3 days post agroinfiltration of 
leaf tissue and subjected to western blotting alongside protein samples harvested by 
homogenization (lysate). In addition to the experimental sample, a negative control sample 
(NSs) was included whereby leaves were infiltrated with LBA4404 (pBIN-NSs). The samples 
were elecrophoresed in parallel with a 20 ng µl aliquot of recombinant CN54 envelope 




















Figure 3.28: Western blotting to detect recombinant H5 antigen expression in A) 
apoplastic protein lysate and B) crude protein lysate. Protein was harvested 7 days post 
agroinfiltration of leaf tissue, by either direct apoplastic proteinextraction or leaf 
homogenization, and subjected to western blotting alongside crude LBA4404 (pBIN-NSs) 
agroinfiltrated leaf lysate. 
3.16. Summary of plant expression parameters 
 
In summation, preliminary attempts to express the newly designed antigens were 
unsuccessful even when a PTGS was co-expressed along with the proteins. The 
extraction of the antigens under denaturing conditions was partially successful, 
although impractical for the recovery of intact proteins. Increasing the culture density 
of A. tumefaciens infiltrated into plant leaves and direct extraction of the antigens 
from the apoplast allowed the recovery of low levels of the recombinant proteins, 
although insufficient for further characterization (Table 3.5). 
 
Table 3.5: Summary of the expression levels achieved by varying protein expression and 









(- = no detectable expression, + = very low expression, ++ = low expression) 
Reaction stage Expression 
Preliminary expression studies - 
Influence of PTGS suppressor - 
Protein extraction under denaturing conditions + 
Impact of infiltration culture density ++ 




CHAPTER 4:                          
DISCUSSION & CONCLUSION 
 
The development of a heterologous DNA prime-protein boost immunization regimen 
is a promising approach to induce neutralizing antibodies against the HIV-1 envelope 
glycoprotein. However, conventional vaccine production platforms are expensive and 
therefore represent an additional complication to developing a globally implemented 
HIV-1 vaccine. In this study two vaccine platforms, namely a novel DNA vaccine and 
a transient plant expression system, were investigated to produce 3 HIV-1 envelope 
immunogens. 
 
We have developed DNA vaccines based on the pTHPcapR vector system which 
enables dose sparing by employing a porcine circovirus type 1 enhancer element, to 
drive high levels of antigen expression (354). We have also exploited a transient A. 
tumefaciens mediated plant-based expression platform for the production of 
recombinant HIV-1 envelope proteins in order to reduce production costs associated 
with heterologous expression systems and to potentially improve the immunogenicity 
of the antigens (293). Plant-derived pharmaceutical proteins are cheaper than both 
conventional cell culture and bacterial fermentation production platforms, largely due 
to the reduction in generic production costs associated with this system (66, 91, 256, 
293, 346). Additionally, plant-based expression platforms are potentially infinitely 
scalable and could be exploited for the large scale production levels required for the 
implementation of a vaccine on a global scale (293, 410). The feasibility of this 
expression system is best demonstrated for influenza haemagglutinin subunit 
vaccines, with commercially viable yields of subunit vaccines having been reported 
by a number of different research groups (157, 158, 183, 226, 323–326, 336). Lastly, 
there is evidence to suggest that glycoproteins passing through the plant cell secretory 
pathway may bud into the apoplastic spaces, along with plant-derived lipids, to form 




4.1. Characterization of pTHPcapR DNA vaccines encoding novel 
HIV-1 envelope antigens 
 
A HIV-1 subtype C envelope gene, derived from a secondary HIV-1 infection, was 
obtained from a CAPRISA Acute Infection Cohort donor who later developed cross 
neutralizing PG9/16-like antibodies (114, 232). The envelope glycoprotein in question 
was selected for vaccine development on the basis of its documented sensitivity to 
prototype monoclonal antibodies comprising the main regions of vulnerability of the 
HIV-1 glycoprotein, ensuring both the integrity and exposure of the cognate epitopes 
on the parental virus (235). These included antibodies PG9, PG16 and PGT145 which 
target  an epitope involving residue N160, PGT128 which recognizes the glycan at 
N332, 4E10 which interacts with the MPER of gp41 and VRC01 which binds to the 
CD4bs (41, 235, 377, 379, 418).  
 
This is in stark contrast to the approach employed to select vaccine immunogens for 
efficacy trials which have been chosen to represent the predominating subtypes in the 
given geograpical region where the trial was taking place (30, 93, 115, 125, 279). 
Recently, a more rationale approach has been applied to developing an immunogen 
capable of inducing cross-neutralizing antibodies. Hoffenberg and colleagues have 
reported the identification of an HIV-1 subtype A envelope protein 
(BG505.W6M.ENV.C2) that is recognized by most known HIV-1 envelope broadly 
cross-neutralizing monoclonal antibodies. Furthermore immunogenicity studies in 
rabbits with an adjuvanted recombinant gp120 antigen, derived from this envelope, 
resulted in the induction of antibodies recognizing the CD4-binding site, the N160 
epitope defined by PG9 and a glycan dependent epitope defined by PG126 (142). 
Further development of this envelope variant as an antigen has resulted in the 
production of stable, soluble, cleaved trimers that retain the epitopes recognized by 
broadly neutralizing antibodies without exposing non-neutralizing epitopes (298). 
 
Three novel antigens were designed in this study, based on the CAP256 envelope 
coding sequence, for use in genetic immunizations and as recombinant protein 
immunogens. The first antigen, gp150, comprised of a truncated form of the envelope 
protein whereby the cytoplasmic tail region had been shortened to improve the 
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exposure of antibody-sensitive epitopes and to enhance expression of the protein (83, 
374). This approach has also been employed by the South African AIDS Vaccine 
Initiative for the expression of an HIV-1 envelope antigen from both DNA and MVA 
vaccine modalities that are currently being evaluated in clinical trials (34, 35, 317).  
 
The other 2 antigens, gp120-HA2 and gp140-HA2tr, comprised of chimeric proteins 
that contained elements of the HIV-1 envelope glycoprotein (gp160) and the 
transmembrane subunit (HA2) of H5N1 influenza haemagglutinin glycoprotein. The 
main rationale underlying this approach is the possibility that chimeric glycoproteins 
containing the influenza transmembrane subunit may form particulate structures, 
along with plasma membrane-derived lipids, when passing through the plant cell 
secretory pathway (61). This approach has been successfully demonstrated by 
Medicago who have reported the formation of chimeric VLPs for HIV-1, Varicella 
Zoster and Rabies virus antigens when translationally fused to the transmembrane and 
cytoplasmic domains of influenza H5 haemagglutinin (61). The formation of such 
VLPs could potentially circumvent the low envelope densities associated with 
conventional vaccine approaches (263). Lastly, these chimeras may also promote 
increased surface density following genetic immunization which could be expected to 
improve antibody responses to the vaccine (383). 
 
The DNA vaccines were characterized in vivo to verify expression of the antigens and 
to obtain an indication of their subcellular localization. Western blotting experiments 
of transfected HEK293 cells verified promising expression of each of the antigens in 
the DNA vaccines constructed for this project. However expression of the full length 
CAP256 envelope from which the vaccines were designed could not be detected. This 
plasmid differed from the vaccines in that it had coding sequence for additional 
elements of the HIV-1 genome which will have altered the proximity of the envelope 
gene to the plasmid’s promoter. These elements included the 3’ region of rev exon 1, 
the 5’ end of the nef gene and the full length vpu gene. Although the pcDNA3.1 
plasmid, encoding the parental CAP256 envelope glycoprotein, had the same 
Cytomegalovirus-promoter/enhancer and bovine polyadenylation signal as the 
pTHPcapR DNA vaccine, it lacks the porcine enhancer element. A luciferase assay, 
performed to determine the transfection efficiency of the co-transfected pGL4.13 
122 
 
(luc2/SV40) reporter plasmid, verified that the transfection was successful.  These 
findings preclude the possibility that the lack of detectable CAP256 envelope protein 
is a reflection on either poor transfection efficiency or a lack of antibody reactivity. 
Additionally, the genetic integrity of the plasmid had previously been confirmed by 
sequencing and expression of the protein and indirectly confirmed by the use of 
CAP256 envelope-derived pseudovirus in TZM-bl luciferase assays (114, 232, 235). 
Collectively this suggests that the CAP256 envelope glycoprotein is poorly expressed 
from plasmid pLM1 and that the levels of protein in the lysate may be below the 
threshold of detection by western blotting. 
 
The DNA vaccines were also characterized by immunostaining of transfected 
HEK293 cells, followed by confocal microscopy. Consistant with western blotting of 
transfected HEK293 cell lysate, high levels of antigen expression were observed for 
the gp150, gp120-HA2 and gp140-HA2tr antigens. In contrast, poor expression of the 
full length CAP256 envelope was observed for cells transfected with the pLM1 
expression construct. Interestingly, the expression of the gp120-HA2 antigen appeared 
to be predominantly localized to the periphery of transfected cells. In contrast, the 
fluorescent signal for the gp150 and gp140-HA2tr proteins appeared to be more 
diffuse in subcellular localization, as witnessed for the SAAVI DNA-C2 envelope 
protein. These observations suggest that the presence of the full length influenza HA2 
glycoprotein subunit may promote increased surface density of the glycoprotein 
antigen.  
 
Further work will be required to validate these assertions by demonstrating co-
localization of the fluorescent signal for the antigen with a plasma membrane-specific 
stain, such as Nile Red. If this hypothesis can be confirmed it would suggest that the 
ectodomain of the HA2 subunit may somehow promote the association of the 
glycoprotein with the plasma membrane as the gp140-HA2tr immunogen (which is 
identical except for its ectodomain) did not give rise to a similar localization pattern. 
In contradiction to this theory, Wang et al., have proposed that the discrepancy in 
glycoprotein densities between HIV-1 and influenza virions may be a reflection on the 
increased length of the HIV-1 envelope cytoplasmic tail compared to influenza 
haemagglutinin (383). However, even when the cytoplasmic tail of the HIV-1 
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antigens was truncated, in the case of the gp150 antigen and the SAAVI DNA-C 
envelope, there was no evidence to suggest comparable levels of membrane 
association. The detection of the gp150 antigen but not the full length CAP256 
envelope may be a reflection of inhibitory signals in the cytoplasmic region that 
preclude high levels of expression. Alternatively, the higher levels of gp150 
expression may be due to the porcine enhancer element in the pTHPcapR DNA 
vaccine which is not present in pLM1 (354). In contrast to the CAP256 envelope, the 
high expression levels observed for the gp150 antigen, encoded by the SAAVI-C2 
DNA vaccine, suggest that this envelope is efficiently produced. 
 
Consistent with the observations from the immunostaining experiment, influenza 
virions are known to have a greater glycoprotein density than HIV-1 viral particles 
(134). A recent cryoelectron tomography study of influenza virions suggested that 
each virion contained approximately 375 glycoprotein spikes compared to the 
estimated 14 glycoprotein trimers per HIV-1 virion (130, 419). Furthermore, it has 
been reported that substitution of the HIV-1 envelope transmembrane and cytoplasmic 
domains with analogous regions from influenza virus culminates in increased 
glycoprotein density on the surface of pr55
gag
 particles, in insect cell culture (383). 
 
In essence, the in vivo characterization of the 3 DNA vaccines constructed for this 
project demonstrated high levels of expression for each antigen and 
immunofluorescence assays suggested that the presence of the full length influenza 
HA2 subunit may promote increased surface density. The low level expression of the 
parental CAP256 envelope is possibly a reflection on the selective pressures acting on 
the transmission bottleneck  prior to the establishment of infection (74, 122, 161, 
282). It is plausible that low glycoprotein density on the CAP256 virion may have 
enabled the virus to evade antibody responses, in the donor, prior to the transmission 
event to CAPRISA participant 256. Unfortunately no information regarding the 
donor’s immune response to infection is available and this hypothesis is purely 
speculative. The CAP256 envelope was derived from the superinfecting virus which 
is believed to have established infection 13-15 weeks after the primary infection, prior 
to the development of neutralizing antibodies (114, 232, 235). Therefor the low 
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envelope density on the transmitted virus is unlikely to have conferred a selective 
advantage to the virus during the transmission event. 
4.2. Expression of recombinant HIV-1 envelope antigens in planta 
 
The expression of a viable plant-produced HIV-1 envelope vaccine candidate will 
constitute a significant development in biopharming and HIV-1 vaccine development 
alike. To date a limited number of studies have reported the expression of vaccine 
relevant HIV-1 envelope proteins in plants and therefore a major aim of this study 
was also to investigate the capacity of plants to express HIV-1 envelope immunogens. 
In this study we have systematically investigated various parameters that have been 
shown to influence the expression of recombinant proteins in planta, with the aim of 











Figure 4.1: Schematic diagram outlining the systematic approach used to optimize 
recombinant HIV-1 envelope antigen expression in planta. 
 
Recombinant A. tumefaciens strains were generated, with specialized pTRA-A 
expression vectors, encoding matched antigens to the priming DNA vaccines. Initial 
attempts to transiently express the 3 recombinant immunogens by agroinfiltation of N. 
benthamiana leaves failed to yield any discernible protein expression, even when a 
PTGS suppressor was co-expressed with the antigens. However based on the 
expression time trial of the A. tumefaciens (pTRA-A: H5-ELP) strain, used as an 
infiltration control, it was apparent that supressing PTGS could profoundly improve 
the expression of heterologous proteins in plants. Western blotting of crude 
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agroinfiltrated leaf lysate suggested that the NSs suppressor enhanced both the 
magnitude and duration of H5-ELP antigen expression suggesting that circumventing 
PTGS was a promising approach to enhance the yield of recombinant antigens. 
 
In order to account for the possibility that the antigens were sequestered in the cell 
membranes and not liberated into the soluble protein fraction during protein 
extraction, the experiments were repeated and leaf protein extracted under denaturing 
conditions. This approach enabled the detection of faint expression of gp140-HA2tr, 
but not the other antigens, suggesting that the presence of the influenza 
haemagglutinin transmembrane domain on the gp140-HA2tr antigen precluded 
efficient recovery of the antigen by homogenization of leaf tissue. Despite the 
promising results yielded by including urea in the extraction buffer, the use of 
detergents precludes the recovery of proteins in their native conformations rendering 
it unsuitable for the purification of our antigens. We therefore compared the influence 
of different culture densities of the recombinant A. tumefaciens strains, on 
heterologous protein expression, when infiltrated into N. benthamiana plants.  
 
Variation of the culture density at infiltration appeared to have a positive impact on 
the expression of each of the recombinant antigens, with detectable levels of antigen 
expression witnessed within 3 days post infiltration.  Interestingly, a faint band was 
detected for all 3 antigens on days 1 and 3 at an OD600 of 0.5 despite being unable to 
detect any protein expression at this culture density under identical experimental 
conditions previously. This observation raises the possibility that considerable 
variation may exist between experimental infiltration procedures. In this vein, it is 
well documented that senescing leaves are associated with higher levels of protease 
activity and agroinfiltration of older leaves may result in higher levels of protein 
degradation (19). 
 
In order to verify that the putative bands yielded by western blotting were not an 
artifact of non-specific antibody reactivity, the western blotting procedure was 
repeated with a different negative control and the experimental procedure refined. 
Each of the experimental lysate samples yielded a single defined band above the 170 
kDa molecular weight standard which was absent from the negative control. These 
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findings support the assertion that the bands of interest do in fact correspond to the 
antigens of interest, although the expression levels were poor. 
 
Lastly, in an attempt to improve recovery of the recombinant proteins from 
agroinfiltrated leaf tissue a direct apoplastic extraction procedure was conducted on 
agroinfiltrated leaves. Western blotting of the samples revealed a blurry, yet 
promising, band for each of the antigens that was absent from the negative control. 
The increased band intensity when the antigens were enriched for by the apoplastic 
protein extraction method supports the assertion that the band of interest corresponds 
to the desired antigens. Additionally, the band of interest was also absent from the 
negative control. Collectively these observations suggest that the 3 recombinant 
antigens were successfully expressed in plants, albeit at very low levels. 
 
The plant-derived envelope antigens migrated at a noticeably higher molecular 
weight, following western blotting, than when the identical antigens had been 
expressed in transfected HEK 293 cells. The detection of the gp140-HA2tr  product in 
the presence of urea, under denaturing western blotting conditions, precludes the 
possibility that the size discrepancy could be attributed to the formation of oligomers. 
It is also unlikely that the size anomaly is a reflection of the inherent differences in the 
glycosylation patterns of plants as neither Medicago nor Rosenberg and colleagues 
reported similar observations (61, 289). The coding sequence of the antigens had also 
been verified, after cloning and in vitro culturing of A. tumefaciens, confirming that 
the unexpected size difference was not due to an error in the DNA sequence of the 
genes. The unexpected size difference of the antigens could possibly be attributed to 
modification of the proteins as they passed through the cell secretory pathway. It is 
possible that the gene coding sequence may have contained processing signals that 
were recognized by plants but not mammalian cells. However, further work will be 
required to determine the exact cause of this size anomaly. 
 
Medicago, a Quebec-based plant biotechnology company, have reported promising 
expression levels of similar HIV-1 envelope antigens comprising of translational 
fusions between the envelope coding sequence and the transmembrane and cytosolic 
domains of influenza H5 or H3 (61). Several disparities could account for the 
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conflicting results arising from our study when compared to the data generated by 
Medicago; pertaining both to the choice of envelope and the expression systems used 
(Table 4.1). Firstly, it is noteworthy that the HIV-1 envelope coding sequence used 
by Medicago was based on a group M consensus sequence as opposed to a naturally 
derived sequence. Furthermore the envelope protein was extensively engineered by 
shortening the variable regions and deleting the cleavage site, fusion peptide and 
immunodominant region of gp41. In stark contrast, the envelope protein chosen for 
this study was derived from a naturally occurring viral isolate whereby the structure 
was preserved as far as possible. Additionally, the coding sequences of the 
immunogens used by Medicago were optimized to represent preferred human codon 
usage whereas the gene sequences used in this study were based on the native viral 
sequence (198). The expression system used by Medicago is also considerably 
different to the system used in this study. Notably; the Medicago expression system 
employs the Alfalfa Protein disulphide isomerase signal sequence to direct the 
recombinant antigens into the leaf apoplast. Lastly, the Medicago expression cassette 
exploits the P19 silencing suppressor as opposed to the NSs suppressor that was used 
in this study.  
 
An independent study by Rosenberg et al., also reported promising expression of 
recombinant HIV-1 envelope in plants using a truncated protein whereby the cleavage 
site, fusion peptide and immunodominant region of gp41 had been removed. The 
study reported the successful expression of the gp140 ΔCFI protein in both the 
cytoplasm and ER, using a similar pTRA vector system to that described in this study, 
along with the P19 suppressor.  The codon usage of the gene sequence in the study 
was not disclosed. Interestingly, in addition to the expected band for the antigen, 
western blotting of agroinfiltrated plant extracted yielded an additional higher order 








Table 4.1: Comparative summary of the differences in antigens and expression systems used in this study and the Medicago study (61) 
 pTRA-A: gp150 pTRA-A: gp120-HA2 pTRA-A: gp140-HA2tr 995 997 999 
Insert gp150: 
 
CAP 256 HIV-1 
envelope 
glycoprotein 





Full length exterior 
subunit (gp120) of CAP 
256 HIV-1 envelope 
glycoprotein fused in 
frame to full length HA2 
subunit of influenzaH5. 
gp140-HA2tr: 
 
Full length exterior 
subunit and ectodomain 
of CAP 256 HIV-1 
envelope glycoprotein 
fused in frame to 



















ConS-ΔCFI lacking the 
native TM and 
cytosolic domains 
fused to the 
transmembrane and  





ConS-ΔCFI lacking the 
native TM and 
cytosolic domains 
fused to the 
transmembrane and 





Native Native for HIV 
Humanized for HA 
Native for HIV 
Humanized for HA 
Humanized Humanized Humanized 
Signal 
peptide 









pTRA-A pTRA-A pTRA-A 2X35S-CPMV-
HT 
2X35S-CPMV-HT 2X35S-CPMV-HT 
localization Apoplast Apoplast Apoplast Apoplast Apoplast Apoplast 
Bacterial 
strain 
GV3101::pMP90RK GV3101::pMP90RK GV3101::pMP90RK AGL1 AGL1 AGL1 
Silencing 
suppressor 
NSs NSs NSs P19 P19 P19 
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In the light of these studies, it is likely that the poor expression of the antigens 
observed in this project may be a reflection on the codon usage of the gene sequences 
and that codon optimization of the DNA may be beneficial. The coding sequences of 
our 3 antigens were based on the CAP256 envelope coding sequences and were 
therefore representative of the wild type codon usage. It has been suggested that the 
native HIV-1 codon usage is not amenable to high levels of expression and has been 
reported to hinder the expression of a model protein, Thy-1, when expressed using the 
preferred HIV-1 codon bias (123). 
 
Codon optimization is often exploited to achieve optimal levels of expression of 
heterologous proteins in plants, although the ideal codon usage is largely empirically 
determined rather than being governed by any pre-existing rationale (292, 293).  To 
illustrate this point, early work by Biemelt and colleagues demonstrated that human 
codon optimization of the HPV L1 protein achieved superior expression to plantized 
and native sequences in transgenic plants (24). A similar study conducted by our 
research group corroborated these findings using a transient A. tumefaciens mediated 
expression system  (209). Initial attempts by our group to express both plantized and 
native HIV-1 Gag particles in transgenic plants were unsuccessful and no discernable 
Gag expression could be discerned using standardized diagnostic assays (294). A 
subsequent study managed to achieve detectable levels of Gag particles derived from 
plantized, but not native, gene sequences (227). In some cases, it has been our 
experience that mycobacterial codon optimized genes are amenable to higher levels of 
expression in plants than their native counterparts, presumably attributable to the 
improved mRNA stability conferred by their high GC content (Personal 
communication; Ann Meyers). Post hoc analysis of the gene sequences used in this 
study revealed that they had surprisingly low GC contents, especially when compared 
to the full H5 protein that was used as an expression control (Table 4.2).  
 
 
Another strategy that could be exploited to improve the levels of heterologous protein 
expression is to alter the subcellular localization of the antigens. Once again the 
outcome of this approach is unpredictable and whether this may confer any benefit 
can only be established emperically (292, 293). Lastly, it cannot be discounted that 
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the poor levels of protein expression may be an intrinsic property of the CAP256 
envelope glycoprotein itself, rather than a reflection on the expression system. 
 
Table 4.2: Summary of the GC content of the antigen coding sequences used in this 
study. 
 






4.3. Future prospects 
 
The promising expression of each of the HIV-1 envelope antigens from the 
pTHPcapR DNA vaccine vector strongly supports their further development. A recent 
study reported the induction of robust antibody responses against influenza H5N1 
Haemagglutinin using the pTH DNA vaccine vector system from which the DNA 
vaccine vector in this study was derived (237). Immunization studies are currently 
being planned in rabbits to determine whether these candidate vaccines have the 
capacity to induce neutralizing antibodies against the HIV-1 envelope glycoprotein.  
Concurrent with these studies, co-localization experiments are planned to determine 
whether the influenza HA2 transmembrane subunit promotes increased association 
with the plasma membrane. 
 
The low expression levels of the plant-derived antigens are not sufficient for further 
characterization or immunogenicity studies. Unfortunately due to the time constraints 
inherent in this study the expression of these proteins could not be further optimized.  
The low expression levels of the recombinant protein expression will be addressed by 
optimizing both the GC content and codon usage of the gene sequences. Additionally, 
the influence of targeting the antigens to different subcellular locations may be 
explored using a panel of pTRA plant expression vectors available in our lab (209). 
The antigenicity of each of the immunogens will also need to be evaluated in order to 
determine whether the broadly neutralizing epitopes, that are present on the parental 
virus, are reproduced in the context of the synthetic proteins that were designed in this 
study. This will be particularly important in the case of the plant-derived antigens due 
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to the inherent differences in plant glycosylation which may influence the 
conformation of the protein (109). It is possible that different conformations of the 
antigens may alter the exposure of neutralizing antibody epitopes, influencing both 
the antigenicity and immunogenicity of the recombinant subunit vaccines. In 
conclusion 3 promising DNA vaccines have been developed in this study warranting 
further characterization and immunogenicity studies. A highly systematic process was 
employed to optimize the expression of matching recombinant proteins in plants. The 
levels of the recombinant proteins, expressed in plants were low at best and further 
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APPENDIX A:                      
ADDITIONAL PROTOCOLS 
 
A.1. Protein quantification of transfected cell lysate 
 
The protein concentrations of the transfected cell lysate samples were quantified using 
the Bio-Rad DC Protein Assay in accordance with the manufacturer’s instructions. A 
serial dilution series of Bovine Serum Albumen (BSA) standards were prepared in 1× 
Glo Lysis Buffer (Promega) with concentrations ranging from 0.1 mg/ml to 1.6 
mg/ml. Aliquots of 5 µl of each standard were transferred, in triplicate, to a 96 well 
microtiter plate.  The cell lysate samples were diluted 2-fold in sterile dPBS and 5 µl 
transferred to a 96 well microtiter plate, in triplicate. Triplicate samples of dPBS were 
loaded alongside the experimental samples as a blank. Aliquots of 25 µl of reagent A 
(Bio-Rad) and 200 µl of reagent B (Bio-Rad) were added to each well. The microtiter 
plate was gently agitated to mix the contents of each well, before being incubated for 
15 minutes at room temperature. The OD750 values were then determined for each 
well using the VERSAmax Microplate Reader with the DC750pr template. The values 
derived from the BSA standards were used for the construction of a standard curve. 
The lysate samples were corrected for the dilution factor and their protein 
concentrations extrapolated from the standard curve. 
 
A.2. Luciferase assay to measure the transfection efficiency 
 
A serial dilution series of QuantiLum® Recombinant Luciferase (Promega) was 
prepared in 1× Glo Lysis Buffer (Promega); with concentrations ranging from 7.8125 
pg/ml to 500 pg/ml. Aliquots of 0.2 µg/ml of total protein, derived from transfected 
cells, were prepared in a 350 µl volume of 1× Glo Lysis Buffer (Promega). Control 
samples, comprising of lysate derived from untransfected cells, were prepared in 
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parallal with the experimental samples.  Aliquots of 100 µl of the luciferase standards 
and the experimental samples were dispensed, in triplicate, into a Nunc-immuno™ 
Microwell™ 96 well polystyrene plate (Sigma-Aldrich). Lastly, 100 µl aliquots of 
Glo lysis buffer were loaded, in triplicate, alongside the experimental samples as a 
blank. An aliquot of 100 µl of Bright-Glo™ substrate (Promega) was dispensed into 
each well using a multichannel pipette. Luminescence was measured immediately, 
using a luminometer, and a standard curve generated from the luciferase standards.  
The average triplicate relative luciferase value was extrapolated from the standard 
curve and the transfection considered to be successful if the average triplicate relative 




APPENDIX B:                             
BUFFERS, MEDIA AND SOLUTIONS 
 
Luria Bertani liquid broth (100 ml) 
 
Tryptone   1 g 
Yeast Extract   0.5 g 
NaCl    0.5 g 
Water    adjust to 100 ml 
** Autoclave 
    
Luria Bertani agar (100 ml) 
 
Tryptone   1 g 
Yeast Extract   0.5 g 
NaCl    0.5 g 
Agar    1.5 g 
Water    adjust to 100 ml 
** Autoclave 
 
Transfer and storage (TSB) buffer (100ml): 
 
Peptone   1.6 g 
Yeast extract   1.0 g 
NaCl    0.5 g 
PEG    10.0 g 
DMSO    5 ml 
1 M MgCl2   1 ml 
1 M MgSO4   1 ml 
Water    adjust to 100 ml 
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TSGB media (100ml): 
 
20% w/v glucose  2 ml 
TSB buffer    98 ml 
 
5 × Tris-Borate-EDTA (TBE) buffer (1 liter) 
 
Trizma base   54.0 g 
Boric acid   27.5 g 
0.5 M EDTA (pH 8.0) 20 ml 
Water    adjust to 100 ml 
 
Induction media (100 ml) 
 
Tryptone powder  1 g 
Yeast Extract   0.5 g 
NaCl    0.5 g 
MES    0.1952 g 
Water    adjust to 100 ml 
*Adjust pH to 5.6 
**Autoclave 
 
Infiltration media (1 litre) 
 
MES     1.952 g 
MgCl2    2.03 g 
Sucrose   30 g 
Water    adjust to 1 l 
*Adjust pH to 5.6 







Solution I: (100 ml) 
 
1 M Tris-HCl (pH 8.0) 2.5 ml 
0.5 M EDTA (pH 8.0) 10.0 ml 
20% w/v glucose  5 ml 
Water    82.5 ml 
 
Solution II: (10 ml) 
 
10 M NaOH   0.2 ml 
10% SDS   1.0 ml 
Water    8.8 ml 
 
Solution III: (10 ml) 
 
5 M Potassium acetate 60 ml    
Glacial acetic acid  11.5 ml    
Water    28.5 ml 
 
Block/wash buffer (100 ml) 
 
1 × PBS   100 ml 
Instant milk powder  5 g 
10% Tween 20  1 ml 
 
1 × Transfer buffer (1 litre) 
 
1 × Tris base    5.82 g 
Glycine   2.93 g 
Methanol   200 ml 





10 × Ponceau S solution (1 litre) 
 
Ponceau S   2.0 g 
Trichloroacetic acid  30 g 
5-Sulfosalicylic acid  30 g 
Water    adjust to 1 litre 
 
Complete Growth Media (GM) 
 
Dulbecco’s Modified Eagle Medium  450 ml  
Heat inactivated Fetal Calf Serum  50 ml 
Penecillin-Strepromycin   5 ml 
Fungin      500 µl 
 
4x Resolving Buffer 
 
Tris base    36.3g 
adjust pH to 8.8 with HCl 
water    Adjust to 200 ml 
 
4x Stacking Buffer 
 
Tris base    3.0g 
Adjust pH to 6.8 with HCl 
Water     Adjust to 50 ml 
 
10x Electrophoresis Running Buffer 
 
Tris base    30.3 g 
Glycine    144.2g 
SDS    10g 
Adjust pH to 8.5 with HCl 
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Water     Adjust to 1 liter 
 
5x Sample Loading Buffer  
  
10% SDS   940 µl 
1M TrisCl pH 7.5  470 µl 
100mM EDTA  95 µl 
Glycerol  2.45 ml 
Distilled water  545 µl 
Mercaptoethanol   205 µl 
1% Bromophenol blue 10 µl  
 
 
